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ABSTRACT 
EMILY RENEE OLSON:  Parametric and Non-Parametric Approaches to Quantitating 
Pharmacodynamic Response 
(Under the direction of Gary M. Pollack, Ph.D.) 
 
The goal of this project was to evaluate factors that impact pharmacokinetic- 
pharmacodynamic (PK-PD) relationships, and to develop novel approaches for analysis of 
those relationships utilizing opioids as a model pharmacologic class. The role of protein 
binding in in vitro-to-preclinical and preclinical-to-clinical estimates of opioid potency was 
investigated; the optimal metric for characterizing in vivo potency was unbound brain EC50.  
The role of P-glycoprotein (P-gp) efflux at the blood brain barrier (BBB) in attenuating 
central nervous system (CNS) concentrations and pharmacologic response was evaluated in 
mice receiving loperamide, methadone, alfentanil or fentanyl.  An integrated PK-PD model 
fit to the time course of antinociception and serum/brain concentrations revealed the 
influence of P-gp on brain:plasma ratio and brain:plasma equilibration half-life.  The 
influence of behavioral responses in the hotplate latency antinociception assay was 
investigated for loperamide, methadone and sufentanil.  PK-PD modeling suggested that 
processed responses, jumping and hind-paw licking, reflected centrally-mediated processes, 
whereas reflexive responses, lifting or shaking of the hind paw, were mediated predominately 
in the periphery, with a slight additive central contribution.  The influence of truncating the 
dynamic range of pharmacologic effect on recovery of PD parameters was investigated with 
fentanyl and morphine.  Incorporating Emax as a parameter, as opposed to a fixed value, in 
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PK-PD modeling improved model predictions when compared to assigning a fixed value at 
an artificial ceiling.  The utility of area bounded by a hysteresis loop (ABH) as a non-
parametric descriptor of dissociation between pharmacodynamics and pharmacokinetics was 
assessed with five opioids administered to P-gp-competent and P-gp-deficient mice.  A 
Matlab routine was developed to calculate ABH, and this novel quantitative approach was 
evaluated relative to image analysis of the hysteresis loop.  ABH correlated with area under 
the curve (AUC) and the model-derived parameters EC50 and ke0.  Taken together, these 
approaches provide a framework for understanding the multiplicity of factors that influence 
drug concentrations and pharmacologic effect, and provide insight into how information 
derived from parametric and non-parametric analyses can be used to characterize PK-PD 
relationships and predict the behavior of PK-PD systems.    
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CHAPTER 1 
PROJECT OVERVIEW 
 
Pharmacokinetic-pharmacodynamic (PK-PD) modeling is increasingly being 
recognized as a critical component of the drug development process.  Advances in 
computational power and bioanalytical specificity, sensitivity and reproducibility over the 
last twenty years have led to the inclusion of PK-PD analysis as a routine part of drug 
development programs.  While tremendous progress has been made in describing drug 
disposition and effect since Gerhard Levy (1966) commented that “the multiplicity of factors 
which are expected to be involved in the response of intact animals to drugs seems to have 
discouraged investigations of the kinetics of gross pharmacologic effect,” the underlying 
problem remains, and a satisfactory definition of what pharmacologic response is and how it 
shall be interpreted is missing.  This deficiency can, in part, be attributed to the “multiplicity 
of factors” that mediate pharmacologic effect, including the ability of receptor populations in 
physiologically distinct locales to produce the same pharmacologic response, multiple 
responses mediated by one drug molecule, and intra- and inter-individual assay variability 
and insensitivity. 
This project overview has been constructed to 1) review concepts associated with 
characterizing pharmacokinetics and pharmacodynamic response, 2) introduce the challenges 
associated with characterizing central nervous system (CNS) PK-PD, 3) explain why the 
opioids are an ideal drug class for examining CNS penetration and response as fundamental 
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processes, and 4) lay out the parametric and non-parametric techniques used in this 
dissertation project to quantify pharmacodynamic response. 
PRINCIPLES OF PHARMACOKINETIC-PHARMACODYNAMIC MODELING 
Characterizing the relationship between drug administration, the time course of drug 
concentrations, and the pharmacologic effect produced by these concentrations is a critical 
component of any drug development program.  Integrating what the body does to a drug, 
pharmacokinetics, with what the drug does to the body, pharmacodynamics, forms a 
therapeutically-relevant relationship that can be used to predict responses following changes 
to the system (i.e. dose route, frequency or concentration).  The following sections will serve 
as an introduction to modeling time-independent and time-dependent relationships between 
drug kinetics and response.  In addition, methods that address dissociations between effect 
and concentration will be addressed. 
Time-independent relationship between effect and concentration 
When pharmacologic effect is receptor-mediated, the magnitude of biologic response 
is assumed to be proportional to the fraction of the receptor population occupied at a 
particular drug concentration. If concentrations in the receptor biophase (CE) are in 
immediate equilibrium with concentrations in blood (CB), and the effect (E) is 
instantaneously reversible and time-invariant, the relationship between E and CB can be 
described using a parametric model such as the sigmoidal Emax (or Hill) equation (Figure 
1.1).  More detailed descriptions of commonly used PD models can be found in a number of 
articles (Holford and Sheiner 1982; Meibohm and Derendorf 1997; Bellissant, Sebille et al., 
1998).  The neuromuscular blocker turbocurarine holds true to these assumptions, and a 
sigmoidal relationship between the degree of paralysis and blood concentrations can be 
 3 
demonstrated (Gibaldi and Levy 1972).  The scenario where pharmacologic response is 
directly related to plasma concentrations is atypical, however, with few drugs conforming to 
the strict assumptions associated with this model. 
Time-dependent relationships between effect and concentration  
A far more common occurrence is the presence of a time-dependent dissociation 
between drug disposition and pharmacologic effect.  The development of acute tolerance, 
such as occurs in response to nasally-administered cocaine, is a classic example of time-
dependent changes in the concentration-effect relationship (Jones 1990). In this example, 
blood cocaine concentrations initially increase and produce a commensurate increase in 
euphoria.  Receptor desensitization ensues and, despite continued increases in concentration, 
euphoria rapidly diminishes.  The relationship between the euphoric effect and blood 
concentration reveals what is known as a hysteresis loop that progresses temporally in a 
clockwise direction (Figure 1.2A). 
While tolerance is manifested as a clockwise hysteresis, the more common situation 
is the presence of a counterclockwise hysteresis loop.  Dissociation between effect and blood 
concentrations producing counterclockwise hysteresis behavior can result from a number of 
physiologic processes: indirect responses following drug-receptor binding, production of a 
pharmacologically active metabolite, or drug distribution to a structurally distinct 
compartment containing the receptor biophase (Figure 1.3).  Drug concentrations at the 
receptor biophase often are unknown, and the PK-PD model therefore must characterize the 
relationship between drug response and serum concentrations.  For example, an intravenous 
bolus dose of morphine initially will produce high blood concentrations, but the onset of 
effect will lag behind the maximum concentration (Cmax) because of the temporal delay in 
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morphine distribution to the brain (the presumed locale of response).  Similarly, just as slow 
accumulation in brain can result in delayed onset of effect, prolonged residence of drug in the 
brain can result in an offset of effect slower than would be predicted based on the rate of 
decline in blood concentrations. Assuming that the receptor biophase is in equilibrium with 
brain concentrations, a time-independent sigmoidal relationship will be observed between 
pharmacologic response and brain concentrations, while the temporal dissociation between 
response and blood concentrations will produce a hysteresis loop that temporally progresses 
counterclockwise (Figure 1.2B). 
Techniques used to address pharmacokinetic-pharmacodynamic hysteresis loops 
In the presence of hysteresis behavior, recovery of PD parameter estimates from the 
relationship between effect and central compartment (blood) concentrations is not feasible. 
For example, in the presence of significant hysteresis, two distinct concentrations will 
correspond to 50% of maximal effect, neither of which will be representative of the true 
EC50.  This effect-concentration disconnect is most commonly addressed with the application 
of the indirect-link PK-PD model, which uses the temporal relationships for effect and blood 
concentrations to predict the time course of drug concentrations in a hypothetical effect 
compartment (Holford and Sheiner 1982).  Estimates of fundamental pharmacodynamic 
parameters (EC50 and γ) then can be recovered from effect versus effect compartment 
concentration relationship. This analytical process is referred to as “collapsing the hysteresis 
loop”.  An alternative approach taken by Gastonguay and Schwartz (1994) characterized 
pharmacodynamics in the presence of processes that result in competing hysteresis behavior: 
distributional delays of drug presentation to the receptor biophase and onset of acute 
pharmacodynamic tolerance. This approach was based on computationally minimizing the 
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contribution of distribution to the net hysteresis behavior.  While these approaches address 
distribution-based hysteresis loops, other methods have been explored to rectify hysteresis 
behavior resulting from other physiologic processes. 
Hysteresis loops can be attributed to differences in venous, arterial and effect 
compartment concentrations.  For example, a drug that equilibrates rapidly between arterial 
and venous blood, but exhibits slow distribution from arterial blood to the effect site, will be 
associated with a counterclockwise hysteresis between pharmacologic response and venous 
concentrations.  Verotta et al. (1989) developed a semiparametric model that incorporates 
distribution between arterial and venous blood, together with distribution between arterial 
blood and the effect compartment, to address the hysteresis resulting from the dissociation 
between effect and sampled venous blood concentrations.  By incorporating the rate 
constants recovered from this analysis, the hysteresis collapses and the ensuing relationship 
between pharmacologic response and effect compartment concentrations can be used to 
recover estimates of fundamental pharmacodynamic parameters. 
CENTRAL NERVOUS SYSTEM PHARMACOKINETICS AND PHARMACODYNAMICS 
Describing the link between pharmacologic effect and drug concentrations is 
particularly challenging for drugs with central nervous system (CNS) activity.  Systemic 
concentrations of a drug are influenced primarily by lumped absorption, distribution, 
metabolism and elimination (ADME) processes, whereas CNS concentrations, and 
consequently pharmacologic effect, are determined by protein binding, blood-brain barrier 
(BBB) permeability, active transport, local metabolism, and cerebrospinal fluid (CSF) 
turnover.  Access to the brain and CSF is highly regulated by the BBB and blood-
cerebrospinal fluid barrier (BCSFB), respectively.  While the BCSFB is poorly characterized 
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compared to the BBB, it serves a largely protective role by regulating the entry of potential 
neurotoxins and metabolizing and/or effluxing xenobiotics from the CSF, via many of the 
same active transporters and metabolizing enzymes found in the BBB (de Lange 2004; Graff 
and Pollack 2004).  Due to the small surface area of the BCSFB (~0.02% of the BBB surface 
area), the BBB is considered the primary interface between systemic concentrations and the 
CNS (Kusuhara and Sugiyama 2001).  The following sections provide an introduction to 
mechanisms of brain uptake, experimental approaches to assessing brain disposition and the 
use of opioids as model CNS active drugs. 
Central Nervous System Disposition 
The BBB is an anatomical, biochemical, and functional barrier situated between the 
CNS and systemic circulation that serves to supply the brain with essential nutrients and to 
regulate entry and efflux of endogenous and exogenous substances.  The primary physical 
attributes that restrict brain penetration are the highly-developed tight junctions that link 
brain capillary endothelial cells, adjacent brain parenchymal cells (glial cells and astrocytes), 
an absence of microvascular fenestrations, and minimal pinocytotic activity (Engelhardt 
2003; Ohtsuki and Terasaki 2007).  While chemical structure and physicochemical properties 
(molecular weight, polar surface area, lipophilicity, and hydrogen bonding) dictate passive 
diffusion across the BBB, with small, lipophilic compounds being more permeable, the 
presence of active uptake and efflux transporters enables the passage of many substrates into 
and out of the brain (Feng 2002; Mahar Doan, Humphreys et al. 2002).  CNS homeostasis is, 
in part, maintained by specific transporters for essential nutrients and physiologic substrates: 
glucose, neuropeptides, monocarboxylic acids, amino acids, hormones, and electrolytes 
(Graff and Pollack 2004; Hawkins, O'Kane et al. 2006). 
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The presence of efflux transporters at the BBB limits the brain exposure of many 
pharmacologic agents and should be considered in the evaluation of new compounds.  The 
predominant transmembrane efflux transporters expressed at the BBB belong to the ABC 
(ATP-binding cassette) superfamily and include P-glycoprotein (P-gp; ABCB1), breast cancer 
resistance protein (BCRP; ABCG2), and multidrug resistance proteins (MRP; ABCC family), 
in addition to the organic cation transporters (OCTs; SLC2s) and organic anion transporting 
polypeptides (OATPs; SLCOs) that also are present (Golden and Pollack 2003; Hagenbuch 
and Meier 2004).  A comprehensive overview of BBB (and BCSFB) uptake and efflux 
transporters is provided by Graff and Pollack (2004).  Ultimately, pharmacologic response of 
a CNS active agent is, in part, dictated by the relative balance achieved between passive and 
active uptake and efflux at the BBB. 
Initially identified in tumor cells with a multi-drug resistance phenotype, P-gp is a 
170-kDa, ATP-dependent membrane bound transport protein encoded by the multidrug 
resistance gene ABCB1 (formerly MDR1) in humans and mdr1a and mdr1b in rodents 
(Sharma, Inoue et al. 1992).  P-gp serves to attenuate intestinal absorption, secrete drugs into 
bile and urine, and protect sanctuary tissues such as the CNS and reproductive organs from 
toxic drug exposure (Matheny, Lamb et al. 2001).  The latter role, impeding the entry of 
potential toxins into a sanctuary site, is achieved by P-gp expression on the luminal surface 
of brain endothelial cells (Cordon-Cardo, O'Brien et al. 1989).  The role of active and passive 
transport at the BBB has received considerable attention, and a number of methods have been 
developed to identify substrates of P-gp efflux at the BBB. 
While the collection of blood and urine is relatively straightforward and can be 
repeated over time, characterizing CNS drug disposition is more challenging and often 
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requires invasive, labor-intensive, and costly approaches.  For this reason, in vitro systems 
such as cultured brain microvessel endothelial cells (BMECs) and transfected Madin-Darby 
canine kidney (MDCK) cells have been used as surrogate models to characterize BBB 
permeability and transporter-mediated efflux (Biegel, Spencer et al. 1995; Johnson and 
Anderson 1999; Letrent, Polli et al. 1999; Mahar Doan, Humphreys et al. 2002).  These 
systems can be used in coordination with chemical inhibitors or transfected cells to identify 
the role of P-gp and other BBB transporter proteins on brain penetration.  While these 
methods have proven useful, they differ from the intact BBB and exhibit increased 
paracellular permeability, leaky tight junctions and decreased transendothelial electrical 
resistance (TEER) compared to in vivo estimates (Wolburg, Neuhaus et al. 1994).  Recent 
techniques have attempted to improve in vitro methodology by co-culturing BMECs with 
astrocytes and with the use of specific cellular markers to verify BMEC composition. 
Nevertheless, in vivo studies provide more reliable and relevant results (Yamagata, Tagami et 
al. 1997; Yousif, Marie-Claire et al. 2007). 
Two strains of mice deficient in P-gp are commonly used to characterize the impact 
of P-gp efflux: the CF-1 strain, which possess a naturally occurring mutation in the mdr1a(-/-
) gene and the FVB strain, which serves as the platform for creating knockout mice deficient 
in both mdr1 isoforms expressed in brain, mdr1a and mdr1b (Schinkel, Wagenaar et al. 1996; 
Lankas, Cartwright et al. 1997; Schinkel, Mayer et al. 1997; Umbenhauer, Lankas et al. 
1997).  The collection of whole tissues from intact animals (Chen and Pollack 1998) or the 
use of in situ brain perfusion in P-gp-competent and P-gp-deficient mice (Dagenais, 
Rousselle et al. 2000) are frequently-used methods of determining net distribution across the 
BBB and initial brain uptake of compounds, respectively.  Other techniques, including brain 
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microdialysis and CSF sampling, have been utilized but are highly invasive and, in the case 
of microdialysis, limited to preclinical species.  An alternative, non-invasive technique that 
can be used in both humans and preclinical species is positron emission tomography (PET) 
(Hsiao, Sasongko et al. 2006; Hsiao, Bui et al. 2007).  However, the lack of metabolite 
specificity, the need for specialized facilities, and cost have limited the widespread adoption 
of this approach. 
Opioids: A model pharmacologic class with central nervous system activity 
The diversity in chemical structure, BBB penetration, physicochemical properties, 
potency and duration of effect, make opioids an ideal group of compounds for probing a 
multiplicity of phenomena that determine CNS pharmacokinetics and pharmacodynamics.  
This class of drugs is  well understood in preclinical and clinical settings, and extensive 
attention has been paid to elucidating the post-receptor binding signal transduction pathways 
that mediate analgesia and the undesirable effects of respiratory depression, decreased 
gastrointestinal motility, and tolerance development (Bailey and Connor 2005; Lotsch 2005).  
Moreover, pharmacologic effect is easily assessed over time by characterizing alterations in 
rate, frequency or time of response following exposure to a noxious stimulus (Le Bars, 
Gozariu et al. 2001).  Moreover, the different categories of noxious stimuli that can be used 
to assess antinociception has led to adoption of numerous assays.  While most opioids 
produce analgesia via opioid receptors in central locales, others (i.e., loperamide) do not 
cross the BBB readily and are devoid of centrally-mediated effects at therapeutic doses 
(Niemegeers, McGuire et al. 1979).  The use of knockout mice has been instrumental in 
assessing the role of P-gp in attenuating brain uptake and antinociception of loperamide, 
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methadone, DPDPE ([D-penicillamine(2,5)] enkephalin) (Chen and Pollack 1998; Thompson, 
Koszdin et al. 2000; Dagenais, Graff et al. 2004). 
Characterizing pharmacologic response of opioids 
Assessing pharmacologic effect can be particularly challenging because drugs can 
produce multiple responses, drug-receptor interactions in distinct compartments can mediate 
the same overt effect, and homeostatic mechanisms and counter-adaptations can influence 
observed response.  In addition, physiologic differences between preclinical species and 
humans often necessitate the use of different assay methodologies.  An obvious difference is 
the absence of verbal communication in animals that requires the investigator to interpret 
vocal and behavioral responses to a noxious stimulus (the hot plate latency assay, the paw 
pressure test, the tail flick assay, and electrical vocalization stimulation).  In contrast, opioid-
induced antinociception can be assessed in humans using verbal responses to a stimulus by 
referencing numerical- or image-based pain scales, through use of transcutaneous electrical 
stimuli, with pupillometry, or by the extent of respiratory depression (Le Bars, Gozariu et al. 
2001; Lotsch 2005).  While assay overlap between species exists in the form of 
electroencephalogram (EEG) power spectrum analysis, the most commonly-used animal 
assays monitor behavioral responses following exposure to a painful stimulus. 
A number of disadvantages, primarily related to the influence of ancillary physiologic 
processes, accompany the use of behavioral assays.  For example, thermal assays and 
pressure tests are nondiscriminatory in the activation of nociceptors and either 
thermoreceptors or low-threshold mechanoreceptors, respectively (Le Bars, Gozariu et al. 
2001).   Some drugs elicit motor incoordination that may delay response time following 
exposure to the noxious stimulus, leading to a potential underestimate of the EC50 for 
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antinociception. In these instances, parallel motor incoordination assays may be necessary 
(Parsons 2001).  One also must consider the influence of learning on performance in 
behavioral assays when a subject is repeatedly exposed to a noxious stimulus (Milne, Gamble 
et al. 1989).  Moreover, one common criticism of preclinical antinociceptive assays is the 
lack of clinically relevant, persistent pain states.  While this is an assay limitation, ethical 
considerations dictate the minimization of exposure to noxious stimuli, accomplished with 
stimulus removal upon observation of the desired response.  Overall, characterizing 
antinociception, particularly in preclinical settings, is challenging, and the experimenter must 
carefully consider and, to the extent possible, control for all processes that influence 
responsivity. 
PROJECT OVERVIEW 
Time-dependent dissociations between pharmacologic effect and drug concentration 
are a particularly challenging aspect of pharmacokinetic-pharmacodynamic data analysis and 
modeling.  While mathematical and experimental approaches have been developed to address 
such dissociations, they often are inadequate or require hypothetical constructs that limit their 
utility.  The goal of this dissertation project was to develop model-dependent and model-
independent methods of characterizing and quantitating the relationship between drug 
response and systemic drug exposure.  Consequently, this dissertation is divided into two 
sections.  Part I communicates the results of an experimentally-based approach to describe 
opioid pharmacokinetic-pharmacodynamic relationships and to improve predictions between 
in vitro, preclinical, and clinical predictions of potency.  Part II is based on the development 
of novel model-dependent and –independent approaches to characterizing the relationship 
between between response and concentration. 
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Opioids frequently are used to treat acute, severe, and chronic pain.  Repeat exposure 
results in the rapid development of tolerance to the analgesic effects but tolerance to the side 
effects develops less rapidly, often limiting dose increases.  A number of kinetic and dynamic 
alterations have been proposed as contributing to the onset of analgesic tolerance, and 
multiple PK-PD models have been developed to characterize the time-dependent decrease in 
response.  A comprehensive review of these mechanisms and the corresponding 
mathematical models used to describe opioid tolerance is provided in Chapter 2. 
The use of cell culture models of the BBB is a popular strategy in drug discovery to 
screen compounds for CNS penetration.  These in vitro models differ from whole organism 
studies of brain disposition in that they represent just one of multiple routes of central 
penetration, they lack the complex cytoarchitecture that comprises the BBB, and they exhibit 
greater cell permeability.  Preclinical in vivo studies are useful for predicting CNS disposition 
and response in humans, but differences in transporter and metabolism expression, blood 
flow and intrinsic potency can influence these observations.  In order to determine the best 
preclinical measure of CNS intrinsic potency, the relationship between either in vitro-to-
preclinical or preclinical-to-clinical potency and receptor binding affinity was evaluated 
using a series of seven opioids (Chapter 3).  The role of P-gp efflux in attenuating brain 
uptake and antinociception was assessed using a compound set consisting of four opioids 
(Chapters 4 and 5).  Loperamide, a known P-gp substrate, was used as a probe to identify 
potential differences in drug disposition and response between the two P-gp-deficient mouse 
strains, CF-1 [mdr1a(-/-)] and FVB [mdr1a(-/-) and mdr1b(-/-)] (Chapter 4). 
Preclinical models of antinociception often fail to predict opioid efficacy in humans.  
While humans are able to communicate degree of discomfort verbally, preclinical models of 
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nociception often rely on interpretation of behavioral responses to assess antinociception.  
The role of behavioral endpoint criteria in determining quantitative measures of 
antinociception with the hotplate latency assay was investigated and used in a novel approach 
to isolate central and peripheral nervous system contributions to overall observed 
antinociception (Chapter 6).  Another common problem associated with the hotplate latency 
assay is the imposition of an artificial effect ceiling resulting from a 60 sec cut-off exposure 
time.  Chapter 7 presents an alternative approach to modeling data where the value of Emax is 
truncated.     
Counterclockwise hysteresis loops represent time-dependent dissociations between 
pharmacologic effect and drug concentration.  Methods to collapse the hysteresis loop and 
recover relevant PD parameters such as EC50 and γ are well-established, but possess well-
understood deficiencies.  A key hypothesis underlying Part II of this dissertation project was 
that the size of the hysteresis loop may provide an additional, non-parametric parameter to 
describe the extent of temporal dissociation between concentration and effect.  A quantitative 
method to assess area bounded by the hysteresis loop was developed and used to characterize 
the influence of fundamental pharmacokinetic-pharmacodynamic parameters on hysteresis 
area (Chapter 8).  This approach was validated by quantifying the area of the opioid effect-
concentration hysteresis loops and relating the area bounded by the hysteresis to model-
derived parameters (Chapter 9). Finally, the results of this research effort are discussed in the 
context of the existing literature, and suggestions for a research agenda that will extend the 
present results are provided (Chapter 10). 
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Figure 1.1.  PK-PD model depicting a direct relationship between plasma drug concentration 
and pharmacologic response. 
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Figure 1.2.  Depiction of clockwise (A) and counterclockwise (B) hysteresis loops.  Arrows 
represent the progression of time. 
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Figure 1.3.  Time-dependent PK-PD models include (A) production of an active metabolite, 
(B) indirect pharmacologic response, and (C) drug distribution between plasma and effect 
compartment which mediates pharmacologic response. 
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CHAPTER 2 
OPIOID TOLERANCE DEVELOPMENT:  A PHARMACOKINETIC- 
PHARMACODYNAMIC PERSPECTIVE 
This chapter is an invited review that has been submitted for 
publication to The AAPS Journal and is presented in the style of that 
journal. 
 
ABSTRACT 
The opioids are commonly used to treat acute, severe, and chronic pain.  Long-term 
opioid administration eventually reaches a dose ceiling that is attributable to the rapid onset 
of analgesic tolerance coupled with the slow development of tolerance to the untoward side 
effects of respiratory depression, nausea and decreased gastrointestinal motility.  The need 
for effective-long term analgesia remains.  In order to develop new therapeutics and novel 
strategies for current use of current analgesics, the processes that mediate tolerance must be 
understood.  This review highlights potential pharmacokinetic (changes in metabolite 
production, metabolizing enzyme expression, and transporter function) and 
pharmacodynamic (receptor type, location and functionality; alterations in signaling 
pathways and cross-tolerance) aspects of opioid tolerance development, and presents several 
pharmacodynamic modeling strategies that have been used to characterize time-dependent 
attenuation of opioid analgesia. 
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INTRODUCTION 
Opioid analgesics are commonly used to treat acute, severe, and chronic pain 
associated with surgical interventions or disease states such as cancer.  Opioids produce a 
diverse spectrum of centrally- and peripherally-mediated responses, including respiratory 
depression, nausea, sedation, euphoria or dysphoria, decreased gastrointestinal motility, and 
itching (1).  Long-term use of opioids can be problematic due to the rapid development of 
profound tolerance to the analgesic effects coupled with slow development of tolerance to 
many of the untoward effects of these agents.  It is the inability to tolerate these undesirable 
side effects that eventually limits dose escalations and analgesic efficacy.  
The World Health Organization (WHO) has recommended adoption of a three-step 
“analgesic ladder” to meet the therapeutic challenges presented by opioid tolerance.  In this 
approach, analgesic therapy is initiated with a non-opioid analgesic co-administered, if 
necessary, with an adjuvant. As the underlying condition progresses and pain becomes more 
intractable, a weak opioid is substituted for the non-opioid.  Eventually, a strong opioid is 
introduced as a final step (2).  While these recommendations are designed to improve quality 
of life for chronic pain sufferers, the underlying problem of opioid tolerance persists, and the 
clear and compelling need for effective long-term analgesics, or for effective strategies for 
applying existing analgesics to control chronic pain, remains.  This goal may be achieved 
through the specific design and development of new agents that are not subject to tolerance 
development, or through the use of adjunct treatments that can minimize or reverse tolerance. 
In either case, a comprehensive understanding of the mechanisms underlying tolerance, as 
well as the kinetics of tolerance development and regeneration of responsivity, is required. 
The purpose of this paper is to review the pharmacokinetic and pharmacodynamic 
mechanisms involved in the development of opioid tolerance.  Pharmacokinetic 
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considerations such as the production of metabolites, alterations in metabolic enzyme 
activity, and modulation of drug transporter expression or function are addressed.  
Pharmacodynamic processes such as receptor binding type and location, alterations in signal 
transduction, and cross-tolerance also are considered.  Finally, approaches to comprehensive 
pharmacokinetic and pharmacodynamic (PK-PD) modeling of opioid antinociception and 
tolerance development are discussed. 
ETIOLOGY OF TOLERANCE 
Tolerance is defined as a decrease in pharmacologic response following repeated or 
prolonged drug administration.  Tolerance can be separated into two main classifications: 
innate or acquired.  Innate tolerance is a predisposition to exhibit drug sensitivity or 
insensitivity due to pharmacogenetic makeup.  In most situations, innate tolerance is 
determined upon administration of the initial dose.  In contrast, acquired tolerance is a 
consequence of repeated drug exposure, and can be subdivided into three general types based 
on the prevailing mechanism: pharmacokinetic, pharmacodynamic, or learned.  
Pharmacokinetic tolerance occurs when drug disposition or metabolism is altered as a 
function of time, often a consequence of the drug being an inducer or inhibitor of a specific 
metabolic enzyme or transporter system, resulting in a time-dependent decrease in 
presentation of the active moiety to the receptor biophase.  Pharmacodynamic tolerance 
occurs when the intrinsic responsivity of the receptor system diminishes over time. 
Acute tolerance is mediated predominantly by pharmacodynamic mechanisms, 
manifested as a decreased response following a single administration of the agent or during 
repeat-dosing but over a short time frame.  This phenomenon is exemplified by nasally-
administered cocaine. Initially, the relationship between cocaine-associated euphoria and 
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blood cocaine concentrations is proportionate. However, at later points in time, the euphoric 
response decreases despite continued, or even increased, circulating concentration (3).  In 
contrast to acute tolerance, chronic tolerance can be mediated through either pharmacokinetic 
or pharmacodynamic mechanisms, with an end result of a long-term decrease in drug 
response in the face of constant systemic exposure.  In cases in which chronic tolerance 
develops, cross-tolerance within the pharmacologic class also may occur. Replacing the 
initial drug with a comparable agent will result in a lower pharmacologic response compared 
to that experienced by a drug-naive individual.  Cross-tolerance is the principle underlying 
methadone substitution in the treatment of heroin addicts. Although methadone produces 
opioid effects in heroin-addicted subjects, euphoria and side effects are minimized by the 
tolerance produced by long-term heroin exposure.  The significance of pharmacokinetic and 
pharmacodynamic mechanisms in relation to tolerance development will be examined in 
depth in subsequent sections of this review. 
The final class of acquired tolerance is attributed to learning, either behavioral or 
conditioned.  Behavioral tolerance occurs when an individual learns to function despite 
repeat exposure to a drug. Chronic alcohol abusers, for example, may not exhibit an outward 
appearance of motor impairment as a consequence of intoxication because of learned motor 
function adaptations and awareness of their impairment.  Conditioned tolerance follows 
“Pavlovian” principles in which situational cues are associated with drug administration. 
Removal of these environmental cues will result in an enhancement in pharmacologic effect.  
For example, when morphine-tolerant rats are placed in a novel environment and challenged 
with morphine, antinociceptive tolerance is reduced (4). Analysis of behavioral tolerance has 
been reviewed in detail elsewhere (5). 
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MORPHINE AND RELATED AGONISTS 
The medicinal value of opium has been acknowledged for centuries.  Despite 
possessing an extensive side-effect profile, morphine, isolated from opium more than 200 
years ago, remains the gold standard for treating pain.  Structurally similar, semisynthetic 
morphine-like derivatives as well as structurally distinct opioids have been synthesized in a 
search for compounds that improve analgesia and minimize side effects.  The common, 
clinically-used opioid analgesics are semisynthetic morphine derivatives, as well as synthetic 
phenylpiperidine, anilidopiperidine, and diphenylpropylamine derivatives (Table 2.1).  Due 
to the structural similarities between these drugs and morphine, they primarily bind to the 
same receptor subtypes (μ-opioid receptors), produce analgesia, and exhibit similar side 
effect profiles.  However, divergence in congener pharmacokinetic-pharmacodynamic 
parameter values allows the clinician to select a drug based on specific patient needs (1).  For 
example, an ideal drug for a short surgical procedure would have rapid onset and offset of 
effect, such as the piperidine derivative alfentanil.  Overall, opioid selection depends on a 
number of factors, including the nature of pain, predisposition to opioid responsivity, and 
previous opioid exposure. 
PHARMACOKINETIC MEDIATORS OF OPIOID TOLERANCE 
Receptor occupancy theory holds that pharmacologic response will be proportional to 
the fraction of the target receptor population that is occupied at a particular drug 
concentration (6).  As the drug concentration in the vicinity of the receptor increases, the 
likelihood of drug binding to the receptor and producing an effect also increases.  Gibaldi and 
Levy (7) applied this principle in describing the sigmoidal relationship between tubocurarine-
mediated paralysis and dose or blood concentration.  For this simplest of pharmacodynamic 
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systems, drug concentrations in the receptor biophase must be in immediate equilibrium with 
concentrations in blood, and response must be instantaneous, reversible and time-
independent.  However, the relationship between the magnitude or time course of drug 
response and the kinetics of drug disposition generally is more complex, evidenced by time-
dependent dissociations between pharmacologic response and systemic pharmacokinetics.  A 
variety of factors, including slow equilibration of drug between the target receptor and blood 
or slowly-elaborated pharmacologic responses post-receptor binding, can cause such kinetic-
dynamic dissociation.  However, a particularly complicated underlying factor is the 
development of tolerance. 
Metabolic and Distributional Mediators of Tolerance 
One source of the extensive variability in drug concentrations, and consequently, 
response, within a population can be attributed to differences in drug absorption, distribution 
and metabolism.  The opioids undergo significant Phase I and II biotransformation, and 
polymorphisms in the cytochrome P450s (CYPs) and uridine-5’-diphosphate-
glucuronosyltranserases (UGTs) will influence individual opioid disposition and response.  
For example, depending on the allelic combinations of the highly polymorphic CYP2D6, 
patients are characterized as one of four phenotypes: poor, intermediate, extensive and 
ultrarapid metabolizers (8). Subjects who exhibit the poor-metabolizer phenotype will not 
convert codeine to morphine efficiently, and therefore will exhibit a reduced effect compared 
to patients who can form morphine (9).  In addition to the important role these enzymes play 
in mediating opioid concentrations and responses, it has been suggested that 
biotransformation processes contribute to morphine tolerance secondary to induced 
enzymatic expression (10, 11).  However, there is a lack of evidence to support this 
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observation, as long-term administration of methadone or morphine does not alter the parent 
drug to metabolite concentration ratios, indicating that autoinduction is unlikely (12, 13).  
Ultimately, metabolite formation could influence tolerance development through 
pharmacodynamic mechanisms, but there is a lack of evidence supporting time-dependent 
changes in the formation clearance of opioid metabolites. 
In addition to metabolism, drug transport can play a significant role in mediating drug 
exposure at the target site, and therefore the time course and magnitude of pharmacologic 
response.  Many of the common opioids are substrates of the efflux transporter P-
glycoprotein (P-gp), an ATP-dependant, 170-kDa transmembrane protein encoded by the 
MDR1 (human) and mdr1a/mdr1b (rodent) genes (14).  P-gp is expressed in a number of 
tissues in which it plays a protective role as a barrier transporter, limiting absorption from the 
intestines or penetration into organs such as testes or brain, as well as an excretory transport 
system in the kidney and liver (15).  P-gp also functions to modulate the secretion of 
centrally synthesized opioid peptides and neurotransmitters from the brain to the systemic 
circulation (16). 
Studies with P-gp-deficient mice have revealed that P-gp-mediated efflux attenuates 
the brain-to-serum ratio (Kp,brain) and antinociceptive effect of fentanyl, methadone and 
loperamide by ~2-, 7-, and 45-fold, respectively (17).  Considering the extent to which P-gp 
mediates transport of some opioids, upregulation of this barrier transporter could further limit 
CNS penetration and antinociceptive effects of some opioids.  Indeed, exposing transgenic 
mice expressing human pregnane X receptor (hPXR) to rifampin, an acute P-gp inhibitor and 
long-term P-gp inducer, upregulated expression of P-gp in brain capillary endothelium and 
attenuated the antinociceptive effect of the P-gp substrate methadone by 70% (18).  Based on 
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the results of this study, if an opioid is both a substrate and inducer of P-gp, chronic 
treatment could result in higher blood brain barrier (BBB) P-gp expression, with a 
consequent decrease in CNS penetration and antinociception (i.e., pharmacokinetic 
tolerance).  Although autoinduction of BBB P-gp remains a possible mechanism underlying 
opioid tolerance, increases in P-gp expression following chronic treatment with morphine 
and oxycodone appear to be modest (2- and 1.3-fold, respectively; (19, 20).  This minor 
increase in expression (≤ 2-fold) coupled with a negligible alteration in function (a 1.4-fold 
reduction in paclitaxel brain distribution) suggests that opioid-mediated P-gp upregulation, at 
least in experimental animals, does not influence opioid antinociceptive tolerance to an 
extent that can be distinguished from population PK-PD variability (19). 
Metabolite Contributions to Opioid Response and Tolerance 
Tolerance also may result from the production of metabolites that accumulate in the 
systemic circulation over time, penetrate the site of action, and interfere with pharmacologic 
response whether by competing with the parent compound for receptor binding (e.g., 
antagonists or partial agonists) or by down-regulating the responsivity of the receptor system 
or downstream events.  The contribution of derived metabolites to morphine 
pharmacodynamics has received significant attention. In humans, morphine is metabolized in 
the liver by UGT2B7 to form morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G).  Although morphine is metabolized preferentially to M3G (~5:1 M3G to M6G 
formation ratio), this metabolite does not contribute to antinociceptive response. In contrast, 
M6G is considered to be an unusual Phase II metabolite in that it is biologically active, and in 
fact appears to be somewhat more potent (2- to 4-fold) than morphine (21). 
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Some studies have suggested that, rather than contributing to antinociception, M3G 
attenuates the response to morphine. In this scenario, time-dependent M3G accumulation 
could be responsible for the appearance of morphine tolerance. For example, Smith and 
Smith (22) observed an inverse relationship between morphine-associated antinociception 
and M3G concentrations.  However, careful examination of the influence of M3G 
pretreatment on morphine antinociception in rats revealed that acute M3G exposure, at 
concentrations similar to those produced by pharmacologically-relevant doses of morphine, 
does not attenuate antinociception to a significant extent (23, 24).  In contrast, M3G 
concentrations that are far in excess of those produced by pharmacologic doses of the parent 
drug can evoke neuroexcitatory behavioral responses that oppose the analgesic effects 
mediated by morphine binding to opioid receptors. Such neuroexcitation would account for 
the observed M3G-associated decrease in morphine-related antinociception (25).  These 
excitatory responses are independent of the opioid receptor system, as evidenced by the 
absence of naloxone reversibility, and may be mediated through interactions at the N-methyl-
D-aspartate (NMDA) and the γ-amino-butryic acid (GABAA) receptors (25, 26).  Overall, it 
appears that M3G may influence antinociception and tolerance, although through a 
mechanism other than μ-opioid receptor (MOR)-mediated interactions, and it is unlikely that 
accumulation of this metabolite formed from morphine contributes substantially to the 
development of functional morphine tolerance. 
PHARMACODYNAMIC MEDIATORS OF OPIOID TOLERANCE 
While inherent inter-individual pharmacokinetic variability can influence analgesia 
within a population, time-dependent changes in systemic disposition appear to play a 
minimal role in the development of opioid tolerance.  In contrast, a number of 
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pharmacodynamic processes have been characterized as potential mediators of opioid 
tolerance.  These adaptations include, but are not exclusively limited to, genetic 
predisposition, receptor subtypes, cross-tolerance, receptor affinity, alterations in secondary 
mediators such as the nitric oxide synthase pathway and transcription alterations, and 
receptor binding in the central versus the peripheral nervous system. 
Mu Opioid Receptor-Mediated Changes 
The biologic effects that are characteristic of opioids are a consequence of agonist 
binding to opioid receptors with subsequent alterations in signal transduction and ion 
conductance that reduce neuronal pain transmission.  The three major mammalian types of 
opioid receptors (OR) are designated µ, δ, and κ (27-29). Pharmacologic studies with opioid 
receptor ligands and receptor knockout mice identified the µ-opioid receptor (MOR) as the 
primary mediator of both the therapeutic and side effects associated with opioids such as 
morphine (30-32).  The role of the δ- and κ-opioid receptors in mediating analgesia and 
tolerance will be discussed more thoroughly in subsequent sections of this review. 
The MOR is a seven-transmembrane protein belonging to the G-protein coupled 
receptor (GPCR) superfamily.  Binding of an agonist to the MOR results in the replacement 
of the α-subunit GDP with GTP and the subsequent dissociation of the α- and βγ-subunits 
from the Gαβγ heterotrimer (33, 34).  These mechanisms result in acute inhibition of 
neuronal transmission due to alterations in the conductance of ion channels (Na+, K+, Ca2+), 
the stimulation of protein kinase A (PKA), and the transient inhibition of the adenylyl 
cyclase (AC) pathway (35).  Chronic opioid use enhances the cAMP pathway via the 
superactivation of AC, alterations in ion channel conductance, an increase in 
neurotransmitter release, and altered gene expression through changes in cAMP-responsive 
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element binding protein (CREB) phosphorylation and expression (36, 37).  Overall, 
antinociception is mediated through a complex sequence of downstream effectors, which can 
differ following acute versus chronic opioid exposure. 
In addition to alterations in signaling, opioid tolerance is associated with decreases in 
opioid receptor sensitivity and expression in the plasma membrane.  Following receptor 
binding of some, but not all (e.g., morphine), opioids, the MOR is phosphorylated by G-
protein receptor kinase (GRKs), with opioid efficacy related to the extent of phosphorylation 
(38, 39).  Receptor phosphorylation is the first step in the desensitization and internalization 
of the MOR, and precedes association of β-arrestin to the receptor complex, which uncouples 
the receptor from G proteins. This uncoupling event desensitizes the receptor and attenuates 
the second messenger signal cascade, reducing agonist efficacy (40).  The role of β-arrestin 
in receptor desensitization was characterized in β-arrestin KO mice that exhibited enhanced 
and prolonged analgesia with a lack of antinociceptive tolerance (41, 42).  β-arrestin also can 
modulate tolerance by recruiting adaptor proteins that link the receptor complex to clathrin, 
resulting in endocytosis in clathrin-coated pits.  Following internalization, the receptor is 
retained and recycled to the plasma membrane as a resensitized receptor or, upon recognition 
of an interaction with the GPCR-associated sorting protein (GASP), the receptor will be sent 
to the lysosome for degradation (33, 43).  Agonist binding therefore results in diverse cellular 
adaptations that mediate antinociception and onset of tolerance. 
The mechanisms underlying morphine tolerance appear to be different from those of 
other opioid agonists. Despite significant and prolonged efforts directed towards 
understanding morphine tolerance, the specific pathway has remained obscure.  In contrast to 
most opioids, morphine-receptor binding does not initiate GRK-mediated MOR 
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phosphorylation that results in receptor internalization (40).  This observation is further 
supported by the absence of increased membrane internalization protein expression (e.g. β-
arrestin and GRK) that accompanies most opioids (44).  Even in the absence of receptor 
internalization, the interaction between the morphine-bound receptor and β-arrestin persists, 
evidenced by a reduction in tolerance in β-arrestin KO mice, suggesting that morphine 
induces tolerance by sustaining signaling pathways and cellular adaptations such as AC 
superactivation (41, 45).  An alternative explanation for the reduction in morphine tolerance 
observed in β-arrestin KO mice is that, although it is not an internalizing opioid, morphine 
binds to MORs that exist as heterodimers, with the second OR subtype interacting with β-
arrestin and the subsequent internalization of the morphine-heterodimer complex (46, 47).  
However, the validity of this hypothesis appears unlikely, as the results were not 
reproducible in later experiments and depended on the co-administration of morphine with an 
internalizing opioid for dimer endocytosis, and chronic morphine exposure does not change 
MOR expression (46, 48, 49). 
Another contributor to morphine tolerance is the slow recovery of resensitized MORs 
because morphine desensitized receptors do not participate in the traditional pathway of 
internalization, recycling and reinsertion into the plasma membrane (50).  Ultimately, the 
specific molecular mechanisms governing morphine tolerance have not been fully elucidated, 
and the possibility that mechanisms of morphine tolerance vary depending on the specific 
brain and spinal cord region requires further investigation (51). 
MOR Receptor Polymorphisms 
Analgesic variability within a population can, in part, be attributed to opioid 
pharmacogenetics.  The human MOR has over 100 identified single nucleotide 
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polymorphisms (SNPs), some of which are thought to influence opioid responsiveness, abuse 
potential, and tolerance (52, 53).  Of these SNPs, the most well-characterized is the A118G 
nucleotide substitution, which changes the amino-acid sequence at position 40 from 
asparginine to aspartic acid, eliminating an extracellular N-linked glycosylation site (54, 55).  
Clinically, this variant reduces the analgesic effects of alfentanil and M6G (56, 57).  These 
alterations are not likely a consequence of altered binding affinity, as in vitro studies 
demonstrated that the N40D substitution did not affect binding of the exogenous opioids 
morphine, fentanyl, or methadone, nor that of the endogenous opioids Met- and Leu-
enkephalin, endomorphin-1 and-2 and D-Ala2, N-methyl-Phe4, Glycol5]enkephalin 
(DAMGO) (54).  Although this study demonstrated a 3-fold increase in binding affinity of 
the endogenous opioid peptide β-endorphine, subsequent studies did not detect any difference 
in β-endorphine binding, or receptor endocytosis, desensitization or resensitization in the 
N40D substitution (54, 58, 59).  Additional work on human MOR polymorphisms 
characterized amino acid substitutions of N15D, R265H, and S268P. The latter substitution, 
located in the intracellular domain, exhibited a significant loss of receptor signaling (58).  
The human MOR intracellular loop polymorphisms reduced the extent of MOR-calcium 
calmodulin CaM interactions (R265H and S268P) and the R260H and R265H variants 
exhibited a reduction in basal MOR signaling (60). 
Despite these detailed studies, the relationship between MOR polymorphisms and 
binding affinity, signaling pathways and ion channel conductance is not entirely clear.  These 
alterations may, in part, mediate differential development of opioid tolerance within a 
population.  For example, individuals expressing the N40D variant exhibit decreased 
analgesia, and may require larger opioid doses to achieve equipotent pain relief. It is 
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conceivable that this dose differential could influence the development of tolerance in these 
subjects compared to normal MOR expressers.  Research focused on MOR polymorphisms is 
continuing, and should shed light on the specific physiologic implications of these variants, 
including opioid responsivity and tolerance development. 
Multiple Opioid Receptors 
While less is known about the specific roles of the two remaining ORs, δ and κ, these 
proteins are expressed throughout the body and mediate antinociception, although to a lesser 
extent than the MOR (61-64).  The κ-opioid receptor (KOR) exhibits tolerance following 
prolonged opioid exposure, a consequence of GRK-mediated phosphorylation of the KOR 
that initiates receptor internalization (65, 66).  While dephosphorylation is the typical 
mechanism of recovering receptor sensitivity, the KOR appears to require regeneration and 
reassembly of the receptor complex for restoration of antinociception (67).  The net effect of 
these processes is a reduction in KOR expression that results in a decreased pharmacologic 
response following long-term opioid exposure.  Similar to the KOR, the δ-opioid receptor 
(DOR) manifests tolerance to specific DOR-agonists via receptor phosphorylation and 
internalization (68, 69).  Despite receiving less attention than the MOR, opioid binding to the 
DOR and KOR also can result in antinociception and tolerance. 
Cross-tolerance 
Long-term exposure to one drug often results in the development of tolerance to the 
effects of other structurally similar drugs in the same pharmacologic class. This phenomenon 
is termed cross-tolerance.  Although opioids frequently exhibit cross-tolerance, it is rarely 
complete, as evidenced by the utility of opioid rotation from morphine to hydromorphone or 
oxycodone, particularly in treatment of cancer pain (70, 71).  However, complete cross 
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tolerance can develop, as evidenced by the lack of analgesia elicited by high-dose morphine 
in patients receiving methadone maintenance therapy (72).  The more common scenario of 
incomplete cross tolerance has been attributed to multiple pharmacologic mechanisms.  This 
preservation of effect may be a function of the inverse relationship between intrinsic opioid 
efficacy and tolerance, as well as that in situations of tolerance, replacing a low efficacy 
opioid such as morphine with fentanyl, a high-efficacy opioid with a high receptor reserve, 
will enhance analgesia (73, 74).  Furthermore, multiplicity in MOR subtypes may play an 
important role in determining the magnitude of cross-tolerance. For example, when one 
opioid is substituted for another, the secondary opioid may bind to a different receptor 
subtype than the initial compound, thereby limiting the apparent extent of cross-tolerance 
(75).  Alternatively, incomplete cross tolerance may be attributed to the ability of the opioid 
receptors to homo- and heterodimerize.  For example, substituting an initial opioid with an 
agonist that binds to a different dimer combination can result in the recovery of analgesia 
because of incomplete tolerance to the new opioid-receptor combination.  (47, 76).  Further 
investigation of the interplay between opioid receptors likely will reveal novel mechanisms 
that mediate antinociception and contribute to opioid tolerance. Clinically, opioid cross-
tolerance presents a challenge when a patient switches to a new opioid regimen. Despite this 
possibility, the lack of complete tolerance generally results in a reduction in pain and fewer 
side effects compared to the initial, tolerant regimen. 
NMDA Receptor Contributions to Opioid Tolerance 
In addition to the direct actions of opioids, neurotransmitters such as dopamine, 
serotonin and glutamine have been implicated as mediators of opioid tolerance and 
antinociception (77-79).  Of particular interest is the NMDA-sensitive glutamate receptor. 
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The intertwined relationship between the MOR and NMDA receptor systems is in part 
attributed to co-localization in central tissues (80, 81).  Mg2+ is bound to the receptor channel 
of the NMDA receptor under normal physiologic conditions, and serves to block the entrance 
of ions such as Ca2+ (Fig. 2.1). Small changes in synaptic cleft concentrations of glutamate 
and inorganic ions can temporarily displace Mg2+ and allow an influx of Ca2+, which will 
bind to and activate the neuronal nitric oxide synthase (nNOS), CaM and PSD-95 complex, 
which converts L-arginine (L-arg) to L-citrulline (L-Cit) and nitric oxide (82, 83). Finally, 
NO mediates the conversion of GTP to cGMP, a mediator of tolerance, via soluble guanylyl 
cyclase (sGC). Chronic opioid exposure enhances NMDA receptor function by increasing 
intracellular Ca2+, NO and cGMP levels, which contribute to the development of opioid 
tolerance.  The use of NMDA receptor antagonists or inhibitors of NOS production from L-
arginine to enhance antinociception and delay the onset of tolerance has proven effective 
(82). Of these approaches, the use of NMDA receptor antagonists has shown preclinical and 
clinical potential in minimizing opioid tolerance. The potential role of NOS in determining 
the time course and magnitude of opioid tolerance is considered in detail in the final section 
of this review. 
Initially viewed as a “miracle” drug class, the clinical use of NMDA receptor 
antagonists has yet to be fully realized.  NMDA receptor antagonists are particularly 
promising drug targets due to a number of modulatory sites with different structural subunit 
combinations, most commonly the NR1 subunit combined with NR2A-D or NR3A-B 
subunits (84, 85).  These modulatory sites result in four general classes of NMDA receptor 
antagonists: the uncompetitive receptor channel blockers (MK-801, ketamine, PCP, 
memantine), the competitive glutamate antagonists (LY235959, D-CPPene), the glycine site 
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antagonists [(+)(R)-HA-966], and the polyamine site antagonists (86).  Preclinical and 
clinical models have been used to demonstrate that NMDA receptor antagonists can attenuate 
tolerance development and enhance antinociception, the latter effect allowing decreases in 
dose which may delay tolerance onset (87). 
The majority of studies characterized the NMDA receptor antagonists as enhancing or 
having no effect on analgesia, whereas a minority demonstrated attenuation of acute 
morphine analgesia (88-93).  One challenge in this area is the absence of consistent results 
identifying which opioids exhibit NMDA receptor antagonist-enhanced antinociception.  For 
example, Redwine and Trujillo (94) found that morphine analgesia was enhanced only when 
co-administered with LY235959 (3 mg/kg); fentanyl analgesia was enhanced in the presence 
of LY235959 (3 mg/kg), dextromethorphan (30 mg/kg) and (+)(R)-HA-966 (30 mg/kg); and 
no difference was observed for morphine or fentanyl when co-administered with MK-801 
(0.1 and 0.3 mg/kg), memantine (3 and 10 mg/kg), or ifendopril (1 and 3 mg/kg).  Additional 
work clearly is needed to identify the specific interactions between each opioid and NMDA 
receptor antagonist.  For example, NMDA receptor antagonist pharmacokinetics are poorly 
characterized. However, it is clear that they are capable of penetrating central tissues, 
evidenced by the appearance of centrally-mediated side effects such as hallucinations, 
memory impairment, blood pressure elevation, catatonia and anesthesia (95).  NMDA 
receptor antagonists of greater selectivity and lower affinity were developed in response to 
these undesirable central effects, and promising alternatives may include the use of low 
affinity channel blockers (e.g., memantine), NR2B subunit selective drugs (ifendopril), or the 
partial glycine site antagonists (96).  Based on these varied observations, further 
characterization of the underlying pharmacologic mechanisms and 
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pharmacokinetic/pharmacodynamic relationships between the opioids and NRAs remains to 
be elucidated. 
The Role of Peripheral Opioid and NMDA Receptors in Mediating Antinociception 
While NMDA receptor antagonists may represent a feasible approach to delay the 
onset and attenuate the extent of tolerance, these compounds manifest intolerable central side 
effects that limit use.  One alternative strategy that may prove effective in treating pain is 
targeting non-centrally located NMDA receptors and/or ORs to achieve antinociception 
while minimizing centrally-mediated side effects and, potentially, the development of 
tolerance.  The feasibility of this approach is, in part, supported by the broad peripheral 
distribution of these receptors. For example, MORs are present in a number of peripheral 
tissues, including the small and large intestines, kidney, lung, spleen, testis, ovaries and 
uterus (97).  While these sites are important in mediating a number of physiologic processes, 
molecular and functional studies suggest that MORs and NMDA receptors localized on 
unmyelinated, cutaneous sensory axons contribute to antinociception (98). Moreover, the 
density of ORs and NMDA receptors on peripheral sensory axons increases in conditions of 
inflammation, suggesting a role in mediating pain perception (99, 100).  Overall, the 
physiologic distribution of the ORs and NMDA receptors suggests a role in mediating 
peripheral antinociception. 
The functionality of peripheral ORs was demonstrated when a systemically inactive, 
subcutaneous dose of morphine into the rat tail exhibited naloxone-reversible antinociception 
(101, 102).  Additional studies identified the ability of locally-administered morphine and 
loperamide to mediate antinociception in a radiant heat tail-flick assay and in an 
inflammatory model, respectively (103).  Furthermore, repeated immersion of the tail in 
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opioid-containing DMSO solutions resulted in local antinociception and tolerance 
development, the latter being reversible following topical or systemic administration of the 
NMDA receptor antagonist MK-801 (104-106).  These results suggest that peripherally-
restricted opioids contribute to antinociception and tolerance, which may be minimized by 
co-administration with non-centrally penetrating NMDA receptor antagonists. 
PHARMACOKINETIC-PHARMACODYNAMIC MODELS OF OPIOID TOLERANCE 
“Black-Box” Approach 
Although it is clear that complex cellular, mechanistic and homeostatic alterations 
contribute to tolerance development, PK-PD models, including those that incorporate 
tolerance as a time-dependent loss of intrinsic activity, often utilize a black-box approach that 
accounts for changes in the response-concentration relationship over time rather than 
incorporating specific biologic mechanisms that serve to drive the development of tolerance.  
Such empirical models tend to exhibit a broad applicability, are useful in characterizing and 
summarizing the temporal aspects of loss of drug response, and can be used to describe 
numerous tolerance scenarios (107).  One such model developed by Porchet et al. (108) 
characterized acute tolerance to the cardioaccelerating effects of nicotine by integrating a 
hypothetical noncompetitive antagonist formed by a first-order process, with nicotine 
concentrations serving as the driving force for formation.  Furthermore, optimal recovery 
from acute nicotine tolerance corresponded with longer intervals between nicotine exposure 
(108). 
The generic approach to modeling tolerance development, which included 
consideration of the relationship between the development of opioid tolerance and 
administration strategy, was utilized by Ouellet and Pollack (109) for two morphine 
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treatment regimens:  multiple increasing i.v. bolus doses over a 12-hr period (24 mg/kg total 
exposure in 7 doses) or one i.v. bolus dose per day (beginning with 1.85 mg/kg on day 1, and 
increasing to 6 mg/kg maximum) for 13 days. The hypothesis underlying this experimental 
design was that tolerance development would be attenuated in the once-daily administration 
group if the kinetics of tolerance offset were rapid (i.e., if significant return to basal 
responsivity occurred within 24 hr after morphine exposure). Morphine disposition did not 
differ significantly between the 12-hr and 13-day treatment groups, indicating that changes in 
systemic morphine disposition could not account for tolerance development. Concentration-
normalized peak analgesic effects remained relatively constant over 12 hr, while the 13-day 
treatment group exhibited a decrease in normalized peak effect from day 1 to 8.  In addition, 
the extent of analgesic tolerance development was similar whether morphine was 
administered as a multiple i.v. bolus or constant infusion. Taken together, these observations 
suggested that morphine tolerance development was dependent on systemic drug 
concentrations (i.e., the extent of exposure), but was independent of the kinetics of morphine 
administration (i.e., the rate of morphine exposure or the presence of relatively brief “drug 
holidays” in the administration regimen). 
The apparent independence of the rate or extent of tolerance development and the 
kinetics of drug administration was an unexpected observation, as conventional wisdom 
suggested that continuous presentation of opioids such as morphine would result in the 
production of profound tolerance. An explanation for this observation was formulated 
through comprehensive PK-PD modeling of morphine concentration-time and 
antinociceptive effect-time data obtained from rats during and following continuous 
morphine infusion (109). In this experiment, morphine was infused for 12 hr at several 
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different rates to achieve one of five preselected steady-state concentrations. Blood morphine 
concentrations and antinociceptive response (tail flick) were determined at timed intervals 
during infusion. Separate groups of rats were studied for 18 days after termination of a 12-hr 
morphine infusion, with pharmacologic response compared to that produced 15 min after a 
single intravenous bolus dose (presumably representing a “no-tolerance” state. The data were 
fit with a tolerance model similar to that displayed schematically in Figure 2.2. This model 
assumed accumulation of a hypothetical “inhibitor” that was formed from morphine by a 
first-order process; several different “inhibitor” scenarios (reverse agonist, competitive 
antagonist, non-competitive antagonist, or partial agonist) were evaluated, with the net effect 
(E) produced under each scenario shown in Equations 2.1-4, respectively: 
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(Equation 2.4) 
The results of this study indicated that morphine tolerance development was 
dependent on both morphine concentration and the duration of morphine exposure. As 
morphine concentrations increased, the net change in antinociceptive response (peak effect 
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minus effect at 12 hr) increased; regardless of the steady-state concentration produced, 
antinociceptive responses at 12 hr were similar, resulting in a truncated effect versus 
concentration relationship at 12 hr (Figure 2.3).  The PK-PD model was capable of 
describing the time course of loss (Figure 2.4) and return (Figure 2.5) of pharmacologic 
effect. When the loss-of-response data were fit alone, it was not possible to distinguish 
between the four alternative “inhibitor” scenarios. However, the return-of-response data 
suggested that the kinetics of morphine tolerance behaved as if driven by a partial agonist 
with a very low intrinsic activity (<10% of the maximum response to morphine) and a high 
affinity (IC50 ~ 14 ng/ml). In addition, the combined data set allowed estimation of the rate 
constant associated with tolerance offset (~0.12 day-1), which corresponded to a half-life of 
5.7 days. 
This modeling effort revealed the explanation, if not the underlying mechanism, for 
the apparent independence between the kinetics of tolerance development and the kinetics of 
morphine administration, a situation starkly different from that for nicotine. In fully-tolerant 
animals, a “drug holiday” of nearly six days would be required in order to regenerate 50% of 
the intrinsic responsivity to morphine lost during the development of tolerance. In contrast, 
the half-life associated with return of responsivity to nicotine (35 min) is consistent with 
nearly complete recovery and resensitization when doses are separated by 3 or more hours 
(108, 109).    
As these examples demonstrate, “black-box” modeling of tolerance can provide 
useful information regarding system dynamics, are capable of describing the loss or return of 
pharmacologic effect over time, and can predict responsiveness under differing 
administration scenarios. By their very nature these models have a limited ability to reflect 
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the specific mechanisms underlying tolerance development in a given system. However, 
when used appropriately, such modeling efforts can direct further mechanistic 
experimentation. Subsequent elaboration of mechanistic detail then can be used to inform the 
PK-PD model of tolerance, which in turn provides additional understanding of system 
dynamics and an increased capacity to predict system response under differing conditions. 
An example of this iterative approach to modeling opioid tolerance is provided in the next 
section of this review.  
Mechanistic Approach 
When the specific physiologic alterations that lead to time-dependent loss of 
pharmacologic effect are known, they can be incorporated into mechanistic PK-PD models.  
As discussed earlier in this review, chronic opioid exposure enhances NMDA receptor 
function thereby permitting greater Ca2+ influx; Ca2+ will attach to and activate the NOS 
complex that mediates the conversion of L-Arg to NO.  One method of limiting NO 
production is to coadminister an opioid with an NMDA antagonist or a NOS inhibitor (85, 
87, 110).  Furthermore, coadministering exogenous L-Arg with an opioid increased NO 
levels and attenuated antinociception (84, 111, 112). These observations suggested an 
important, and perhaps causative, role of NO in the induction of opioid tolerance. 
The significance of NO in mediating the time dependent loss of morphine-associated 
antinociception was elaborated in a series of experiments by Heinzen and coworkers.  
Following long-term morphine administration, the extent of antinociceptive tolerance that 
developed in mice deficient in  neuronal nitric oxide synthase (nNOS) was significantly less 
than that in wild-type mice (30% versus 80% loss of effect, respectively) (113). In rats, 
infusion of the NO precursor L-arg increased the concentration of NO in brain tissue and 
 44 
decreased the intrinsic antinociceptive activity of morphine (114-116).  An integrated PK-PD 
model was developed (Figure 2.6) that was capable of describing the time course of changes 
in brain NO in response to L-arg infusion (Figure 2.7). This model required inclusion of 
circadian control of NO production to accurately describe the observed data. Furthermore, 
morphine administration increased the brain concentration of NO, and the temporal pattern of 
apparent nNOS stimulation by morphine was consistent with the time course of loss of 
morphine-associated antinociception due to tolerance development (116). Subsequent 
experiments at the receptor level confirmed that NO alters mu-opioid receptor function (117). 
Taken together, these observations demonstrate that elevated brain content of NO is both 
necessary and sufficient to induce functional antinociceptive tolerance to morphine in rats 
and mice.  
The relationship between morphine concentrations in blood and brain tissue 
(measured by microdialysis sampling), NO production in brain (measured with an indwelling 
amperometric probe), and the development of antinociceptive tolerance (measured by 
electrical stimulation vocalization) was characterized with a comprehensive PK-PD model 
(116).  In this model (Figure 2.8), a two-compartment PK model was fit to morphine blood 
and brain concentrations during and after an 8 hour i.v. morphine infusion in rats.  A multi-
component PD submodel was required to incorporate morphine-associated changes in the 
production of neuronal NO, morphine associated agonism of the mu-opioid receptor 
(expressed as an increase in the threshold for electrical stimulation vocalization), and NO-
associated decreases in the threshold for electrical stimulation vocalization.  This relatively 
complex PK-PD model was similar in structure to preceding “black-box” approaches, but 
utilized an experimentally-determined variable (brain concentration of NO), rather than a 
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hypothetical construct, as the driving force for tolerance development. The model was able to 
provide a good description of the time course of morphine-associated antinociception during 
and following infusion in relation to changes in the blood and brain tissue concentrations of 
morphine (Figure 2.9). Despite the complexity of the model, the data obtained were capable 
of supporting parameter estimates with a reasonable degree of precision (Table 2.2). 
Two aspects of the comparison between the “black box” and “mechanistic” modeling 
approaches for morphine tolerance are noteworthy. First, although both models are capable 
of describing the time course of changes in pharmacologic response, there are fundamental 
differences in the interpretation of those models. With the “black box” approach, the 
hypothetical “inhibitor” of response appeared to be a partial agonist of low intrinsic activity 
and high affinity; in the “mechanistic” approach, NO (presumably the analog of the 
hypothetical “inhibitor” clearly functioned as a reverse agonist. This difference underscores 
the difficulty in extrapolating specific mechanisms from compartmental modeling when 
mechanistic information is absent. Secondly, although the “black box” approach did not 
provide mechanistic detail, it influenced further experimentation that was target towards 
obtaining the missing mechanistic information. Thus, such modeling efforts can be 
extraordinarily useful in the design and interpretation of studies aimed as elucidating 
fundamental mechanisms of kinetic or dynamic behavior. As additional steps in the NO 
pathway for opioid tolerance development are elaborated, or as alternative pathways for 
opioid tolerance are elucidated, for the development of opioid tolerance, more detailed 
mechanistic models can be developed, assuming that the relevant steps in those pathways can 
be studied in vivo.  
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CONCLUSIONS 
Opioid tolerance is a complex phenomenon mediated by diverse behavioral and 
cellular adaptations.  Many of the specific alterations in intracellular signaling, trafficking 
and neurotransmitter activity have been thoroughly characterized using in vitro approaches 
and knockout mice.  Despite these advances, there is in general a lack of integrative system 
approaches characterizing how these cellular adaptations interact within the whole organism.  
Such an approach will be critical in developing comprehensive understanding of opioid 
tolerance. As mechanistic information continues to be generated, increasingly sophisticated 
PK-PD models, with increasing biologic relevance, can be developed. The availability of 
such models, in turn, will support diverse activities ranging from drug discovery to adjunct 
therapy in order to minimize or reverse opioid tolerance. The ability to control the tolerance 
process is a requisite step in devising appropriate pharmacologic strategies for the treatment 
of chronic pain. 
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Table 2.1.  Categorization of the common opioids based on structural similarities. 
Semisynthetic derivatives  Synthetic derivatives 
 Morphine-related agonists   Phenylpiperidines 
  Hydromorphone    Meperidine  
   Hydrocodone    Loperamide  
  Oxycodone   Diphenylpropylamines  
  Oxymorphone    Methadone  
  Codeine    Propoxyphene  
 Morphine-related partial 
agonists and antagonists 
  Piperidines   
    Fentanyl  
  Buprenorphine    Alfentanil  
  Naloxone    Sufentanil  
  Naltrexone    Remifentanil  
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Table 2.2.  Pharmacokinetic/pharmacodynamic parameter estimates and corresponding 
coefficients of variation obtained from simultaneous modeling of morphine disposition, NO 
production, and antinociceptive effects. See Figure 2.6 for model structure. From Heinzen 
and Pollack (116). 
Parameter Estimate CV % 
VBL (L/kg) 2.5 25.9 
VBR (L/kg) 26 22.6 
k10 (hr-1) 2.17 26.3 
k12 (hr-1) 2.15 45.2 
k21 (hr-1) 1.77 10.8 
Emax,S (% stim) 0.19 36.8 
EC50,S  (ng/mL) 15.2 36.7 
γ,S 3.1 115 
kON 258 126 
kOFF 25.8 127 
Emax,E  (% MPE) 100 21.9 
EC50,E  (ng/mL) 26.8 29.8 
γ,E 1.04 14.8 
Imax,E (% MPE) 2726 133 
IC50,E (% SAL) 264 157 
γ,I 5.2 52.4 
keo,low dose morphine (hr-1) 1.56 19.3 
keo,intermediate dose morphine (hr-1) 1.01 15.8 
keo,high dose morphine (hr-1) 0.61 21.4 
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Figure 2.1.  Downstream mediators of antinociception following opioid agonist binding to 
the MOR.  A.  Binding of the agonist changes in ion channel conductance and alters the 
cAMP pathway.  Bold arrows indicate up- or down-regulation of pathways following chronic 
opioid exposure.  B.  Activation of the NMDA receptor/NO pathway.  Chronic opioid 
exposure alters synaptic cleft ion conductance and glutamate expression, leading to the the 
displacement of the Mg2+ block of the NMDA receptor, an influx of Ca2+ and conversion of 
L-Arg to NO, a mediator of tolerance.  Administering an NMDA receptor antagonist 
attenuates and delays the onset of tolerance by blocking Ca2+ influx and associated 
alterations. 
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Figure 2.3.  Relationship between antinociceptive response and morphine concentrations in 
blood during continuous infusion at the time of peak response (circles) or at 12 hr into the 
infusion (triangles). Data are presented as mean for clarity; lines indicate the fit of the Hill 
equation to the data with the following parameter values: peak effect vs. concentration data 
(Emax = 100%, EC50 = 324 ng/ml, γ = 1.92); effect at 12 hr vs. concentration (Emax = 34.8%, 
EC50 = 262 ng/ml, γ = 1.92). Data were obtained from Ouellet and Pollack (119).  
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Figure 2.5.  Recovery of antinociceptive response to a 2-mg/kg bolus dose of morphine 
following termination of a 12-hr morphine infusion (2 mg/kg/hr). Data are presented as mean 
± SE; lines indicate model simulations based on an assumption that tolerance is driven by 
accumulation of a hypothetical reverse agonist (dashed line),competitive antagonist (dotted 
line), non-competitive antagonist (dot-dashed line), or partial agonist (solid line). Adapted 
from Ouellet and Pollack (119). 
 54 
 
Figure 2.6.  PK-PD model for L-arginine-associated stimulation of nitric oxide production in 
rats. From Heinzen and Pollack (115). 
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Figure 2.7.  Concentration-time profiles for brain NO during (A) saline or administration of 
L-arginine [(B) 250 mg/kg/hr, (C) 500 mg/kg/hr, or (D) 1000 mg/kg/hr]. Data are mean±SE. 
Lines indicate the fit of the PK-PD model (Figure 2.6) to the data. From Heinzen and Pollack 
(115). 
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concentration of NO that inhibits 50% of the effect; and γ,I is the shape factor of the 
inhibitory effect of NO on antinociception.  Adapted from Heinzen and Pollack (109,119). 
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Figure 2.9.  Blood morphine concentrations (top), brain morphine concentrations (middle), 
and antinociceptive effect (bottom) during and following an 8-hr morphine infusion at 0.3- 
(circles), 1- (triangles), 2- (squares), or 3- (diamonds) mg/kg/hr. Lines indicate the fit of the 
PK/PD model to data. Adapted from Heinzen and Pollack (116). 
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PART I 
USE OF CLASSICAL APPROACHES TO IMPROVE THE LINK BETWEEN 
PHARMACOKINETIC-PHARMACODYNAMICS 
 
  
CHAPTER 3 
PHARMACOKINETICS AND PHARMACODYNAMICS OF SEVEN OPIOIDS IN PGP-
COMPETENT MICE ASSESSMENT OF UNBOUND BRAIN EC50S AND 
CORRELATION OF IN VITRO, PRECLINICAL, AND CLINICAL DATA 
This chapter has been published in Journal of Pharmacology and 
Experimental Therapeutics and is presented in the style of that journal.   
 
ABSTRACT 
This study was conducted to assess the utility of unbound brain EC50 (EC50,u) as a 
measure of in vivo potency for centrally active drugs. Seven µ-opioid agonists (alfentanil, 
fentanyl, loperamide, methadone, meperidine, morphine, and sufentanil) were selected as 
model central nervous system drugs because they elicit a readily measurable central effect 
(antinociception) and their clinical pharmacokinetics/pharmacodynamics are wecll 
understood. Mice received an equipotent subcutaneous dose of one of the model opioids. The 
time course of antinociception and the serum and brain concentrations were determined. A 
pharmacokinetic/pharmacodynamic model was used to estimate relevant parameters. In vitro 
measures of opioid binding affinity (Ki) and functional activity [EC50 for agonist stimulated 
guanosine 5'-O-(3-[35S]thio)triphosphate binding] and relevant clinical parameters were 
obtained to construct in vitro-to-preclinical and preclinical-to-clinical correlations. The 
strongest in vitro-to-in vivo correlation was observed between Ki and unbound brain EC50,u 
(r2 =0.8). A strong correlation between mouse serum and human plasma EC50 was observed 
(r2 = 0.949); the correlation was improved when corrected for protein binding (r2 = 0.995). 
Clinical equipotent i.v. dose was only moderately related to Ki. However, estimates of ED50 
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and EC50 (total serum, unbound serum, total brain, and unbound brain) were significant 
predictors of clinical equipotent i.v. dose; the best correlation was observed for brain EC50,u 
(r2 = 0.982).  For each opioid, brain equilibration half-life in mice was almost identical to the 
human plasma effect-site equilibration half-life measured clinically. These results indicate 
that the mouse is a good model for opioid human brain disposition and clinical pharmacology 
and that superior in vitro-to-preclinical and preclinical to-clinical correlations can be 
achieved with relevant unbound concentrations. 
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INTRODUCTION 
In drug discovery, in vitro assays and preclinical animal studies are widely used to 
assess compound potency and to identify compound(s) that may have a desirable clinical 
response. Several options for assessing compound potency are available, including in vitro 
(receptor binding or functional assays) and in vivo (animal studies to determine dose-
response or concentration-response relationships) protocols. In vitro binding and functional 
assays, by nature, are designed to estimate the intrinsic affinity or potency at the receptor of 
interest, whereas in vivo experiments take into account the full spectrum of pharmacokinetic 
and pharmacodynamic processes that ultimately determine biological response. 
Ideally, in vitro potency would translate to or predict in vivo potency. Often, this is 
the case, and significant correlations between in vivo ED50 or EC50 and in vitro potency have 
been established for a variety of therapeutic targets (Leysen et al., 1983; Visser et al., 2003). 
However, when there is no correlation between in vivo and in vitro potency measures, the 
validity of the in vitro assay, the animal model, and the target may be questioned. Therefore, 
establishing strong in vitro-to-in vivo relationships is a necessity for drug development, 
because it aids in target validation and it boosts confidence in the in vitro and in vivo 
pharmacology models. Historically, in vitro-to-in vivo correlations have been established by 
comparing an in vitro measure of affinity or potency, such as Ki or EC50 from a receptor 
binding or a cell-based functional assay, with ED50. Although the ED50 is not necessarily the 
best measure of intrinsic drug potency, it has been widely used because it is a 
straightforward, robust, and readily attainable metric. In vitro-to-in vivo correlations with 
ED50 are most likely to be successful for a compound set, within a discrete pharmacological 
class, that consists of members with large differences in intrinsic potency and relatively 
similar pharmacokinetics. 
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For compounds that evidence large differences in pharmacokinetics, improved in 
vitro-to-in vivo correlations may be obtained by using EC50 as opposed to ED50. Commonly, 
EC50 is estimated from the effect versus plasma concentration relationship. 
Pharmacokinetic/pharmacodynamic (PK/PD) modeling often is used to obtain estimates of 
EC50 from in vivo data, and it is a powerful tool for enhancing mechanistic understanding of 
drug disposition and action. 
In vitro-to-in vivo potency relationships have maximum predictability when the 
relationship between biological response and biophase concentration is known. Total plasma 
and unbound plasma concentrations are most widely used surrogates for biophase 
concentrations. However, systemic concentrations do not always reflect biophase 
concentrations, regardless of whether or not protein binding is taken into account. This is 
especially true for compounds that act on targets within the central nervous system (CNS). 
The blood-brain barrier (BBB) restricts the CNS distribution of many compounds, and in 
many cases, it results in temporal dissociation between biophase and systemic concentrations. 
Therefore, it is important to accurately determine CNS biophase concentration, or a closely 
related surrogate, to make better in vitro-to-in vivo correlations for centrally active 
compounds. When compounds have "good" BBB permeability and they are not substrates for 
transporters, in vitro-to-in vivo correlations can be constructed using unbound plasma or 
cerebrospinal fluid (CSF) concentrations as a surrogate for CNS biophase concentrations. 
When unbound plasma or CSF concentrations are not reflective of CNS biophase 
concentrations, such as when a compound has "poor" BBB permeability or it is subject to 
active BBB transport, other means for estimating CNS biophase concentrations may be 
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needed. One method for estimating CNS biophase concentrations is simply to multiply total 
brain concentrations by brain unbound fraction (fu,brain).  
The present study was conducted to test the hypothesis that the brain EC50,u is the best 
in vivo measure of CNS intrinsic potency. Seven µ-opioid agonists (alfentanil, fentanyl, 
loperamide, methadone, meperidine, morphine, and sufentanil) were selected as probe CNS 
drugs. These agents were selected on the bases of having pronounced differences in potency 
toward the µ-opioid receptor (Terenius, 1975; Leysen et al., 1983), differing physiochemical 
properties (i.e., lipophilicity, unbound fractions, and permeability), and differing extent of 
CNS distribution (i.e., P-gp or non-P-gp substrate) (Dagenais et al., 2004). PK/PD studies 
were conducted in mice to determine five measures of in vivo potency (ED50; total and 
unbound EC50 for both serum and brain) for each opioid. Estimates of in vitro affinity and 
potency (Ki and EC50 for agonist-stimulated [35S]GTPγS binding, respectively) as well as 
relevant clinical parameters were obtained and used to construct in vitro-to-preclinical and 
preclinical-to-clinical comparisons. The most useful measure of in vivo of potency was 
determined by correlation analysis with the in vitro and clinical potency data.  
MATERIALS AND METHODS 
Materials. 
Alfentanil was purchased from Taylor Pharmaceuticals (Decatur, IL). Fentanyl, 
loperamide, methadone, morphine, and oxycodone were purchased from Sigma-Aldrich (St. 
Louis, MO). Meperidine was obtained from Spectrum Chemicals and Laboratory Products 
(Gardena, CA). Sufentanil was purchased from Abbott Laboratories (North Chicago, IL). 
[35S]GTPγS (1250 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences 
(Boston, MA). All opioid drugs used in the [35S]GTPγS binding assay were obtained from the 
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Drug Supply Program of the National Institute on Drug Abuse (Bethesda, MD). Adenosine 
deaminase, GTPγS, and GDP were purchased from Sigma-Aldrich. All other reagents were 
obtained from common sources, and they were of reagent grade or better.  
Animals. 
Male CF-1 mdr1a(+/+) mice (30–40 g; Charles River Laboratories, Inc., Wilmington, 
MA) were maintained on a 12-h light/dark cycle in a temperature- and humidity-controlled 
room with access to water and food ad libitum. All procedures involving mice were approved 
by either The Institutional Animal Care and Use Committee of the University of North 
Carolina or The Institutional Animal Care and Use Committee at Virginia Commonwealth 
University, and they were conducted in accordance with Principles of Laboratory Animal 
Care (National Institutes of Health Publication 85-23, revised in 1985).  
Agonist Stimulated [35S]GTPγS Binding in Membrane Homogenates.  
Mice were sacrificed by decapitation, and the thalamus was dissected on ice. Tissue 
was homogenized in membrane buffer (50 mM Tris-HCl, 3 mM MgCl2, and 1 mM EGTA, 
pH 7.4) with a Polytron homogenizer (Brinkmann Instruments, Westbury, NY), centrifuged 
at 50,000g for 10 min at 4°C, resuspended in membrane buffer, and stored in aliquots of ~2 
mg/ml at –80°C until use. Membranes were thawed and diluted 10-fold in assay buffer, 
centrifuged as described above, resuspended in assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 
50 mM KCl, 50 mM NaCl, and 0.2 mM EGTA, pH 7.4), and preincubated for 10 min at 30°C 
with 4 mU/ml adenosine deaminase to remove endogenous adenosine. Protein was then 
determined by the Bradford method (Bradford, 1976). Each assay tube contained membranes 
(10 µg protein/tube), 0.1 nM [35S]GTPγS, 10 µM GDP, and appropriate agonist in a 1-ml 
total volume. Basal binding was assessed in the absence of agonist, and nonspecific binding 
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was measured with 20 µM unlabeled GTPγS. Assay tubes were incubated for 2 h at 30°C. 
The reaction was terminated by filtration under vacuum through Whatman GF/B glass fiber 
filters (Whatman, Maidstone, UK), followed by three washes with ice-cold Tris buffer. 
Bound radioactivity was determined by liquid scintillation spectrophotometry, at 95% 
efficiency for 35S, after overnight extraction of the filters. Agonist-stimulated [35S]GTPγS 
binding was determined from four to six separate experiments performed in duplicate for 
each opioid. Net agonist-stimulated [35S]GTPγS binding was defined as agonist-stimulated 
minus basal binding. Percentage of stimulation was defined as (net agonist-stimulated 
[35S]GTPγS binding/basal binding) x 100%. Percentage of maximal stimulation was defined 
as (net stimulation by agonist/net stimulation by 10 µM [D-Ala2,N-Me-Phe4,Gly5-ol]-
enkephalin) x 100%. EC50 and Emax values were determined by nonlinear regression analyses 
of concentration-effect curves by iterative curve-fitting using GraphPad Prism 4 (GraphPad 
Software Inc., San Diego, CA).  
Pharmacokinetic/Pharmacodynamic Study.  
Based on the results of pilot experiments, 36 mdr1a(+/+) CF-1 mice in total received a 
single equipotent subcutaneous dose of alfentanil (0.2 mg/kg), fentanyl (0.09 mg/kg), 
loperamide (50 mg/kg), methadone (0.6 mg/kg), meperidine (25 mg/kg), morphine (3.6 
mg/kg), or sufentanil (0.001 mg/kg). Fentanyl and loperamide were prepared in 50:50 
propylene glycol/water, whereas the remaining opioids were prepared in 0.9% saline. 
Antinociception was assessed at selected time points, and four mice per opioid were 
sacrificed by decapitation for collection of brain tissue and blood samples. Trunk blood was 
collected in 1.5-ml microcentrifuge tubes, and it was allowed to clot for ~30 min at room 
 77 
temperature. Serum was harvested after centrifugation. Brain and serum samples were stored 
at –20°C until analysis by HPLC-MS/MS.  
Assessment of Antinociception.  
Antinociception was assessed with the hot-plate latency test as described previously 
(Chen and Pollack, 1997). Before opioid administration, baseline hot-plate latency was 
determined for each animal in triplicate. Hot-plate latency was defined as the time interval 
between placement on the hot-plate (55°C; Columbus Instruments, Columbus, OH) and the 
first observation of a jump or lick of a hind limb. Only animals with an average baseline 
latency <25 s were used in this study. A cut-off latency of 60 s was established to avoid tissue 
damage. The degree of antinociception, expressed as percent maximal possible response 
(%MPR), was calculated as follows: 
 %𝑀𝑃𝑅 = 𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦60 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑥 100% (Eqn. 3.1) 
Evaluation of Protein Binding.  
Plasma and brain unbound fractions were determined in a 96-well equilibrium dialysis 
apparatus (HTDialysis, Gales Ferry, CT) using a previously reported method (Kalvass and 
Maurer, 2002). In brief, fresh mouse plasma and brain tissue were obtained the day of the 
study. Spectra-Por 2 membranes obtained from Spectrum Laboratories Inc. (Rancho 
Dominguez, CA) were conditioned in HPLC water for 15 min, followed by 30% ethanol for 
15 min, and 100 mM sodium phosphate, pH 7.4, buffer for 15 min. Brain tissue was diluted 
3-fold with 100 mM sodium phosphate, pH 7.4, buffer, and it was homogenized with a sonic 
probe. The drug of interest was added to samples of plasma and brain tissue homogenate (3 
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and 1 µM, respectively), and 150-µl aliquots (n = 6) were loaded into the 96-well equilibrium 
dialysis apparatus and dialyzed against an equal volume of 100 mM sodium phosphate, pH 
7.4, buffer for 4.5 h in a 155-rpm shaking water bath maintained at 37°C. Prior experience 
with the equilibrium dialysis apparatus indicated that equilibrium would be achieved by the 
end of the specified incubation period (data not shown). After incubation, 10 µl of matrix 
(plasma or brain homogenate) and 50 µl of buffer were removed from the apparatus and 
added directly to HPLC vials containing 100 µl of an appropriate internal standard in 
methanol. A 50-µl aliquot of control buffer was added to the brain homogenate and plasma 
samples, and a 10-µl aliquot of either control brain homogenate or control plasma was added 
to the buffer samples, to yield identical matrix composition for all samples before analysis. 
The samples were vortex-mixed and centrifuged, and the supernatant was analyzed by the 
HPLC-MS/MS as described below. Plasma unbound fraction was calculated from the ratio of 
concentrations determined in buffer versus plasma samples. Equation 3.2, which accounts for 
the effect of tissue dilution on unbound fraction (Kalvass and Maurer, 2002), was used to 
calculate the brain unbound fraction: 
 𝑈𝑛𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑓௨ =
1
𝐷
ቆ൬ 1𝑓௨,௠௘௔௦௨௥௘ௗ൰ − 1ቇ +
1
𝐷
 (Eqn. 3.2) 
where D represents the -fold dilution of brain tissue, and fu,measured is the ratio of 
concentrations determined in buffer versus brain homogenate samples.  
Quantitation of Serum and Brain Concentrations.  
Opioid brain and serum concentrations were measured using previously described 
methods with slight variation (Kalvass et al., 2007a). In brief, brain samples were 
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homogenized in water [1:2 (v/v)] via sonic probe. An aliquot (2–25 µl) of homogenate or 
serum was transferred to an HPLC vial, and protein was precipitated with 4 to 125 volumes 
of methanol containing internal standard (5 ng/ml loperamide for alfentanil, fentanyl, 
meperidine, methadone, and sufentanil; 20 ng/ml methadone for loperamide; and 100 ng/ml 
oxycodone for morphine). The sample was vortex-mixed and centrifuged, and the supernatant 
was analyzed by HPLC-MS/MS. Samples were injected (2–10 µl; autosampler, CTC 
Analytics, Zwingen, Switzerland) onto a Gemini 110A column (2.0 x 30 mm; 5 µm) 
(Phenomenex, Torrance, CA) maintained at room temperature. The total run time was 3 min. 
Analytes were eluted with a linear gradient consisting of 10 mM ammonium acetate, pH 6.8 
(A), and methanol (B) produced by two LC-10ADVP binary pumps (Shimadzu, Kyoto, 
Japan). An initial condition of 5% B was ramped to 95% B over 2 min, held for 0.5 min, and 
then returned initial condition of 5% B in a single step to re-equilibrate the column. During 
the run, the flow rate was increased from 750 to 1500 µl/min over the first 2 min, held at 
1500 µl/min for 1 min, and then returned the initial flow rate of 750 µl/min in a single step. 
For the morphine samples, the initial conditions were held for 0.5 min before ramping the 
gradient and flow rate. The entire column effluent was diverted from the source of the PE 
Sciex API-4000 quadrupole mass spectrometer (Turbo V Ionspray source, 700°C; 
PerkinElmerSciex Instruments, Boston, MA) for the first 0.8 min and last 0.5 min of the run. 
Alfentanil, fentanyl, loperamide, methadone, meperidine, morphine, oxycodone, and 
sufentanil were measured in positive ionization mode using multiple reaction monitoring 
(417.3→268.3, 337.1→188.3, 477.4→266.0, 248.3→220.3, 310.3→265.2, 286.1→201.1, 
316.0→298.0, and 387.2→238.4, respectively). Standard curves were prepared in brain 
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homogenate, serum, plasma, or buffer, and they were identical in composition to 
corresponding samples. Accuracy of standards and interassay variability was within ± 20%.  
Pharmacokinetic/Pharmacodynamic Analysis.  
A compartmental modeling approach with distribution between serum and brain 
tissue was used to describe opioid pharmacokinetics. The pharmacokinetic model in Fig. 3.1 
was fitted simultaneously to the serum concentration- and brain concentration-time data using 
nonlinear least-squares regression (WinNonlin 4.1; Pharsight Corporation, Mountain View, 
CA). The brain volume (VBr) was fixed at 13.4 ml/kg, assuming a specific gravity of 1.0 g/ml 
(Kalvass et al., 2007b). All other pharmacokinetic parameters were obtained from fitting the 
kinetic model to the data. The pharmacodynamic parameters EC50 and γ were determined 
from fitting a sigmoidal Emax model to the antinociception versus brain concentration (C) 
data. 
 %𝑀𝑃𝑅 = 𝐸୫ୟ୶ 𝑥 𝐶
ఊ
𝐸𝐶ହ଴ + 𝐶ఊ (Eqn. 3.3) 
Emax was defined as 100%. Serum EC50 was calculated from the following equation:  
 𝑆𝑒𝑟𝑢𝑚 𝐸𝐶ହ଴ =
𝐵𝑟𝑎𝑖𝑛 𝐸𝐶ହ଴
𝐾௣,௕௥௔௜௡,௦௦  (Eqn. 3.4) 
The ED50 was calculated, assuming linear pharmacokinetics, from the maximum brain 
concentration predicted by the PK model (brain Cmax), the opioid dose (X0), and the brain 
EC50.  
 𝐸𝐷ହ଴ =
𝐵𝑟𝑎𝑖𝑛 𝐸𝐶ହ଴
𝐵𝑟𝑎𝑖𝑛 𝐶௠௔௫ 𝑥 𝑋଴ (Eqn. 3.5) 
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The time course of the brain-to-serum ratio (Kp,brain) for each opioid was used to estimate the 
brain equilibration rate constant (keq) and steady-state brain-to-serum ratio (Kp,brain,ss) for that 
compound according to the following equation: 
 𝐾௣,௕௥௔௜௡ = 𝐾௣,௕௥௔௜௡,௦௦ (1 − 𝑒ି௞೐೜ ௫ ௧) (Eqn. 3.6) 
The brain equilibration half-life (t1/2eq,brain) was obtained from keq as follows:  
 𝑡ଵ
ଶ,௘௤,௕௥௔௜௡
= 0.693𝑘௘௤  (Eqn. 3.7) 
RESULTS  
The dose administered to produce equivalent antinociception in mice varied by more 
than 4 orders of magnitude between the most and least potent opioid (0.001 versus 50 mg/kg 
for sufentanil and loperamide, respectively). Likewise, the calculated mouse ED50 varied by 
nearly 5 orders of magnitude (Table 3.1).  The large range of effective doses was 
advantageous for subsequent construction of relationships between various in vitro and in 
vivo metrics of response. 
The pharmacokinetic/pharmacodynamic model adequately described the time course 
of antinociception, as well as the brain tissue concentration versus time and serum 
concentration versus time relationships, for each of the opioids studied (Fig. 3.2, A-G).  With 
the exception of fentanyl, the systemic pharmacokinetics of all of the opioids were most 
effectively modeled with a single compartment system and first-order absorption from the 
site of administration (Table 3.2; Fig. 3.2).  The disposition of fentanyl required addition of a 
peripheral distributional compartment with associated parameters [apparent peripheral 
distributional space (Vp); distributional clearance (Cld)]. Estimates of relevant 
pharmacokinetic parameters for each of the opioids are reported in Table 3.2. 
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Pharmacokinetic/pharmacodynamic modeling revealed counterclockwise hysteresis in 
the antinociception versus serum concentration relationship for each opioid (Fig. 3.3), 
consistent with delayed distribution between serum concentrations and biophase 
concentrations. In contrast, all of the opioids exhibited a sigmoidal relationship between 
antinociception and brain tissue concentration, with no evidence of significant hysteresis 
behavior associated with temporal dissociation between CNS pharmacokinetics and 
pharmacodynamics (Fig. 3.4). Brain EC50 and γ values are reported in Table 3.2.  Brain EC50 
estimates differed by more than 2000-fold between the most (sufentanil) and the least 
(meperidine) potent opioid. Similarly the serum, unbound serum, and unbound brain EC50 
estimates evidenced a wide range among the seven opioids. Depending on the particular EC50 
value used as a metric (total brain, unbound brain, total serum, or unbound serum), the rank 
order of opioid potency differed considerably as a consequence of large differences in 
Kp,brain,ss, fu,plasma, and fu,brain among the opioids.  
Kp,brain,ss values differed by more than 50-fold among the opioids (Table 3.2; Fig. 3.5). 
The lowest Kp,brain,ss was observed for loperamide (0.115), and the highest was for meperidine 
(6.8). The t1/2eq,brain ranged from 1 to 74 min, with alfentanil and morphine having the shortest 
and longest t1/2eq,brain, respectively (Table 3.2).  
The in vitro Ki (obtained from the literature) and GTPγS EC50 values were strongly 
correlated (r2 > 0.9; data not shown). In every case, the in vitro-to-in vivo correlation using Ki 
was stronger than the corresponding correlation using GTPγSEC50 (data not shown). 
However, the strengths of the various in vitro-to-in vivo correlations were the same relative 
to each other whether Ki or GTPγS EC50 was used. Therefore, only the in vitro-to-in vivo 
relationships with Ki are reported. In vitro-to-in vivo relationships (Fig. 3.6) revealed that 
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mouse serum EC50 and brain EC50 correlated poorly with in vitro Ki (r2 < 0.5). A modest 
improvement was observed for the correlation between unbound serum EC50,u and Ki (r2 = 
0.583). The strongest relationship observed was between unbound brain EC50,u and Ki (r2 < 
0.799).  
Preclinical-to-clinical relationships indicated that mouse serum and human plasma 
EC50 estimates were well correlated (r2 = 0.949). Despite the strength of this relationship, the 
correlation was improved when the EC50 values were corrected for binding to plasma proteins 
(r2 = 0.995) (Fig. 3.7). Correlations also were explored between human equipotent clinical 
i.v. dose of the opioids and various estimates of in vitro and in vivo potency (Fig. 3.8). The 
relationship between equipotent clinical dose and Ki was relatively poor (r2 = 0.677). 
Equipotent clinical i.v. dose correlated more strongly with mouse ED50 (r2 = 0.932). 
Equipotent clinical i.v. dose also correlated equally well with total and unbound mouse serum 
EC50 (r2 = 0.922 and r2 = 0.937, respectively). Somewhat surprisingly, equipotent clinical i.v. 
dose did not correlate as well with total brain EC50 (r2 = 0.878) compared with the 
relationships with metrics obtained from plasma. However, the equipotent clinical i.v. dose 
correlated most strongly with unbound brain EC50,u values in the mouse (r2 = 0.982).  
The brain equilibration half-life in mouse determined in the present study (t1/2eq,brain) 
was compared with the apparent plasma-biophase equilibration half-life in humans (t1/2,Ke0), 
obtained from the literature, among the opioids examined in this study. The log-log 
correlation between clinical t1/2,Ke0 and mouse t1/2eq,brain was excellent (r2 = 0.988). With the 
exception of morphine, all of the opioids fell within a factor of 1.4-fold relative to the line of 
identity (Fig. 3.9).  
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DISCUSSION 
An integrated pharmacokinetic/pharmacodynamic modeling strategy yielded an 
adequate description of the time course of antinociception, serum concentrations, and brain 
tissue concentrations for each of the opioids examined in this study. Differences in systemic 
pharmacokinetics among the opioids were relatively small (~10-fold for Cl) compared with 
differences in vivo potency measures (~30,000-fold) and brain pharmacokinetics (>70-fold 
for Kp,brain, t1/2eq,brain, and Clup).  
In Vitro-to-Preclinical Correlations.  
Previous studies have established in vitro-to-preclinical correlations for opioid 
potency using Ki. Leysen et al. (1983) reported a correlation (r2 = 0.81) between in vitro Ki 
(displacement of sufentanil in rat forebrain membranes) and ED50 (rat tail withdrawal reflex) 
for 35 opioids from five structural classes, with >100,000-fold difference in receptor affinity. 
However, no correlation existed between Ki and ED50 if only the seven opioids from this 
study were included in their analysis (r2 < 0.15) (Niemegeers et al., 1979; Leysen et al., 
1983). Results from this study show a similarly poor correlation (r2 = 0.167) between in vitro 
Ki and mouse ED50. This lack of correlation can be largely attributed to differences in 
pharmacokinetics and biophase distribution characteristics for the seven opioids. The opioids 
selected for this study come from four different structural classes and several are known P-gp 
substrates (Dagenais et al., 2004). Consequently, these opioids have different physiochemical 
properties and CNS (biophase) distribution characteristics. One would anticipate that Ki 
would be a better predictor of biophase EC50, because the confounding influences of 
pharmacokinetics and biophase distribution are removed.  
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Total plasma, unbound plasma, and CSF concentrations have been used to estimate 
CNS biophase concentration for in vitro-to-in vivo correlations. Visser et al. (2003) 
demonstrated that, for nine GABAA modulators, in vitro-to-in vivo correlations could be 
made between Ki and either total or unbound plasma EC50; however, the unbound plasma 
EC50 correlated better with Ki than total plasma EC50. Another study demonstrated the in 
vitro Ki of alfentanil, fentanyl, and sufentanil correlated well with the in vivo EC50 
determined from CSF concentrations (Cox et al., 1998).  
In the present study, total plasma, total brain, unbound plasma, and unbound brain 
EC50 estimates were used to express opioid potency, and they were evaluated as potential 
surrogates for biophase EC50. Unbound EC50 values were calculated by multiplying the total 
EC50 by the appropriate unbound fraction value (fu,plasma or fu,brain) determined from 
equilibrium dialysis experiments conducted in accordance with the methods of Kalvass and 
Maurer (2002). The total serum and total brain EC50 values were weakly related to in vitro Ki 
(r2 < 0.5). A modest improvement was observed with unbound serum EC50,u (r2 = 0.583). 
However, the strongest relationship was observed between unbound brain EC50,u and Ki (r2 = 
0.799). These results, along with the hysteresis in the antinociception versus serum 
concentration relationship and the sigmoidal relationship between antinociception and brain 
concentration, suggest that unbound brain concentrations determined with fu,brain, estimated 
from brain-homogenate equilibrium-dialysis approach, represent an optimal surrogate for 
CNS biophase concentrations. Furthermore, these results highlight the importance of using an 
appropriate surrogate for biophase concentration, presumably unbound concentration at the 
site of action, when making in vitro-to-in vivo correlations.  
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In this study, the in vitro parameter GTPγSEC50 was also used to construct in vitro-to-
in vivo correlations. In every case, the correlation using Ki was stronger than the 
corresponding correlation using GTPγS EC50 (data not shown). It is unclear why in vivo EC50 
values correlated better with receptor binding Ki values than with EC50 values obtained from 
[35S]GTPγS experiments. Intuitively, one might expect an improved correlation between two 
functional measures of receptor activation than between in vivo function and receptor 
binding. However, differences in the intrinsic efficacy of agonists in the [35S]GTPγS assay 
are generally observed as differences in maximal effect because receptor reserve for G 
protein activation in this assay is low, especially in native tissues such as brain (Selley et al., 
1998). However, an attempt was made to adjust assay conditions to minimize Emax differences 
between full and partial agonists by decreasing both sodium and GDP concentrations relative 
to standard assay conditions (Selley et al., 1997, 2000) so that differences in intrinsic efficacy 
would be observed as potency differences. Nonetheless, under these optimized conditions, 
there were still slight Emax differences, which ranged from 73 to 85% of the full agonist [D-
Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (data not shown). It should be noted that measurement 
of high-affinity agonist binding is also dependent on the formation of functional receptor-G 
protein complexes, so that these measurements when made in the absence of sodium and 
guanine nucleotides apparently provided slightly better correlation than EC50 values obtained 
from direct measurement of G protein activation with the [35S]GTPγS assay.  
Preclinical-to-Clinical Correlations.  
Human efficacious plasma concentrations are often predicted from total plasma 
concentrations in preclinical efficacy models (Danhof et al., 1993; Ito et al., 1993). Assuming 
the drug has similar pharmacology and plasma protein binding in humans and preclinical 
 87 
models, this prediction should be valid. In the present study, mouse total serum EC50 
correlated well with human total plasma EC50 (r2 = 0.949), consistent with similarities 
between mouse and human opioid pharmacology and plasma protein binding. However, the 
correlation improved when EC50 values were corrected for protein binding (r2 = 0.995). On 
average, mouse unbound serum EC50,u overpredicted human unbound human plasma EC50,u 
by 2.8-fold. The murine model seems to be a remarkably effective predictor of relative 
human efficacious serum concentrations among a set of µ-opioids, even when those 
compounds are derived from different chemical classes.  
The ability to predict human dose from in vitro and preclinical data are important. 
Clinical dose often correlates with ED50 obtained from animal models. For example, 
Niemegeers et al. (1979) demonstrated that rat ED50 determined for antidiarrheal and 
analgesic activity strongly correlated with clinical dose for 12 opioids. In the present study, 
the equipotent clinical i.v. dose and mouse ED50 correlated well for the seven opioids 
examined (r2 = 0.932). Although efficacious dose is dependent on many factors, including 
systemic disposition, target-site pharmacokinetics, and intrinsic potency, the observed 
differences in efficacious dose for the examined opioids seem to be dominated by intrinsic 
potency. Therefore, any reliable measure of opioid in vivo intrinsic potency should correlate 
well with the clinical equipotent i.v. dose for these opioids.  
Various in vitro and in vivo measures of opioid potency were correlated with clinical 
equipotent i.v. dose to evaluate predictive potential. The in vitro Ki was a weak predictor of 
equipotent clinical i.v. dose (r2 = 0.677). Equipotent clinical dose correlated better with in 
vivo measures, including mouse ED50 (r2 = 0.932) and total or unbound mouse serum EC50 
(r2 = 0.922 and r2 = 0.937, respectively). It was surprising that equipotent clinical dose did 
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not correlate as well with total brain EC50 values (r2 = 0.879) as with either serum 
concentration measure or murine effective dose, suggesting that nonspecific opioid binding in 
brain is substantial. As expected, the equipotent clinical dose correlated best with unbound 
brain EC50,u (r2 = 0.982), consistent with unbound brain EC50,u being the best measure of in 
vivo intrinsic opioid potency.  
It is interesting to note that the t1/2eq,brain determined in mice, derived from the kinetics 
of drug equilibration between brain tissue and serum (Fig. 3.5), was almost identical to the 
clinical t1/2,Ke0, an inferred value from the kinetics of pharmacological response in the context 
of kinetics of systemic disposition (Fig. 3.9). Morphine evidenced the largest discrepancy 
between these metrics, with t1/2,Ke0 being 2.4-fold larger than mouse t1/2eq,brain. Morphine-6-
glucuronide, an active metabolite of morphine in humans (Glare and Walsh, 1991) that is not 
formed extensively in mice, possesses a long t1/2,Ke0 (>3600 min; Lötsch, 2005). Because 
morphine and its active metabolite exist in combination after morphine administration in 
humans, the t1/2,Ke0 estimate obtained will reflect the contribution of both parent drug and 
metabolite. The remarkable relationship between t1/2,Ke0 and t1/2eq,brain, together with the strong 
interspecies correlation between unbound serum/plasma EC50, suggests that the brain 
distribution characteristics are similar between humans and mice.  
Relative Potency and Kp,brain.  
Even though all seven opioids examined are µ-agonists, they do not have the same 
primary indication. The primary indication of a given opioid seems not to be related mainly to 
intrinsic opioid potency, but rather to differences in brain distribution characteristics and 
systemic pharmacokinetics. For example, the two anesthetic opioids, alfentanil and sufentanil, 
have the shortest mouse systemic half-life (8 and 14 min, respectively) and t1/2eq,brain (1 and 4 
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min, respectively) of the opioids examined. The short systemic half-life, combined with the 
short t1/2eq,brain, results in a rapid onset and offset of action, allowing for rapid adjustment of 
response during i.v. infusion. Fentanyl, methadone, meperidine, and morphine, in contrast, 
have longer half-lives and t1/2eq,brain, rendering them more suitable as analgesics. The brain 
distribution of loperamide is limited due to P-gp-mediated efflux (Schinkel et al., 1996), 
allowing it to act selectively on µ-opioid receptors in the intestinal tract versus the CNS and 
conferring ideal antidiarrheal properties. These relationships indicate that systemic 
pharmacokinetics and biophase distribution characteristics are more important than intrinsic 
potency for optimizing an opioid action toward a given indication (anesthetic, analgesic, or 
antidiarrheal). Undoubtedly, potency and biophase distribution characteristics must be 
balanced with other properties and considerations (i.e., solubility, permeability, 
bioavailability, systemic clearance, and half-life) to achieve compounds that will be useful 
clinical agents. However, the current data clearly indicate the importance of target-site 
pharmacokinetics and activity in determining qualitative, as well as quantitative, clinical 
response.  
Kp,brain often is used as a measure of CNS exposure, under the assumption that larger 
values of Kp,brain equate with higher CNS exposure. CNS drug discovery programs have 
devoted much effort and resources to predicting and maximizing the Kp,brain of drug 
candidates. Although not the main intent of this work, the results presented herein can be 
used to illustrate the fallacy of pursing this strategy. As demonstrated previously, Ki, ED50, 
EC50, and equipotent i.v. clinical doses are appropriate parameters for constructing in vitro-
to-in vivo and preclinical-to-clinical correlations. The same cannot be said for Kp,brain. Even 
though Kp,brain values differed by more than 50-fold among the opioids examined, there was 
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no correlation between Kp,brain and any relevant pharmacodynamic parameter (r2 < 0.2) for Ki, 
EC50, EC50,u, ED50, equipotent i.v. clinical dose, fu,plasma,fu,brain, t1/2eq,brain, and t1/2,Ke0). With the 
exception of loperamide, all of the opioids examined are marketed as CNS-active drugs 
exhibiting Kp,brain values ranging between 0.19 and 6.8. This large range of Kp,brain values, 
which was not meaningfully correlated with any relevant measure of opioid action, indicates 
that Kp,brain is not a useful parameter. In contrast to Kp,brain, the unbound brain and unbound 
plasma concentrations were useful for in vitro-to-in vivo and preclinical-to-clinical 
predictions, and the ratio of unbound brain to unbound plasma concentrations better reflects 
pharmacologically relevant brain exposure.  
In summary, these results suggest that the mouse is a good model for opioid brain 
disposition and pharmacology and that superior in vitro-to-preclinical and preclinical-to-
clinical correlations can be established when making comparisons between relevant unbound 
concentrations. 
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Figure 3.1.  Pharmacokinetic/pharmacodynamic model for opioid disposition and 
antinociception in mice. Pharmacokinetic parameters were obtained by fitting the model to 
the time course of serum and brain concentrations in mdr1a(+/+) mice after subcutaneous 
administration. The absorption rate constant (Ka), central volume (Vc), systemic clearance 
(Cl), Vp, Cld, brain uptake clearance (Clup), and brain efflux clearance (Clefflux) were estimated 
for each opioid. The VBr was fixed. The effect parameters EC50 and γ were obtained by fitting 
a sigmoidal Emax model to the brain concentration versus antinociception data. Emax was 
defined as 100%. 
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Figure 3.2.  Time course of antinociception (?), serum (?) and brain (▲) concentrations 
after 0.2 mg/kg s.c. dose of alfentanil (A), 0.9 mg/kg s.c. dose of fentanyl (B), 50 mg/kg s.c. 
dose of loperamide (C), 25 mg/kg s.c. dose of meperidine (D), 2 mg/kg s.c. dose of 
methadone (E), 3.6 mg/kg s.c. dose of morphine (F), or 0.001-mg/kg s.c. dose of sufentanil 
(G) in CF-1 mdr1a(+/+) mice. Data are presented as mean ± S.E. [concentration data (n ≥ 3); 
antinociception (n = 4–36)]. Lines represent the fit of the PK/PD model to the 
antinociception and concentration data. 
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Figure 3.3.  Relationship between plasma concentration and antinociception for µ-opioid 
agonists. Symbols represent data from CF-1 mdr1a(+/+) mice. Lines represent the fit of the 
PK/PD model to the antinociception-serum concentration data. Symbols are as follows: 
sufentanil (▲), fentanyl (?), alfentanil (?), methadone (?), meperidine (▲), morphine 
(?), and loperamide (?). All opioids exhibited a counter-clockwise hysteresis in the 
antinociception versus serum concentration relationship. Data are presented as means [serum 
concentration (n = 2–4); antinociception (n = 4–36)] 
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Figure 3.4.  Relationship between brain concentration and antinociception for µ-opioid 
agonists. Symbols represent data from CF-1 mdr1a(+/+) mice. Lines represent the fit of a 
sigmoidal Emax model to the antinociception-brain concentration data. Data are presented as 
means [brain concentration (n = 2–4); antinociception (n = 4–36)]. 
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Figure 3.5.  Time course of opioid Kp,brain in CF-1 mdr1a(+/+). Solid lines represent the fit of 
a kinetic model to the data. Data are presented as mean ± S.E. (n≥3). 
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Figure 3.6.  Correlation analysis for various in vivo measures relative to in vitro potency. 
The dashed line represents the line from log-log orthogonal regression analysis. 
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Figure 3.7.  Correlation between mouse serum and human plasma EC50s. The dashed line 
represents the line from log-log orthogonal regression analysis. 
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Figure 3.8.  Correlation of equipotent clinical dose with in vitro Ki values, mouse ED50 
values, and mouse EC50 values. The dashed line represents the line from log-log orthogonal 
regression analysis.  
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Figure 3.9.  The log-log correlation between human plasma-biophase equilibration half-life 
(t1/2,Ke0) and mouse brain equilibration half-life (t1/2eq,brain). The solid line represents the line 
of unity; the dashed line represents the line from log-log orthogonal regression analysis. With 
the exception of morphine, all of the opioids fell within 1.4-fold of the line of unity. 
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CHAPTER 4 
INFLUENCE OF BLOOD-BRAIN BARRIER P-GLYCOPROTEIN ON BRAIN 
PENETRATION AND ANTINOCICEPTIVE EFFECTS OF MODEL OPIOIDS 
This chapter has been submitted for publication in Journal of 
Pharmacology and Experimental Therapeutics and is presented in the 
style of that journal. 
ABSTRACT 
This study assessed the pharmacokinetic-pharmacodynamic (PK-PD) implications of 
variable substrate interactions with blood-brain barrier (BBB) P-glycoprotein (P-gp). Opioids 
were selected as model compounds because they elicit a readily-measured central effect 
(antinociception) and evidence a range of interactions with P-gp (loperamide: high; 
methadone: intermediate; fentanyl: low). P-gp-competent [mdr1a(+/+)] and P-gp-deficient 
[mdr1a(-/-)] CF-1 mice received equipotent subcutaneous doses of loperamide, methadone, 
or fentanyl. FVB [mdr1a/b(+/+)] and [mdr1a/b(-/-)] mice also received equipotent 
subcutaneous doses of loperamide in order to assess the potential influence of mdr1b on 
opioid brain penetration and antinociception. The time courses of antinociception and 
brain/serum concentrations were determined. Brain-to-plasma concentration ratios (Kp,brain), 
brain equilibration half-life (t1/2eq,brain), and pharmacokinetic/pharmacodynamic parameters 
were estimated by fitting appropriate kinetic or kinetic/dynamic models to the data. 
Mdr1a(+/+) mice required 50- and 5-fold higher doses of loperamide and methadone, 
respectively, to produce antinociceptive activity similar to mdr1a(-/-) mice. P-gp efflux 
reduced the Kp,brain of loperamide, methadone, and fentanyl by ~40-, ~7-, and ~2-fold, 
respectively. However, P-gp efflux had no effect on brain EC50, indicating that the only 
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influence of P-gp on loperamide-, methadone-, and fentanyl-associated antinociception was 
through limiting CNS exposure across the BBB. P-gp efflux decreased brain uptake 
clearance, Kp,brain, and t1/2eq,brain. The ~2-fold decrease in the time to brain/plasma 
equilibration for loperamide and methadone is consistent with theoretical considerations for 
BBB efflux transport, assuming that the egress rate from brain determines brain/plasma 
equilibration half-life. 
INTRODUCTION 
Several opioids, including fentanyl, methadone, and loperamide, are substrates for the 
efflux transporter P-glycoprotein (P-gp) (Dagenais et al., 2004). P-gp was first identified in 
tumor cells for its ability to confer multi-drug resistance against chemotherapy agents 
(Juliano, 1976; Gros et al., 1986). P-gp is also expressed in several normal organs and 
tissues, such as the intestine, liver, kidneys, testes, and brain. P-gp expression at these sites 
appears to serve a protective role by limiting absorption, facilitating excretion, and reducing 
tissue distribution of potentially harmful xenobiotics, including calcium channel blockers, 
HIV protease inhibitors, immunosuppressants, and opioids to sensitive tissues, including the 
brain (Matheny et al., 2001).  
While human P-gp is encoded by the MDR1 gene, rodents encode the transporter 
through two distinct genes, mdr1a and mdr1b. Two strains of P-gp-deficient mice have been 
used in a variety of experimental protocols to study the influence of P-gp on the 
pharmacokinetic and pharmacodynamics of drugs: the CF-1 mouse strain, which naturally 
lacks the mdr1a gene product, and mdr1a/b double knockouts, which were developed in the 
FVB murine line (Schinkel et al., 1994; Chen et al., 2003). The mdr1a isoform is expressed 
on the apical membrane of capillary endothelial cells comprising the BBB, and is thought to 
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be the prominent isoform restricting the entry of P-gp substrates into the brain (Schinkel et 
al., 1994).  In contrast, the mdr1b isoform has been reported to be expressed in brain 
parenchyma (Golden and Pardridge, 2000); the role of mdr1b P-gp in attenuating opioid-
associated antinociception is unknown. Studies with P-gp-competent and P-gp-deficient mice 
of both strains have shown that P-gp is responsible for attenuating brain uptake, decreasing 
brain tissue concentrations, and reducing the antinociceptive action of some opioids 
(Schinkel et al., 1996; Chen and Pollack, 1998; Thompson et al., 2000; Dagenais et al., 
2004). 
It has been proposed that P-gp expression within brain parenchyma may serve as a 
tertiary barrier to substrate approach to pharmacologic targets such as opioid receptors 
(Golden and Pollack, 2003). Some experimental evidence supports this hypothesis. For 
example, the brain tissue EC50 of the metabolically stable cyclic opioid peptide [D-
penicillamine2,5]-enkephalin (DPDPE) was 10-fold lower in P-gp-deficient as compared to P-
gp-competent mice (Chen and Pollack, 1998).  It was proposed that the difference in brain 
tissue EC50 was due to P-gp within the brain parenchyma effluxing drug away from the 
receptor site. However, this explanation remains speculative. 
The anti-diarrheal agent loperamide is devoid of central activity at therapeutic doses, 
despite being a potent mu opioid agonist, due to substantial P-gp-mediated efflux (Schinkel et 
al., 1996). Efflux by BBB P-gp decreases the loperamide brain-to-plasma ratio (Kp,brain) by 
~60-fold (Kalvass et al., 2004). P-gp-mediated efflux also has been reported to decrease the 
Kp,brain for methadone and to attenuate fentanyl-associated antinociception in mice 
(Thompson et al., 2000; Wang et al., 2004). The effect of P-gp on opioid flux is in the order 
loperamide > methadone > fentanyl, making this a useful compound set for comprehensive 
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evaluation of the role of P-gp in modulating central opioid response. A side-by-side 
comparison of the pharmacokinetics and pharmacodynamics of these compounds will allow a 
better understanding of the effect of on brain penetration and antinociception of opioids. The 
specific goal of the present study was to use a PK-PD modeling approach to assess the 
influence of P-gp-mediated BBB efflux on the pharmacokinetics, brain disposition, and 
antinociception of fentanyl, methadone, and loperamide. 
MATERIAL AND METHODS 
Materials 
Fentanyl, methadone, and loperamide were purchased from Sigma-Aldrich (St. Louis, 
MO). All other reagents were obtained from common sources and were of reagent grade or 
better. 
Animals 
Male CF-1 [mdr1a(+/+) and mdr1a(-/-)] and FVB [mdr1a/b(+/+) and mdr1a/b(-/-)] 
mice (30-40 g; Charles River Laboratories, Inc. Wilmington, MA; and Taconic, 
Germantown, NY, respectively) were maintained on a 12-h light/dark cycle in a temperature- 
and humidity-controlled room with access to water and food ad libitum. All procedures 
involving mice were approved by The Institutional Animal Care and Use Committee of the 
University of North Carolina and were conducted in accordance with “Principles of 
Laboratory Animal Care” (NIH Publication No. 85-23, revised in 1985).  
Opioid Pharmacokinetics and Pharmacodynamics  
Based on the results of pilot studies, 36 mdr1a(-/-) and 36 mdr1a(+/+) CF-1 mice 
received equipotent subcutaneous doses of loperamide (1 or 50 mg/kg, respectively), 
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methadone (0.2 or 0.6 mg/kg, respectively), or fentanyl (0.09 mg/kg, respectively).  The 
loperamide and fentanyl doses were prepared in 50/50 propylene glycol/water, whereas the 
methadone dose was prepared in 0.9% saline. In a separate experiment designed to assess the 
significance of mdr1b on opioid brain penetration and antinociception, 36 mdr1a/b(-/-) and 
36 mdr1a/b(+/+) FVB mice received equipotent subcutaneous doses of loperamide (1 or 25 
mg/kg, respectively). For both sets of experiments, antinociception was assessed; 4 mdr1a(-/-
) and 4 mdr1a(+/+) mice were sacrificed by decapitation for collection of brain tissue and 
trunk blood at selected time points. Trunk blood was collected in 1.5-ml microcentrifuge 
tubes and was allowed to clot for ≥ 30 min at room temperature. Serum was harvested 
following centrifugation. Brain and serum samples were stored at -20°C until analysis by 
HPLC-MS/MS.  
Assessment of Antinociception 
Antinociception was assessed with the hot plate latency test as described elsewhere 
(Chen and Pollack, 1997). Prior to administration of opioids, baseline hotplate latency was 
determined for each animal in triplicate. Hotplate latency was defined as the time interval 
between placement on the hot plate (55°C; Columbus Instruments, Columbus, OH) and first 
observation of a jump or lick of the hind limb(s). Animals with an average baseline latency 
<25 sec were used in the study. A cut-off latency of 60 sec was used to avoid tissue damage. 
The degree of antinociception was calculated as: 
 %𝑀𝑃𝑅 =  𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑥 100% (Eqn. 4.1) 
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Quantitation of Opioids in Serum and Brain Tissue Samples  
Brain samples were homogenized in water (1:2 v/v) via sonic probe. A 25-µl aliquot 
of homogenate or serum was transferred to a HPLC vial, and protein was precipitated with 
100 µl methanol containing internal standard (5 ng/ml loperamide for fentanyl and 
methadone; 20 ng/ml methadone for loperamide). The sample was vortex-mixed, 
centrifuged, and the supernatant was analyzed by HPLC-MS/MS. Samples were injected (3 
µl; CTC Analytics autosampler, Zwingen, Switzerland) onto a Phenomenex 2.0 x 30 mm, 5 
µm Gemini 110A column (Phenomenex, Torrance, CA) maintained at room temperature. 
The total run time was 3 min. Analytes were eluted with a linear gradient consisting of 
ammonium acetate (pH 6.8; 10 mM) [“A”] and methanol [“B”] produced by two Shimadzu 
LC-10ADVP binary pumps. An initial condition of 5% “B” was ramped to 95% “B” over 2 
min, held for 0.5 min, and then returned initial condition of 5% “B” in a single step to re-
equilibrate the column. During the run, the flow rate was increased from 750 to 1500 µl/min 
over the first 2 min, held at 1500 µl/min for 1 min, and then returned the initial flow rate of 
750 µl/min in a single step. The entire column effluent was diverted from the source of the 
PE-Sciex API-4000 quadrupole mass spectrometer (Turbo V Ionspray source, 700˚C, 
PerkinElmerSciex Instruments, Boston, MA) for the first 1 min and last 0.5 min of the run. 
Fentanyl, loperamide, and methadone were measured in positive ionization mode using 
multiple reaction monitoring (337.1→188.3, 477.4→266.0 and 310.3→265.1, respectively). 
Standard curves were prepared in brain homogenate, serum, plasma, or buffer and were 
identical in composition to corresponding samples. 
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Pharmacokinetic-Pharmacodynamic Analysis 
A compartmental modeling approach with distribution between serum and brain 
tissue was used to describe fentanyl, loperamide, and methadone pharmacokinetics. The 
pharmacokinetic model in Figure 4.1 was fit simultaneously to the serum and brain tissue 
concentration-time data using nonlinear least-squares regression analysis (WinNonlin 4.1; 
Pharsight Corporation, Mountain View, CA). The brain volume (Vb) was determined 
experimentally (0.47 ml) assuming a specific gravity of 1.0 ml. All other pharmacokinetic 
parameters were obtained from fitting the kinetic model to the data. The pharmacodynamic 
parameters, EC50 and γ, were determined from fitting a sigmoidal Emax model to the 
antinociception versus brain concentration (C) data. 
 %𝑀𝑃𝑅 = 𝐸୫ୟ୶ 𝑥 𝐶
ఊ
𝐸𝐶ହ଴ + 𝐶ఊ (Eqn. 4.2) 
Emax was defined as 100%, and γ was constrained to the same value for P-gp-competent and 
P-gp-deficient mice. The time course of brain-to-serum ratio (Kp,brain) was used to estimate 
the brain equilibration rate constant (keq) and steady-state brain-to-serum ratio (Kp,brain,ss) 
according to: 
 𝐾௣,௕௥௔௜௡ = 𝐾௣,௕௥௔௜௡,௦௦ (1 − 𝑒ି௞೐೜ ௧) (Eqn. 4.3) 
The brain equilibration half-life (t1/2eq,brain) was obtained from keq: 
 𝑡ଵ
ଶ,௘௤,௕௥௔௜௡
= ln (2)𝑘௘௤  (Eqn. 4.4) 
RESULTS 
In order to achieve similar antinociception between mdr1a(+/+) and mdr1a(-/-) mice, 
mdr1a(+/+) animals received 5- and 50-fold larger doses of methadone and loperamide, 
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respectively. Consistent with receiving a larger dose, the serum concentrations of methadone 
and loperamide in mdr1a(+/+) mice exceeded those in mdr1a(-/-) mice. However, brain 
tissue concentrations were similar between the two strains of mice. The time course of serum 
and brain tissue concentrations in the mdr1a(-/-) and mdr1a(+/+) mice following 
subcutaneous dose of loperamide, methadone, and fentanyl are reported in Figure 4.2. In 
general, the brain concentrations for each opioid were similar between the two mouse strains, 
consistent with the fact that equipotent doses were administered. However, because larger 
doses were administered to P-gp-competent mice, opioid concentrations in the systemic 
circulation were higher in these animals as compared to their P-gp-deficient counterparts, and 
were approximately dose-proportional. Again consistent with the administration of 
equipotent doses in the two mouse strains, the magnitude and duration of fentanyl-, 
methadone-, and loperamide-associated antinociception were similar between mdr1a(-/-) and 
mdr1a(+/+) mice (Figure 4.3).  The fit of the PK/PD model to the concentration vs. time and 
antinociception vs. time data is shown in Figures 4.2 and 4.3, respectively. Corresponding 
estimates of pharmacokinetic and pharmacodynamic parameters obtained from the model are 
reported in Table 4.1.  
The systemic pharmacokinetics of fentanyl and methadone did not differ substantially 
between mdr1a(-/-) and mdr1a(+/+) mice, so in the implementation of modeling estimates of 
systemic pharmacokinetic parameters were constrained to the same values for both mdr1a(-/-
) and mdr1a(+/+) mice. However, differences in loperamide systemic pharmacokinetics 
between P-gp-deficient [mdr1a(-/-) and mdr1a/b(-/-)] and P-gp-competent [mdr1a(+/+) and 
mdr1a/b(+/+)] mice were apparent. Hence, independent estimates of pharmacokinetic 
parameters were obtained for P-gp-deficient and P-gp-competent mice for this agent. The 
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systemic pharmacokinetics of fentanyl were most consistent with a two-compartment model, 
whereas a one-compartment model best described the systemic pharmacokinetics of 
methadone and loperamide (Table 4.1 and 4.2). 
The antinociception versus opioid serum and brain concentration relationships are 
shown in Figures 4.4 and 4.5, respectively.  For each of the opioids, the antinociception 
versus serum concentration relationship evidenced a counterclockwise hysteresis, consistent 
with delayed distribution between serum and the biophase. Compared to mdr1a(-/-) mice, the 
antinociception versus serum concentration relationship in mdr1a(+/+) mice was shifted 
rightward 1.9-, 7-, and 44-fold for fentanyl, methadone, and loperamide, respectively. In 
contrast, no hysteresis or rightward shift was observed in the antinociception versus brain 
concentration relationships. A sigmoidal Emax model was capable of adequately describing 
the relationship between antinociception and brain concentrations. There was no difference in 
brain EC50 between mdr1a(-/-) and mdr1a(+/+) mice for any of the opioids examined. The 
brain EC50 estimates for loperamide in mdr1a/b(-/-) and mdr1a/b(+/+) mice were consistent 
with the brain EC50 from mdr1a(-/-) and mdr1a(+/+) mice (Table 4.1 and 4.2). The time 
course of Kp,brain, as well as the antinociception versus serum and brain tissue concentration 
relationships (Figure 4.7, panels C, D, and E, respectively), were similar between the P-gp-
competent CF-1 mdr1a(+/+) and FVB mdr1a/b(+/+) mice, and between the P-gp-deficient 
CF-1 mdr1a(-/-) and FVB mdr1a/b(-/-) mice.  
P-gp-mediated efflux reduced the Kp,brain of fentanyl, methadone, and loperamide by 
1.9-, 7.2-, and 44-fold, respectively (Figure 4.6 and Table 4.1). P-gp efflux did not prolong 
the brain equilibrium half-life. To the contrary, P-gp efflux decreased the time to 
brain/plasma equilibration of loperamide and methadone by ~2-fold. 
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DISCUSSION 
Previous studies have indicated that P-gp-mediated efflux attenuates the brain uptake 
and antinociception of fentanyl, methadone, and loperamide. In this study, a PK/PD 
modeling approach was used to more fully elucidate the mechanism(s) by which P-gp 
attenuates brain penetration and antinociception. Multiple mechanisms may be involved in 
the attenuation of antinociception, including alteration in systemic pharmacokinetics (e.g., 
decreased bioavailability or increased clearance), reduction in brain penetration (e.g., 
decreased brain uptake and/or increased brain efflux), and alteration of drug distribution 
within the brain (e.g., increased brain EC50). 
Estimates of systemic pharmacokinetic parameters for fentanyl and methadone were 
similar between mdr1a(-/-) and mdr1a(+/+) mice, indicating no change in systemic 
pharmacokinetics due to P-gp-mediated efflux. However, different pharmacokinetic 
parameters were necessary to fit the model to the loperamide serum concentration vs. time 
data from the mdr1a(-/-), mdr1a(+/+), mdr1a/b(-/-), mdr1a/b(+/+) mice. This difference in 
loperamide pharmacokinetics between the different groups of mice may not be due to P-gp-
mediated efflux, but rather to non-linear pharmacokinetics.  
The loperamide serum concentrations in mdr1a(-/-) mice were poorly described by 
the pharmacokinetic model in Figure 4.1, regardless of whether the one- or two-compartment 
system was used. The estimate for Ka from the model consistently converged to the 
maximum valued allowed, and had a large associated variance. Since the Ka was large and 
could not be estimated with reasonable accuracy, the data set was treated as an i.v. bolus and 
Ka was removed as a fitted parameter. A two-compartment model with bolus input, 
consistent with this approximation, yielded parameter estimates with the lowest variance, and 
was best able to fit the serum concentration-time data in mdr1a(-/-) mice.  
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In order to avoid acute toxicity in the P-gp-competent FVB mice, it was necessary to 
reduce the dose of loperamide by half compared to the P-gp-competent CF-1 mice (25 vs. 50 
mg/kg).  The increased sensitivity towards loperamide toxicity in the FVB P-gp-competent 
mice is attributed to lower systemic clearance (28 vs 58 ml·min-1·kg-1), not to any innate 
difference in pharmacology or P-gp activity. Serum and brain tissue concentrations, as well 
as antinociception, were similar between the FVB mdr1a/b(+/+) and CF-1 mdr1a(+/+) mice 
at one-half the dose.  
A counterclockwise hysteresis in the antinociceptive effect versus serum 
concentration relationship was observed for both mdr1a(+/+) and mdr1a(-/-) mouse strains, 
consistent with delayed distribution between the serum and the biophase. The antinociception 
versus serum concentration relationship shifted rightward in P-gp-competent animals, in 
proportion to the fold change in Kp,brain. Similarly, the ED50 of loperamide and methadone in 
P-gp-competent mice shifted rightward ~30-fold and ~5-fold compared to P-gp-deficient 
mice (data not shown).  No hysteresis was observed in the antinociceptive effect versus brain 
concentration relationship. The brain EC50 was identical between P-gp-deficient and P-gp-
competent mice. These results are consistent with the brain being the site of opioid action. 
The loperamide brain EC50 estimates for the mdr1a(+/+), mdr1a(-/-), mdr1a/b(+/+), and 
mdr1a/b(-/-) mice were similar suggesting that P-gp (neither the mdr1a nor the mdr1b gene 
product) had no effect on brain EC50 and that brain EC50 were similar between CF-1 and FVB 
mouse strains. 
Previously, this laboratory demonstrated a 10-fold difference in brain tissue EC50 
between mdr1a/b(-/-) and mdr1a/b(+/+) mice for the cyclic opioid peptide DPDPE (Chen 
and Pollack, 1998). This observation has been used to support the hypothesis that P-gp efflux 
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not only limits access to the brain via the BBB, but parenchymal expression of P-gp may also 
limit access of P-gp substrates to biophase once the P-gp substrates have crossed the BBB. 
Another study conducted with morphine indicated that P-gp-mediated efflux had no effect in 
brain tissue EC50 between mdr1a(-/-) and mdr1a(+/+), even though P-gp efflux increased the 
ED50 by reducing the Kp,brain,ss (Zong and Pollack, 2000). Results from this study are 
consistent with the previous observations for morphine, as there was no difference in brain 
EC50 of fentanyl, methadone, and loperamide between mdr1a(-/-) and mdr1a(+/+) mice. 
However, it should be noted that DPDPE is specific agonist for the delta opioid receptor, 
whereas fentanyl, methadone, and loperamide are mu opioid agonists.  Whether this 
difference has any bearing on P-gp related difference in brain EC50 requires further 
investigation. 
P-gp-mediated efflux reduced the Kp,brain of fentanyl, methadone, and loperamide by 
1.9-, 7.2-, and 44-fold, respectively. These results are consistent with previously reported 
values for methadone and loperamide (16- and 65-fold, respectively) (Kalvass et al., 2004; 
Wang et al., 2004).  The Kp,brain was reduced through the attenuation of brain uptake and the 
enhancement of brain efflux. This is evident by the fact that the Clup was smaller, and the 
Clefflux was larger, in the P-gp-competent mice compared to P-gp-deficient mice. The effect 
of P-gp-mediated efflux on brain uptake was generally more significant than on brain efflux. 
The location of P-gp on the apical membrane of capillary endothelial cells allows it to more 
effectively attenuate brain uptake than enhance brain efflux (Thiebaut et al., 1989).  This is 
consistent with the present observation that P-gp-mediated efflux attenuated the brain uptake 
clearance of loperamide by ~20-fold (0.8 vs 0.04 ml·min-1·kg-1) and enhanced brain efflux of 
loperamide only by ~1.5-fold (0.2 vs 0.3 ml·min-1·kg-1). Furthermore, the brain equilibration 
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rate constant was about 2-fold higher, and the brain equilibrium half-life was shorter, in P-
gp-competent as compared to P-gp-deficient animals. Consistent with P-gp attenuating brain 
uptake and enhancing brain efflux, P-gp-mediated efflux reduced the extent (Kp,brain) but not 
the rate (Keq,brain) of brain distribution.  
An explanation for why P-gp efflux affects uptake to a larger extent than efflux can 
be achieved by considering the orientation of P-gp in the BBB, and by taking into account 
the diffusional barriers a molecule must traverse to cross the BBB. In order for a molecule to 
transverse the BBB, it must cross both the apical and basolateral membranes of the 
endothelial cell. P-gp is present on the apical membrane and pumps in the direction of the 
capillary lumen (Tsuji et al., 1992). During brain uptake, a drug first encounters the apical 
membrane followed by the basolateral membrane. The presence of P-gp on the apical 
membrane allows it to severely limit brain uptake. However, during egress from the brain the 
drug first encounters the basolateral membrane followed by the apical membrane. In the 
complete absence of P-gp, the basolateral and apical membranes equally dictate the rate of 
drug egress from the brain. When P-gp-mediated efflux is present and is sufficiently large, P-
gp efflux reduces the resistance of the apical membrane to the point that it is no longer a 
diffusional barrier, and only the basolateral membrane is a barrier to movement out of the 
brain. In the absence of efflux, two barriers restrict drug egress from the brain. However, 
with efflux these two barriers can be effectively reduced to one barrier, resulting in an 
increase in drug efflux. If the membrane permeability is similar between the apical and 
basolateral membranes, then P-gp would be expected to increase efflux from the brain by no 
more than 2-fold. Further evidence supporting this hypothesis is that the brain equilibration 
half-life, which is inversely proportional to the rate of efflux from the brain, was about 2-fold 
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shorter in the P-gp-competent animals. Other studies indicate a similar effect of P-gp efflux 
on  brain equilibration half-life (Letrent et al., 1999; Sugiyama et al., 2003). 
In summary, this study demonstrated that P-gp-mediated efflux reduced 
antinociception of fentanyl, methadone, and loperamide by attenuating Kp,brain. This was 
evident by rightward-shifts in the antinociception versus serum concentration relationship, 
identical brain tissue EC50 between P-gp-competent and P-gp-deficient mice, and that brain 
Clup was increased while brain Clefflux was decreased in P-gp-competent mice. Although the 
extent of brain penetration (Kp,brain) was reduced by P-gp efflux, the rate of equilibration 
(Keq,brain) of drug between serum and brain was increased by P-gp efflux. The effects of P-gp-
mediated efflux on opioid brain penetration and antinociception appear to be due to the 
mdr1a isoform of P-gp.  
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Table 4.2.  Parameter estimates for loperamide in FVB mice 
Parameter loperamide (FVB mice) 
 mdr1a/b(+/+) mdr1a/b(-/-) 
Ka (min-1) 0.12±0.04 0.24±0.11 
Cl (ml·min-1·kg-1) 28±4 100±20 
Vc (ml·kg-1) 13000±1000 15000±3000 
Cld (ml·min-1·kg-1) - - 
Vp (ml·kg-1) - - 
Clup (ml·min-1·kg-1) 0.02±0.05 0.88±0.19 
Clefflux (ml·min-1·kg-1) 0.2±0.7 0.27±0.06 
   
EC50 (ng/g) 82±6 61±5 
γ 2.9±0.6 
   
Kp,brain 0.13±0.02 18±3 
Keq (min-1) 0.009±0.003 0.0028±0.0008 
t1/2eq,brain (min) 77±20 250±70 
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Figure 4.1.  Pharmacokinetic-pharmacodynamic model for opioid disposition and 
antinociception in mice. Pharmacokinetic parameter were obtained by fitting the above 
model to the time course of serum and brain concentrations of mdr1a(-/-) and mdr1a(+/+) 
mice following subcutaneous administration of opioid. Except for loperamide, the absorption 
rate constant (Ka), central volume (Vc), and systemic clearance (Cl), peripheral volume (Vp), 
and distributional clearance (Cld) were held constant between mdr1a(-/-) and mdr1a(+/+) 
mice; whereas, the brain uptake (Clup) and brain efflux clearances (Clefflux) were allowed to 
vary between mdr1a(-/-) and mdr1a(+/+) mice. The brain volume (Vb) was fixed. The effect 
parameters, EC50 and γ, were obtained by fitting a sigmoidal Emax model to the brain 
concentration versus antinociception data. Emax was defined as 100%. 
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CHAPTER 5 
PHARAMCOKINETICS AND PHARMACODYNAMICS OF ALFENTANIL IN P-
GLYCOPROTEIN-COMPETENT AND P-GLYCOPROTEIN-DEFICIENT MICE: P-
GLYCOPROTEIN EFFLUX ALTERS ALFENTANIL BRAIN DISPOSITION AND 
ANTINOCICEPTION. 
This chapter has been published in Drug Metabolism and Disposition 
and is presented in the style of that journal. 
ABSTRACT 
Previous studies have indicated that P-glycoprotein (P-gp) attenuates the central 
nervous system penetration and central activity of some opioids. The impact of P-gp-
mediated efflux on the disposition and efficacy of the synthetic opioid alfentanil currently is 
unknown. In this study, P-gp-competent [mdr1a(+/+)] and P-gp-deficient [mdr1a(–/–)] mice 
were used to investigate the impact of P-gp-mediated efflux on the systemic 
pharmacokinetics, brain disposition, and central activity of alfentanil. Equipotent doses of 
alfentanil were administered to mdr1a(+/+) and mdr1a(–/–) mice (0.2 and 0.067 mg/kg, 
respectively), and the time course of brain and serum concentrations as well as 
antinociception were determined. A pharmacokinetic-pharmacodynamic (PK-PD) model was 
fit to the data and used to assess the impact of P-gp on parameters associated with alfentanil 
disposition and action. The mdr1a(+/+) mice were less sensitive to alfentanil than mdr1a(–/–) 
mice, requiring a 3-fold higher dose to produce similar antinociception. PK-PD modeling 
revealed no differences in alfentanil systemic pharmacokinetics between P-gp expressers and 
nonexpressers. However, the steady-state brain-to-serum concentration ratio (Kp,brain,ss) was 
~3-fold lower in mdr1a(+/+) mice compared with mdr1a(–/–) mice (0.19 ± 0.01 versus 0.54 ± 
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0.04, respectively). Consistent with the 3-fold lower Kp,brain,ss, the antinociception versus 
serum concentration relationship in mdr1a(+/+) mice was shifted 3-fold rightward 
compared with mdr1a(–/–) mice. However, there was no difference in the antinociception 
versus brain concentration relationship, or in the brain tissue EC50 (11 ± 1.8 versus 9.2 ± 1.7 
ng/g), between mdr1a(+/+) and mdr1a(–/–) mice. These results indicate 1) that alfentanil is 
an in vivo P-gp substrate and 2)  are consistent with the hypothesis that P-gp-mediated efflux 
attenuates antinociception by reducing alfentanil Kp,brain,ss.  
INTRODUCTION 
P-glycoprotein (P-gp) is the 170-kDa protein product of the multidrug resistance gene 
(mdr1) first identified for its ability to confer multidrug resistance in tumor cells (Juliano, 
1976; Gros et al., 1986). P-gp mediates excretory and barrier functions in several tissue (e.g., 
proximal tubular cells of the kidneys, the canalicular membrane of hepatocytes in the liver, 
the apical membrane of intestinal enterocytes, and the luminal membrane of brain capillary 
endothelial cells) (Thiebaut et al., 1987; Cordon-Cardo et al., 1989, 1990). P-gp seems to 
play a protective role in intact mammals by attenuating absorption, facilitating excretion, and 
restricting distribution to several tissue sites, including the central nervous system, of many 
structurally diverse xenobiotics, including calcium channel blockers, human 
immunodeficiency virus protease inhibitors, immunosuppressants, and opioids (Matheny et 
al., 2001).  
Concomitant administration of P-gp inhibitors with P-gp substrates may lead to 
clinically significant drug interactions (Ho and Kim, 2005). For example, although the 
antidiarrheal agent loperamide is a potent opioid agonist, it is not centrally active due, in part, 
to P-gp-mediated efflux at the blood-brain barrier (BBB) (Schinkel et al., 1996). However, 
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when loperamide and the P-gp inhibitor quinidine were coadministered to subjects, 
respiratory depression was observed, which was attributed to an increase in loperamide brain 
concentration caused by P-gp inhibition (Sadeque et al., 2000). Although the precise 
mechanism of this interaction has not been verified, the potential for enhanced central effects 
of P-gp substrates due to P-gp inhibition is nonetheless clear.  
Studies have demonstrated that P-gp attenuates the brain distribution and central 
activity of several opioids. For example, Thompson et al. (2000) showed that fentanyl, 
morphine, and methadone resulted in increased and prolonged antinociception in mdr1a(–/–) 
mice compared with mdr1a(+/+) mice. Likewise, the cyclic peptide opioid [D-Pen2,D-Pen5]-
enkephalin produced increased antinociception in mdr1a(–/–) mice as opposed to their P-gp-
expressing counterparts (Chen and Pollack, 1998). The P-gp inhibitor GF120918 was able to 
restore [D-Pen2,D-Pen5]-enkephalin-mediated antinociception in mdr1a(+/+) mice to levels 
observed in the mdr1a(–/–) mice (Chen and Pollack, 1999). The P-gp inhibitor verapamil also 
was capable of increasing morphine brain concentrations and morphine-associated 
antinociception in mdr1a(+/+) mice (Zong and Pollack, 2000).  
Alfentanil is a synthetic opioid used for the induction of surgical anesthesia and the 
management of postsurgical pain. The alfentanil dose needs to be individualized based on 
numerous factors, including pathological condition, use of other medicines, and the type and 
duration of the surgical procedure (Scholz et al., 1996). Because alfentanil is a CYP3A4 
substrate, CYP3A4 activity is another important determinant of the required alfentanil dose 
(Kharasch and Thummel, 1993). Many compounds are substrates of both CYP3A4 and P-gp. 
If alfentanil is a P-gp substrate, P-gp may be a determinant of the required alfentanil dose, a 
possible a source of interpatient variability, and a potential locus of drug-drug interactions.  
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The impact of P-gp-mediated efflux on the pharmacokinetics and central 
pharmacodynamics of alfentanil is unknown. Initial pilot experiments in this laboratory 
indicated P-gp-mediated efflux reduces alfentanil-associated antinociception. To investigate 
these observations further, and to evaluate whether P-gp efflux activity may contribute to 
interpatient variability in alfentanil response or serve as a locus of drug-drug interactions, the 
present study was undertaken to determine the impact of P-gp-mediated efflux on the 
systemic pharmacokinetics, brain disposition, and central activity of alfentanil. A PK-PD 
modeling approach was used to assess the mechanism(s) by which P-gp-mediated efflux 
influences alfentanil-associated antinociception.  
MATERIALS AND METHODS 
Materials.  
Alfentanil was obtained from Taylor Pharmaceuticals (Decatur, IL), and loperamide 
was purchased from Sigma-Aldrich (St. Louis, MO). All other reagents were obtained from 
common sources and were of reagent grade or better.  
Animals.  
Male CF-1 mdr1a(+/+) and mdr1a(–/–) mice (30–40 g; Charles River Laboratories, 
Inc., Wilmington, MA) were maintained on a 12-h light/dark cycle in a temperature- and 
humidity-controlled room with access to water and food ad libitum. All procedures involving 
mice were approved by The Institutional Animal Care and Use Committee of the University 
of North Carolina and were conducted in accordance with Principles of Laboratory Animal 
Care (National Institutes of Health Publication 85-23, revised in 1985).  
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PK-PD Study.  
Based on the results of pilot studies, 36 mdr1a(–/–) and 36 mdr1a(+/+) mice received 
equipotent subcutaneous doses of alfentanil in physiological saline (0.067 and 0.2 mg/kg, 
respectively). At 0.5, 1, 2, 4, 8, 15, 30, 45, and 60 min postadministration, antinociception 
was assessed, and four mdr1a(–/–) and four mdr1a(+/+) mice were sacrificed by decapitation 
for collection of brain tissue and trunk blood. Trunk blood was collected in 1.5-ml 
microcentrifuge tubes and was allowed to clot for 30 min at room temperature. Serum was 
harvested following centrifugation. Brain and serum samples were stored at –20°C until 
analysis by HPLC-tandem mass spectrometry.  
Assessment of Antinociception.  
Antinociception was assessed with the hot-plate latency test as described previously 
(Chen and Pollack, 1997). Before administration of alfentanil, baseline hot-plate latency was 
determined for each animal in triplicate. Hot-plate latency was defined as the time interval 
between placement on the hot-plate (55°C; Columbus Instruments, Columbus, OH) and first 
observation of a jump or lick of the hind limb(s). Animals with an average baseline latency 
<25 s were used in the study. A cut-off latency of 60 s was used to avoid tissue damage. The 
degree of antinociception was calculated as follows: 
 %𝑀𝑃𝑅 = 𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦60 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑥 100% (Eqn. 5.1) 
Quantitation of Alfentanil in Serum and Brain.  
Brain samples were homogenized in water (1:2, v/v) with a sonic probe. A 25-µl 
aliquot of homogenate or serum was transferred to an HPLC vial, and protein was 
precipitated with 100 µl of methanol containing internal standard (5 ng/ml loperamide). The 
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sample was vortex-mixed and centrifuged, and the supernatant was analyzed by HPLC-
tandem mass spectrometry. Samples (3 µl) were injected (autosampler; CTC Analytics, 
Zwingen, Switzerland) onto a Gemini 110A column (2.0 by 30 mm, 5 µm; Phenomenex, 
Torrance, CA) maintained at room temperature. The total run time was 3 min. Analytes were 
eluted with a linear gradient consisting of 10 mM ammonium acetate, pH 6.8 (A) and 
methanol (B) produced by two Shimadzu LC-10ADVP binary pumps. An initial condition of 
5% B was ramped to 95% B over 2 min, held for 0.5 min, and then returned initial condition 
of 5% B in a single step to re-equilibrate the column. During the run, the flow rate was 
increased from 750 to 1500 µl/min over the first 2 min, held at 1500 µl/min for 1 min, and 
then returned to the initial flow rate of 750 µl/min in a single step. The entire column effluent 
was diverted from the source of the API-4000 quadrupole mass spectrometer (Turbo V 
Ionspray source, 700°C; PerkinElmerSciex Instruments, Boston, MA) for the first 1 min and 
last 0.5 min of the run. Alfentanil and loperamide were measured in positive ionization mode 
using multiple reaction monitoring (417.3 268.3 and 477.4 266.0, respectively). Standards 
were prepared in brain homogenate and serum and fitted with a quadratic equation with 1/y 
weighting (0.1–500 ng/ml). Accuracy of standards was within ± 15%.  
Pharmacokinetic-Pharmacodynamic Analysis.  
A compartmental modeling approach with distribution between serum and brain 
tissue was used to describe alfentanil pharmacokinetics. The pharmacokinetic model shown 
schematically in Fig. 5.1 was fit simultaneously to the serum and brain concentration data 
from both mdr1a(–/–) and mdr1a(+/+) mice using nonlinear least-squares regression 
(WinNonlin 4.1; Pharsight, Mountain View, CA). The absorption rate constant (Ka), central 
volume (Vc), and systemic clearance (Cl) did not differ between mdr1a(–/–) and mdr1a (+/+) 
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mice; therefore, they were assumed to be identical when fitting the model to the data from 
both mouse strains simultaneously. The brain uptake (Clup) and brain efflux (Clefflux) 
clearances were allowed to vary between mdr1a(–/–) and mdr1a(+/+) mice. The brain volume 
(Vb) was determined experimentally as 13.4 ml · kg–1, assuming a specific gravity of 1.0 ml. 
The pharmacodynamic parameters EC50 and γ were determined directly from fitting a 
sigmoidal Emax model to the antinociception versus brain concentration (C) data: 
 %𝑀𝑃𝑅 = 𝐸୫ୟ୶ 𝑥 𝐶
ఊ
𝐸𝐶ହ଴ + 𝐶ఊ (Eqn. 5.2) 
Emax was defined as 100%, and γ was constrained to the same value for mdr1a(–/–) 
and mdr1a(+/+) mice. The time course of the brain-to-serum concentration ratio (Kp,brain) was 
used to estimate the brain equilibration rate constant (keq) and steady-state brain-to-serum 
ratio (Kp,brain,ss) according to the following: 
 𝐾௣,௕௥௔௜௡ = 𝐾௣,௕௥௔௜௡,௦௦ (1 − 𝑒ି௞೐೜ ௫ ௧) (Eqn. 5.3) 
The brain equilibration half-life (t1/2eq,brain) was obtained from keq: 
 𝑡ଵ
ଶ,௘௤,௕௥௔௜௡
= 0.693𝑘௘௤  (Eqn. 5.4) 
 RESULTS 
Alfentanil Pharmacokinetics.  
Alfentanil was absorbed rapidly following subcutaneous administration, with peak 
serum and brain concentrations achieved in less than 10 min (Fig. 5.2). Alfentanil clearance 
was high (approximately equivalent to hepatic blood flow), assuming complete absorption 
from the subcutaneous site, and half-life was short (t1/2 < 15 min). Alfentanil serum 
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concentrations were 3-fold lower in the mdr1a(–/–) mice, consistent with those animals 
receiving a 3-fold lower dose than their transporter-competent counterparts. However, the 
time course of brain concentrations in the mdr1a(–/–) and mdr1a(+/+) mice were nearly 
superimposable (Fig. 5.2). Both the systemic and brain tissue pharmacokinetics were capable 
of being described by the pharmacokinetic model (Fig. 5.2; Table 5.1). Parameter estimates 
obtained from the pharmacokinetic model are reported in Table 5.1.  
Alfentanil Pharmacodynamics.  
Pilot experiments indicated that, at equivalent doses, antinociceptive activity was 
lower in mdr1a(+/+) mice than in mdr1a(–/–) mice (data not shown). However, at a 3-fold 
higher dose (0.20 versus 0.067 mg/kg), the magnitude and duration of antinociception in 
mdr1a(+/+) were identical to those in mdr1a(–/–) mice (Fig. 5.3). In both mdr1a(+/+) and 
mdr1a(–/–) mice, alfentanil had a rapid onset of antinociception, a peak effect of ~85% MPR, 
and a rapid offset of action with nociceptive response returning to baseline within 60 min of 
administration. Consistent with a lower alfentanil potency in mdr1a(+/+) mice (due to P-gp-
mediated efflux from the brain), there was a 3-fold rightward shift in the serum 
concentration-effect relationship in transporter-competent versus transporter-deficient mice 
(Fig. 5.4). There was no difference in the brain concentration-effect relationship or brain 
EC50 values between the mdr1a(+/+) and mdr1a(–/–) mice (Fig. 5.5; Table 5.1). The PK-PD 
model adequately described the time course of antinociception, the serum concentration-
effect relationships, and the brain concentration-effect relationships in both mouse strains 
(Figs. 5.3, 5.4, 5.5, respectively). The PK-PD model indicated the presence of a slight 
counterclockwise hysteresis in the antinociceptive effect versus serum concentration 
relationship (Fig. 5.4). However, there was no hysteresis in the antinociceptive effect versus 
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brain concentration relationship (Fig. 5.5). Pharmacodynamic parameter estimates obtained 
from the PK-PD model are reported in Table 5.1.  
Alfentanil Brain Disposition.  
Equilibration of alfentanil between brain and serum occurred rapidly, with state-
steady Kp,brain reached within approximately 4 min. The time course of alfentanil Kp,brain is 
shown in Fig. 5.6. The Kp,brain,ss was less than unity for both mdr1a(+/+) and mdr1a(–/–) 
mice, and the Kp,brain,ss in mdr1a(–/–) mice was 3-fold higher than in mdr1a(+/+) mice (Table 
5.1; Fig. 5.6). Estimates of Clup and Clefflux differed between mdr1a(+/+) and mdr1a(–/–) 
mice, with Clup increased (1.6-fold) and Clefflux decreased (1.6-fold) in mdr1a(–/–) mice. The 
t1/2eq,brain was short ( 1.5 min) in both mdr1a(+/+) and mdr1a(–/–) mice. However, t1/2eq,brain 
was ~1.5-fold longer in mdr1a(–/–) mice (Table 5.1). Consistent with implicit assumptions of 
the PK model, the ratios of Clup/Clefflux [0.18 and 0.47 in mdr1a(+/+) and mdr1a(–/–) mice, 
respectively) were comparable with the respective Kp,brain,ss values (Table 5.1).  
DISCUSSION 
The ATP-dependent efflux transporter P-gp is the protein product of the mdr1 gene, 
and it is expressed in variety of tissues, including the luminal membrane of the BBB 
(Cordon-Cardo et al., 1989, 1990). Several studies have indicated that some opioids have 
reduced brain penetration and attenuated central activity due to P-gp-mediated efflux (Chen 
and Pollack, 1998; Thompson et al., 2000; Zong and Pollack, 2000; Dagenais et al., 2004). 
The influence of P-gp on the pharmacokinetics and central pharmacodynamics of the 
synthetic opioid alfentanil had not been explored previously. Pilot experiments in this 
laboratory indicated that alfentanil produced less antinociception in mdr1a(+/+) mice than in 
mdr1a(–/–) mice, consistent with P-gp-mediated efflux at the BBB. In this study, the time 
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course of antinociception as well as serum and brain concentrations of alfentanil were 
evaluated in mdr1a(+/+) and mdr1a(–/–) mice to investigate the impact of P-gp-mediated 
efflux on the systemic pharmacokinetics, brain disposition, and central activity of alfentanil.  
To achieve a similar degree of antinociception in both mdr1a(+/+) and mdr1a(–/–) 
mice, the dose administered to mdr1a(+/+) mice was 3-fold higher than that in transporter-
deficient animals. Even though the doses were different, pharmacokinetic modeling indicated 
no difference in systemic pharmacokinetics between mdr1a(+/+) and mdr1a(–/–) mice (Table 
5.1). This result was not unexpected, because P-gp often has minimal impact on systemic 
pharmacokinetics following subcutaneous or intravenous administration (Chen et al., 2003).  
In contrast to the serum pharmacokinetics, P-gp had a pronounced effect on alfentanil 
brain pharmacokinetics. The Kp,brain,ss of mdr1a(+/+) mice was ~3-fold lower compared with 
mdr1a(–/–) mice (0.19 versus 0.54). The decrease in Kp,brain,ss was accompanied by a ~1.6-
fold decrease in Clup and ~1.6-fold increase in Clefflux. These observations are consistent with 
the hypothesis that P-gp decreases Kp,brain,ss by both attenuating brain uptake and enhancing 
brain efflux. Similar observations have been reported for other P-gp substrates (Kusuhara et 
al., 1997). The brain and serum concentrations of alfentanil equilibrated rapidly, with a 
t1/2,eq,,brain 1.5 min. This value is similar to previously reported estimates from humans 
(Lotsch, 2005). Unexpectedly, the t1/2,eq,,brain was shorter in the mdr1a(+/+) mice (Table 5.1). 
This observation may be explained by the fact that t1/2,eq,,brain is inversely proportional to 
Clefflux and that P-gp increased Clefflux (~1.6-fold), thereby causing a proportional decrease in 
the t1/2,eq,,brain in mdr1a(+/+) mice (~1.4-fold). Interestingly, this result implies that P-gp-
mediated efflux may reduce equilibration time between brain and systemic concentrations. 
Previously, the short t1/2,eq,,brain of alfentanil had been attributed in part to a small Kp,brain,ss 
 140 
(Upton et al., 1997). In this study, the Kp,brain,ss of alfentanil was less than unity for both 
mdr1a(+/+) and mdr1a(–/–) mice, indicating two important points: first, that a small Kp,brain,ss 
may indeed facilitate rapid equilibrium between systemic and brain concentration, and 
second, that a Kp,brain,ss greater than unity may not be needed, or even desirable, for a central 
nervous system drug with rapid onset and offset of action.  
PK-PD modeling indicated an ~3-fold rightward shift in the antinociception versus 
serum concentration relationship for mdr1a(+/+) mice compared with mdr1a(–/–) mice. PK-
PD modeling also revealed a slight counterclockwise hysteresis in the antinociception versus 
serum concentration relationship for both mdr1a(+/+) and mdr1a(–/–) mice. However, there 
was no hysteresis in the antinociception versus brain concentration relationship, and the brain 
tissue EC50 values between mdr1a(+/+) and mdr1a(–/–) mice were not different. These 
observations are consistent with brain concentrations driving antinociception, and they 
provide compelling evidence that P-gp efflux attenuates alfentanil antinociception by 
reducing Kp,brain,ss.  
This study is the first to show that alfentanil is a P-gp substrate. In contrast, an earlier 
study that examined the transcellular flux of alfentanil across L-MDR1 (expressing P-gp) and 
LLC-PK1 cell monolayers concluded alfentanil was not a P-gp substrate and had low affinity 
toward P-gp (IC50 > 50 µM) (Wandel et al., 2002). There are at least two possible 
explanations for the difference in results between these two studies. First, even though 
murine-human differences in P-gp substrate recognition and transport seem modest for most 
substrates (Yamazaki et al., 2001; Hochman et al., 2002; Takeuchi et al., 2006), there might 
be species differences in the P-gp-mediated transport of alfentanil. This study evaluated the 
in vivo effects of murine P-gp (mdr1a), whereas the previous work studied the human form 
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of P-gp (MDR1) in vitro. Second, in vitro systems often are less sensitive than intact animal 
models for identifying weak P-gp substrates (Polli et al., 2001). In the Wandel et al. (2002) 
study, the basal activity of endogenous efflux transporter(s) in the LLC-PK1 and L-MDR1 
cell lines may have masked P-gp-mediated transport of alfentanil, because flux was higher in 
the basolateral-to-apical direction in both the P-gp-expressing L-MDR1 and control LLC-
PK1 cell monolayers.  
Alfentanil is a CYP3A4 substrate in humans, and it has been used as a noninvasive 
clinical probe to evaluate CYP3A4 activity (Kharasch et al., 2005). The degree of miosis 
produced by alfentanil has been shown to correlate well with alfentanil plasma 
concentrations, and as such alfentanil-pupillometry studies have been used to evaluate 
CYP3A4 activity and to conduct drug-drug interaction studies. An assumption of such studies 
is that any increase or decrease in alfentanil-induced miosis is due primarily to changes in 
CYP3A4 activity (inhibition or induction). The present results showing that alfentanil is a P-
gp substrate indicate that alfentanil-pupillometry studies may have the potential to detect 
alterations in P-gp activity. Previous pupillometry studies conducted with the P-gp substrates 
morphine, fentanyl, methadone, and loperamide have shown that inhibition of P-gp at the 
BBB by the P-gp inhibitor quinidine is modest (Kharasch et al., 2003, 2004ab; Skarke et al., 
2003). Because quinidine is one of the most potent compounds capable of inhibiting P-gp that 
is in clinical use, the likelihood of significant inhibition of P-gp at the BBB seems remote. 
However, future drug-drug interaction studies conducted with alfentanil should be assessed 
carefully to ensure that any observed drug-drug interaction is not caused by P-gp inhibition. 
The clinical significance of alfentanil being a P-gp substrate is not known, but it may be 
modest considering that only a 3-fold P-gp effect was observed in mice, that all human MDR1 
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polymorphisms identified to date retain most functional activity, and that clinically 
significant inhibition of P-gp at the BBB has not been well documented (Ho and Kim, 2005; 
Kerb, 2006).  
In summary, the present study indicated that alfentanil is a P-gp substrate, and that P-
gp-mediated efflux attenuates alfentanil antinociception by reducing Kp,brain,ss. These 
observations may have important implications regarding interindividual differences in 
alfentanil pharmacodynamics and for the risk of drug-drug interactions. Additional studies 
may be warranted to assess the clinical relevance of P-gp efflux as a determinant of alfentanil 
pharmacotherapy. 
  
 143 
Table 5.1.  PK-PD parameters for alfentanil in mdr1a(-/-) and mdr1a(+/+) mice 
Parametera Weighting mdr1a(-/-) mdr1a(+/+) 
Ka (min-1)  0.35 ± 0.03 0.35 ± 0.03 
Cl (ml · min-1 · kg-1) 1/y 82 ± 3 82 ± 3 
Vc (ml · kg-1) 1/y 1000 ± 60 1000 ± 60 
t1/2 (min)  12 ± 0.6b 12 ± 0.6b 
Clup (ml · min-1 · kg-1) 1/y 7 ± 5 4 ± 3 
Clefflux (ml · min-1 · kg-1) 1/y 13 ± 12 22 ± 17 
Vb (ml · kg-1)  13.4 (fixed) 13.4 (fixed) 
EC50 (ng/g) Uniform 9.2 ± 1.7 11 ± 1.8 
γ Uniform 1.8 ± 0.4 1.8 ± 0.4 
Kp,brain 1/y 0.54 ± 0.04 0.195 ± 0.008 
Keq (min-1) 1/y 0.46 ± 0.10 0.64 ± 0.09 
t1/2eq,brain (min)   1.5 ± 0.3 1.08 ± 0.16 
 
a Parameter estimate ± S.E. from nonlinear least-squares regression analysis of pooled 
mdr1a(-/-) or mdr1a(+/+) mouse data. Ka, Cl, Vc, Vb, and γ were constrained to the same 
value for mdr1a(-/-) or mdr1a(+/+) mice. t1/2 and t1/2eq,brain were calculated from 
0.693/(Vc/Cl) and 0.693/Keq,brain, respectively. 
b Propagation of error was used to calculated S.E. 
  
 144 
 
Figure 5.1.  Pharmacokinetic-pharmacodynamic model for alfentanil disposition and 
antinociception in mice. Pharmacokinetic parameters were obtained by fitting the above-
mentioned model to the time course of serum and brain concentrations of mdr1a(–/–) and 
mdr1a(+/+) mice following subcutaneous administration of alfentanil. ka, Vc, and systemic Cl 
were held constant between mdr1a(–/–) and mdr1a(+/+) mice, whereas Clup and Clefflux were 
allowed to vary between mdr1a(–/–) and mdr1a(+/+) mice. The brain volume (Vb) was fixed. 
The effect parameters EC50 and γ were obtained by fitting a sigmoidal Emax model to the 
brain concentration versus antinociception data. Emax was defined as 100%, and γ was 
constrained to the same value for mdr1a(–/–) and mdr1a(+/+) mice. 
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Figure 5.2.  Time course of serum (?) and brain (▲) concentrations following a 0.067- or 
0.2-mg/kg s.c. dose of alfentanil in mdr1a(–/–) (open symbols) or mdr1a(+/+) (solid 
symbols) mice, respectively. Data are presented as mean ± S.E. (n ≥3). Dashed and solid 
lines represent the fit of the PK model to the concentration data for mdr1a(–/–) and 
mdr1a(+/+) mice, respectively. 
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Figure 5.3.  Time course of antinociception following a 0.067- or 0.2-mg/kg s.c. dose of 
alfentanil in mdr1a(–/–) (open symbols) or mdr1a(+/+) (solid symbols) mice, respectively. 
Data are presented as mean ± S.E. (n ≥ 3). Dashed and solid lines represent the fit of the PK-
PD model to the antinociception data for mdr1a(–/–) and mdr1a(+/+) mice, respectively. 
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Figure 5.4.  Relationship between antinociception and serum concentration of alfentanil 
following a 0.067-mg/kg s.c. dose [mdr1a(–/–); ?] or 0.2-mg/kg s.c. dose [mdr1a(+/+); ?]. 
Data are presented as mean ± S.E. [concentration data (n ≥ 3); a                         
ntinociception (n = 4–33)]. Dashed and solid lines represent the fit of the PK-PD model to 
the antinociception and serum concentration data for mdr1a(–/–) and mdr1a(+/+) mice, 
respectively. A slight counterclockwise hysteresis is present for both mdr1a(–/–) and 
mdr1a(+/+) mouse strains. 
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Figure 5.5.  Relationship between antinociception and brain concentration of alfentanil 
following a 0.067-mg/kg s.c. dose [mdr1a(–/–);?] or 0.2-mg/kg s.c. dose [mdr1a(+/+);?]. 
Data are presented as mean ± S.E. [concentration data (n ≥ 3); antinociception (n = 4–33)]. 
Dashed and solid lines represent the fit of a sigmoidal Emax model to the effect data obtained 
from mdr1a(–/–) and mdr1a(+/+) mice, respectively. Gamma was constrained to the same 
value for both mouse strains. 
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Figure 5.6.  Time course of alfentanil Kp,brain in mice following a 0.067-mg/kg s.c. dose 
[mdr1a(–/–);?] or 0.2-mg/kg s.c. dose [mdr1a(+/+);?]. Data are presented as mean ± S.E. 
(n ≥ 3). Dashed and solid lines represent the fit of a kinetic model to the mdr1a(–/–) and 
mdr1a(+/+) data, respectively. 
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PART II 
NOVEL APPROACHES TO CHARACTERIZING PHARMACOKINETICS AND 
PHARMACODYNAMICS 
  
CHAPTER 6 
USE OF A PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODEL 
INCORPORATING SERUM AND BRAIN CONCENTRATIONS TO EXAMINE 
CENTRAL AND PERIPHERAL CONTRIBUTIONS TO ANTINOCICEPTION 
This chapter will be submitted for publication in Journal of 
Pharmacology and Experimental Therapeutics and is presented in the 
style of that journal. 
ABSTRACT 
The purpose of this study was to characterize the influence of behavioral endpoints on 
measures of antinociception assessed using the hot plate latency assay.  The time course of 
opioid antinociception, together with serum and brain tissue concentrations, was determined 
for equipotent doses of loperamide (50 mg/kg), methadone (2 mg/kg), and sufentanil (0.001 
mg/kg).  Antinociception was assessed with two sets of behavioral measures: “standard 
criteria” defined hot plate latency as the time interval between placement on the hotplate and 
the observation of a jump or hind paw lick; “modified criteria” defined latency as the interval 
between placement and observation of a lick, shake or withdrawl of the hind limb(s) or a 
jump.  A PK-PD model was fit to the concentration- and effect- time course, and estimates of 
relevant parameters were recovered.  Loperamide, methadone and sufentanil serum and brain 
concentration time data were best fit by a two-compartment model with first-order absorption 
into the serum, brain tissue residing in a peripheral compartment, and clearance from the 
central (serum) compartment.  A sigmoidal Emax model driven by brain concentrations was 
capable of describing the standard antinociceptive effect, while the modified effect data were 
best fit by an additive sigmoidal Emax model, with components driven separately by serum 
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and brain concentration.  The PD parameter estimates recovered in this analysis were used to 
simulate the individual contributions of serum and brain concentrations to the observed 
modified criteria expression of antinociceptive effect over time.  These simulations revealed 
that serum-mediated antinociception predominates at early timepoints and that as drug 
distributes to central locales, the contribution of brain-driven antinociception to the modified 
effect increases.  This study is the first example of a hot plate latency assay that 
concomitantly assesses central and peripheral opioid antinociception.  The implication of 
these observations is that behavioral endpoint criterion influences measures of hot plate 
latency antinociception, and should be considered when selecting a nociceptive assay. 
INTRODUCTION 
The analgesic effect mediated by opioid receptor binding is a result of the signal 
transduction pathway that induces membrane hyperpolarization, ultimately reducing pain 
transmission.  The three major mammalian types of opioid receptors are designated as µ, δ, 
and κ (Evans et al., 1992; Chen et al., 1993; Li et al., 1993).  Pharmacologic studies using 
opioid receptor ligands and receptor knockout mice identified centrally-located µ-opioid 
receptors (MOR) as the primary mediators of the therapeutic effects associated with 
traditional, alkaloid-derived opioids such as morphine (Matthes et al., 1996; Kieffer, 1999).  
While centrally-mediated antinociception has been the primary focus of opioid research, less 
is known about the role of peripheral opioid receptors as mediators of antinociception. 
The potential for peripherally-mediated antinociception is, in part, supported by the 
broad distribution of opioid receptors on sensory neurons. The MOR is present in a number 
of peripheral tissues, including the small and large intestines, kidney, lung, spleen, testis, 
ovaries and uterus (Wittert et al., 1996).  The µ, δ, and κ-opioid receptors are present in the 
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peritoneum, on cutaneous nerves and unmyelinated cutaneous sensory axons in both normal 
and inflammatory states (Stein et al., 1990; Coggeshall et al., 1997; Labuz et al., 2007).  
Moreover, these peripheral opioid receptors are functional mediators of antinociception.  The 
co-administration of centrally-acting opioids with a peripherally-restricted opioid receptor 
antagonist, naloxone methiodide, significantly decreased antinociception, nearly approaching 
pre-drug baseline responses (Labuz et al., 2007).  Clinically, local morphine administration 
has proven to be efficacious in producing analgesia when injected intraarticularly, in 
situations of chronic tooth inflammation, or into the intraligamentary space following 
arthroscopic knee surgery (Stein et al., 1991; Dionne et al., 2001).  Topical application of the 
opioids, morphine, [D-Ala2-MePhe4-Gly(ol)5]enkephalin (DAMGO) and morphine-6-
glucuronide (M6G) to mouse tails produces antinociception that, following repeated 
exposures, displays tolerance that can be reversed by application of an NMDA receptor 
antagonist (Kolesnikov and Pasternak, 1999).  While the classic opioid paradigm recognizes 
the supraspinal and spinal contributions of opioids, contemporary research also has focused 
on the functionality of peripherally-mediated antinociception.    
A diverse set of assays, incorporating chemical, mechanical, thermal and electrical 
stimuli, have been developed to assess antinociception.  A survey of primary articles 
published between 1970 and 1999 identified chemical and thermal stimuli as the most 
common tests of antinociception (Le Bars et al., 2001).  Depending on the methodology, one 
advantage of thermal stimulus models is the ability to assess antinociception mediated by 
peripheral, spinal and supraspinal sites.  For example, the hot plate latency assay is 
considered an assay of supraspinally-mediated antinociception because it requires central-
processing of the nociceptive input before a response is observed (Le Bars et al., 2001).  In 
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contrast, the radiant heat tail-flick assay is most commonly considered a measure of spinally-
mediated antinociception in that the tail flick response remains, and is sensitive to opioid 
administration, in spinalized animals (Irwin et al., 1951).   
Peripheral antinociception can be assessed with a modified tail flick assay in which a 
segment of the tail is exposed to a low-dose, topical opioid solution that produces 
antinociception in the exposed portions of the tail but not in the surrounding regions; the use 
of radiolabelled drug confirms that the opioid has not distributed to other receptor 
populations to contribute to the effect.  Overall, there are a variety of thermal assays that, 
depending on the methodology, can be used to determine supraspinal, spinal and peripheral 
contributions to antinociception.   
One drawback to thermal assays is the absence of a consistent methodology. In 
particular, methods for the hot plate latency assay vary markedly between studies, employing 
a range of temperatures, cut-off times and behavioral endpoints.  One rationale for this 
variability is that mice exhibit a range of sensitivity to thermal stimuli (Mogil et al., 1999b; 
Mogil et al., 1999a). While ethical considerations dictate minimizing hot plate exposure 
temperatures and times, it is imperative that the influence of assay methodology on measures 
of antinociception be understood.  For example, a variety of behavioral endpoints, including 
any combination of jumping, licking or lifting of the paws, has been used with the hot plate 
assay; while limiting thermal exposure through study endpoint selection is desirable, it is 
difficult to compare antinociception measured by different methodologies.  The experiments 
reported herein were conducted to test the hypothesis that behavioral endpoint criteria 
influences measures of antinociception, and that simultaneously assessing reflexive 
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responses, such as lifting and shaking of the paw, and processed responses, such as jumping 
and licking, will permit differentiation between central and peripheral antinociception.   
METHODS 
Materials 
Methadone and loperamide were purchased from Sigma-Aldrich (St. Louis, MO). 
Sufentanil was purchased from Abbott Laboratories (North Chicago, IL). All other chemicals 
and reagents were of the highest grade available from commercial sources.   
Animals 
Adult male CF-1 mice (30-40 g; Charles River Laboratories, Raleigh, NC) were 
housed in a temperature- and humidity-controlled room with a 12-h light cycle (7 a.m. to 7 
p.m) and free access to food and water. The experimental protocol was approved by the 
Institutional Animal Care and Use Committee of the University of North Carolina and was in 
accordance with the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 
Washington, DC, 1996).   
Study Design  
Loperamide (50 mg/kg), methadone (2 mg/kg), sufentanil (0.001 mg/kg) prepared in 
50:50 propylene glycol:water (loperamide) or 0.9% saline (methadone and sufentanil), was 
administered (0.1-0.2 ml per 30g) as a single subcutaneous dose to mice (n= 4 per time point, 
8-9 time points per drug).  
Antinociception was determined at timed intervals (n=8-9 per drug) post-dose using 
the hot plate (55°C) latency assay.  Latency to respond to the thermal stimulus was defined 
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using two sets of behavioral endpoints, referred to as the standard and modified criteria.  
“Standard criteria” defined latency as the time interval between placement on the hotplate 
and observation of a jump or hind paw lick.  “Modified criteria” defined latency as the 
interval between placement on the hotplate and observation of a lick, shake or withdrawal of 
the hind limb(s), or a jump.  Pre-drug baseline latency was determined in triplicate, and 
animals with pre-drug latencies >15 sec (modified criteria) or >25 sec (standard criteria) 
were excluded from the study.  Post-drug latency was determined at designated time points, 
with a maximum latency of 30 or 60 sec for the modified and standard criteria, respectively.   
Antinociceptive response was calculated as the percent maximum possible response (%MPR) 
with negative values set to zero. 
 % 𝑀𝑃𝑅 = 𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 × 100% (Eqn. 6.1) 
Immediately following post-drug latency testing, animals (n=4 per time point) were 
sacrificed by decapitation, and brain tissue and trunk blood were collected.  Blood samples 
were allowed to clot at room temperature for at least 30 min, and serum was harvested 
following centrifugation. Whole brain tissue was homogenized in HPLC quality water (1:2 
v/v) using an ultrasonic probe.  Samples were prepared for analysis in an HPLC vial using a 
protein precipitation method. An aliquot of sample (2 to 25 µl of serum or brain homogenate) 
was precipitated with methanol (100-250 μl) containing an appropriate internal standard.  
Loperamide (20 ng/ml) was used as the internal standard for methadone and sufentanil and 
methadone (20 ng/ml) served as the internal standard for loperamide.  Following methanol 
addition, samples were vortex-mixed and centrifuged, and an aliquot of supernatant was 
injected on-column for analysis   
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The concentration of loperamide, methadone, or sufentanil in brain and serum was 
determined by LC-MS/MS (PE-Sciex API-4000 triple quadrupole mass 
spectrometer).   Samples (3 µl; CTC Analytics autosampler, Zwingen, Switzerland) were 
injected onto a Phenomenex 2.0 x 30 mm, 5 µm Gemini 110A column (Phenomenex, 
Torrance, CA). Analytes were eluted by ramping the initial gradient of 5% “B” to 95% “B” 
and increasing flow rate from 750 to 1500 µl/min and over the first 2 min, holding “B” at 
95% for 0.5 min and maintaining flow at 1500 µl/min for 1 min, and finally returning mobile 
phase composition and flow rate to initial conditions, for a total run time of 3 min.  Column 
effluent was sent to the source of the mass spectrometer (Turbo V Ionspray source, 700˚C, 
PerkinElmerSciex Instruments, Boston, MA) from 1 to 2.5 min.  Positive ionization mode 
with multiple reaction monitoring was used to measure loperamide (477.4→266.0), 
methadone (310.3→265.2) and sufentanil (387.2→238.4).  
Pharmacokinetic-Pharmacodynamic Modeling 
Loperamide, methadone and sufentanil serum and brain concentration-time profiles 
were fit with a two-compartment model (Figure 6.1)  incorporating first-order absorption (ka) 
of the dose (X0) into the serum, uptake and efflux clearance (Clup, Clef) between serum and 
brain, and systemic clearance (Cl) from the serum compartment.  Opioid disposition at the 
absorption site (XA), serum (XS), and brain (XB) was characterized with the following 
differential equations: 
 𝑑𝑋஺𝑑𝑡 = −𝑘௔ ∙ 𝑋଴ (Eqn. 6.2) 
 𝑑𝑋ௌ𝑑𝑡 ∙ 𝑉஼ = 𝑘௔ ∙ 𝑋஺ − 𝐶𝑙 ∙ 𝑋ௌ − 𝐶𝑙௨௣ ∙ 𝑋ௌ + 𝐶𝑙௘௙ ∙ 𝑋஻ (Eqn. 6.3) 
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 𝑑𝑋஻𝑑𝑡 ∙ 𝑉஻ = 𝐶𝑙௨௣ ∙ 𝑋ௌ − 𝐶𝑙௘௙ ∙ 𝑋஻ (Eqn. 6.4) 
where VS and VB are the apparent volume of distribution for the serum (central compartment) 
and the physiologic volume of brain, respectively.   Brain volume was fixed as 13.4 ml/kg, 
based on an experimentally determined volume of 0.47 ml, assuming a specific gravity of 1.0 
ml, and an average mouse body weight of 35 g (Kalvass et al., 2006).    
Two pharmacodynamic models were employed to describe the standard and modified 
effect-time profiles.  A sigmoidal Emax model characterized the relationship between drug 
concentration in the brain and the standard antinociceptive effect (Figure 6.1, Model 1) with 
the following equation: 
 𝐸ௌ = ா೘ೌೣ ∙ ஼ಳ
ം
ா஼ఱబം ା ஼ಳം
 (Eqn. 6.5) 
where Es is the effect based on standard criteria, Emax is the maximum effect, defined as 
100%, CB is the brain concentration, EC50 is the brain concentration at 50% of the maximum 
effect and γ is the Hill factor. 
The antinociceptive effect based on modified criteria was characterized by fitting an 
additive sigmoidal Emax model incorporating serum and brain concentrations as contributors 
to pharmacologic response (Figure 6.1, Model 2): 
 𝐸ெ = ா೘ೌೣ ∙ ஼ೄ
ം,ೄ
ா஼ఱబ,ೄം,ೄ ା ஼ೄം,ೄ
+ ா೘ೌೣ ∙ ஼ಳ
ം,ಳ
ா஼ఱబ,ಳം,ಳ ା ஼ಳം,ಳ
 (Eqn. 6.6) 
where EM is the modified effect, Emax is the maximum effect, defined as 100%, CS is the 
serum concentration, CB is the brain concentration, EC50,S is the serum concentration at 50% 
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of the maximum effect,  EC50,B is the brain concentration at 50% of the maximum effect, and 
γ,S and γ,B are the Hill factors for serum and brain, respectively. . Due to the additive nature 
of the modified effect model, the overall maximum effect is 200% MPR, 100% from each 
matrix.  
Nonlinear least-squares regression was used to fit pharmacokinetic and 
pharmacodynamic models to the concentration and effect data using WinNonlin software 
(Pharsight Corporation, Mountain View, CA).  The model schemes were selected based on 
Aikike’s Information Criteria (AIC), the goodness of fit using the coefficients of variation (% 
CV) and visual inspection of the distribution of residual error. 
RESULTS  
Estimates of key pharmacokinetic/pharmacodynamic parameters for loperamide, 
methadone and sufentanil were recovered with stepwise nonlinear least-squares regression.  
Opioid pharmacokinetics (the time course of serum and brain tissue concentrations) were 
best described with a two-compartment model (Figure 6.1) with first-order absorption into 
the central compartment. The ability of the model to describe the disposition of each drug is 
displayed in Figure 6.2.  The best numerical estimates for each pharmacokinetic parameter 
(Table 6.1), obtained in this step of the analysis, were held constant for subsequent modeling 
of the time course of pharmacologic response. 
Antinociceptive response based on standard criteria was characterized by fitting a 
sigmoidal Emax model (Figure 6.1, Model 1) to the effect vs. brain concentration data.  In 
general, this model described the standard criteria effect data well (Figure 6.3), and provided 
final parameter estimates with reasonable apparent precision (Table 6.2).  Pilot studies were 
conducted to determine equipotent doses of loperamide, methadone and sufentanil.  Although 
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loperamide has a ~4.5-fold lower brain EC50 compared to methadone (Table 6.2), a 50-fold 
higher loperamide dose was administered to achieve an antinociceptive effect similar to that 
produced by methadone.  This difference is attributed primarily to P-glycoprotein (P-gp)-
mediated efflux at the blood-brain barrier (BBB); loperamide exhibits a 40-fold P-gp effect 
(attenuation of brain uptake attributable to P-gp) compared to only a 7-fold effect for 
methadone (Kalvass et al., Submitted).  The rank order of BBB penetration is further 
confirmed with Clup parameter estimates of 0.039-, 5.2- and 8.6-ml/min·kg for loperamide, 
methadone, and sufentanil, respectively.  Rapid onset of effect was observed for sufentanil 
and methadone, with a time of maximal effect (Tmax) of 7.5- and 10-min, respectively. In 
contrast, loperamide exhibited a gradual onset of effect, with an Emax of 75% MPR at 120 
min. 
A sigmoidal Emax model incorporating both serum and brain opioid concentrations as 
mediators of overall antinociceptive response was fit to the effect data based on the modified 
criteria (Figure 6.1, Model 2).  This analytical approach recovered estimates of four 
pharmacodynamic parameters for each opioid: EC50,S, γS, EC50,B, and γB (Table 6.3).  
Reflexive behaviors (hind paw lifting and shaking) generally preceded the observation of 
processed behaviors (jumping and licking) and resulted in a lower % MPR over time for the 
modified compared to standard effect profiles.  Furthermore, the modified criteria exhibited 
earlier onset and offset of effect compared to the standard antinociception time course 
(Figure 6.3).   
A counterclockwise hysteresis in the relationship between standard criteria effect 
versus serum concentrations was observed, whereas standard criteria effect versus brain 
concentrations exhibited a sigmoidal relationship with no evidence of hysteresis behavior 
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(Figure 6.4).  These observations suggest that opioid concentrations in serum are not in rapid 
equilibrium with concentrations in brain tissue, and that antinociceptive effect based on the 
standard criteria is driven by brain concentrations for loperamide, methadone and sufentanil.  
In contrast, the relationship between effect based on modified criteria and serum 
concentrations evidenced a slight degree of hysteresis, with a more substantial hysteresis 
behavior observed for the relationship between modified criteria effect versus brain 
concentrations (Figure 6.5).   
The pharmacodynamic parameters recovered from the modified criteria effect data 
(Table 6.3) were used to simulate the apparent individual contributions of serum and brain 
concentrations to overall modified effect (Figure 6.6).  The initial effect was driven 
predominantly by serum concentrations; as time progressed, the contribution of effect driven 
by brain tissue concentrations to the overall modified effect increased.  These changes in 
fractional contribution to overall effect paralleled the time course of brain:serum 
concentration ratios. The contribution of serum concentration-driven response to the 
modified effect exceeded the contribution associated with brain concentrations at all time 
points.   
Figure 6.7 presents the simulated effect vs. concentration relationships for the 
apparent serum and brain contributions to the modified criteria effect.  These effect-
concentration relationships suggest the possibility that an opioid can exhibit substantial 
antinociceptive response that appears to be mediated by serum, as opposed to brain, 
concentrations.  
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DISCUSSION 
The hot plate latency assay is a common method of assessing antinociception in 
preclinical species, particularly mice.  One disadvantage of this assay is an inability to detect 
antinociception in some drug classes (e.g. NSAIDS) that are recognized clinically as 
analgesics (Hammond, 1989).  Thus, this model can be used only to ascertain antinociception 
for specific drug classes, such as opioids.  An additional complication associated with the hot 
plate latency model, as well as with other thermal stimulus assays, is poor predictability of 
clinical analgesia, which can be attributed in part to a diversity of assay methodologies used 
to generate data sets subjected to correlative analysis.  Some of the inter-study differences 
can be attributed to the high degree of variability in rodent thermal sensitivities, where higher 
temperatures or longer exposure times may be required for heat-insensitive strains, whereas 
heat-sensitive strains exhibit shorter response latencies, often at lower temperatures (Mogil et 
al., 1999a).   
While these different methodologies often are selected in order to minimize 
nociceptive input, difficulties are encountered when trying to interpret results from different 
studies.  Furthermore, the hot plate latency behavioral endpoint criteria are highly variable, 
including various combinations of lifting and shaking of the hind paw, jumping or hindpaw 
licking, and to some extent may be subjective.  While each of these responses represent a 
reasonable endpoint, little is known about the mechanistic aspects of antinociception that are 
assessed by each combination of behavioral endpoints.  Ultimately, the ideal assay would 
minimize thermal exposure, assess a specific and known component of antinociception (e.g., 
spinal versus supraspinal), and be transferable between different strains within a given rodent 
species.    
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In the present study, the influence of hot plate behavioral endpoints on measures of 
antinociception was examined.  As would be predicted, reflexive endpoints such as lifting 
and shaking of the hind paw resulted in shorter response latencies compared to centrally-
processed behaviors such as jumping and licking of the hind paws (Figure 6.3).  This 
observation is in agreement with previous work describing two distinct behavioral responses 
following exposure of the shaved back of a rat to a light beam; an initial twitch of the 
exposed skin followed shortly thereafter by a retraction of the entire body (Ercoli and Lewis, 
1945). Results of this study revealed that both the twitching and escape response were 
sensitive to opioid-associated antinociception, with the latter response more sensitive to 
modulation by opioids (Ercoli and Lewis, 1945).  While the different nociceptor populations, 
Aδ fibers (which produce early, pricking sensations) and C-fibers (which cause a second, 
persistent pain state) likely play a role in these observations, the two distinct antinociceptive 
responses suggest the possibility that opioid receptor populations in multiple physiologic 
locales mediate antinociception separately (Yeomans and Proudfit, 1996), with the overall 
response measurement resulting from the combination of all contributing locales. 
The hypothesis that centrally-located opioid receptors play a primary role in 
mediating antinociception is supported in the present study by the sigmoidal relationship 
between the standard criteria effect and brain concentrations (Figure 6.4B).  The 
distributional delay in equilibration of opioid concentrations between serum and brain tissue 
results in a counterclockwise hysteresis behavior in the relationship between the standard 
criteria effect and serum opioid concentrations (Figure 6.4A).   
While central opioid receptors are important mediators of antinociception, recent 
results have implicated peripheral opioid receptors in mediation of antinociception (Reichert 
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et al., 2001; Shannon and Lutz, 2002; Kolesnikov et al., 2004; Labuz et al., 2007).  While 
some of these studies have suggested that peripheral receptors function predominantly in 
states of inflammatory pain, the hypothesis that opioid antinociception is mediated through a 
combination of central and peripheral receptor populations is now broadly accepted.  
One challenge in isolating the contribution of central versus peripheral opioid 
receptors to net antinociceptive response is the absence of an assay that teases apart each 
contribution from the overall effect profile.  While assays that characterize supraspinal, 
spinal and peripheral antinociception have been developed and are well-characterized, they 
often fail to assess the comprehensive physiologic response.  A relevant example of this point 
is provided by the current data.  When describing antinociceptive pharmacodynamics when 
response was expressed with the modified behavioral criteria, neither serum opioid 
concentrations nor brain opioid concentrations alone could adequately describe the 
magnitude and time course of pharmacologic activity.  The ability to describe the time course 
of antinociception was improved (Figure 6.6) by a model that allowed both serum and brain 
tissue concentrations to drive separate but additive antinociceptive responses (Figure 6.1, 
Model 2).   
The relationship between modified criteria effect and serum concentrations was 
characterized by a slight hysteresis (Figure 6.5A), a consequence of the contribution of brain 
receptor occupancy to the net effect.  The large hysteresis behavior observed when the 
modified criteria effect was related to brain tissue concentrations supports the premise that 
opioid receptor occupancy in the brain is a relatively minor contributor to net antinociception 
as expressed by the modified criteria (Figure 6.5B).   
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The pharmacodynamic parameters recovered from fitting Model 2 (Figure 6.1) to the 
modified criteria effect data were used to isolate the peripherally- and centrally-mediated 
contributions to effect over time (Figure 6.6).  All opioids exhibited an early, rapid onset of 
effect that appeared to be mediated by serum concentrations.  As time progressed and drug 
distributed to central sites, the contribution of brain tissue concentrations to overall 
antinociceptive response increased.  Despite this time-dependent increase in the apparent 
contribution of central activity to net effect, in all cases the predicted central response 
contributed less than the peripheral response (driven by serum concentrations) to the overall 
effect based on modified criteria (Figure 6.6).   
The fractional contributions of peripheral (based on serum concentrations) and central 
(based on brain concentrations) antinociception to overall modified criteria effect reveal that, 
while it is possible to achieve 100% serum- or brain-mediated effect (Figure 6.7), in practice 
this may be difficult due to the high doses required and potential for side effects.  
Loperamide serves as an excellent example of this principle, as a 50-mg/kg dose resulted in a 
55% overall effect based on the modified criteria; a 2-fold increase in dose (to 100 mg/kg) 
resulted in 100% mortality (data not shown).  Overall, the additive response that comprises 
the modified effect reveals the importance of opioid receptor populations throughout the 
body.    
The interaction between supraspinal, spinal and peripheral contributions to 
antinociception has been characterized as being synergistic (Kolesnikov et al., 1996).  In 
contrast, the present study utilized an additive model to describe brain- and serum-mediated 
antinociception. This result may provide insight into mechanisms underlying opioid 
tolerance.  For example, if two distinct opioids are administered, one at a low dose that 
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primarily targets central tissues, and the other at a medium to high dose that targets 
peripheral tissues, effective analgesia may be accomplished, with a delay in tolerance onset, 
because the receptor populations are not working synergistically in tolerance development.  
In fact, the effectiveness and increasing popularity of co-administering multiple low-dose 
opioids may in part be attributed to the additive relationship observed in this study.  
One consequence of using different behavioral endpoint criteria is the inability to 
recover consistent pharmacodynamic parameters.  This study used preliminary dose ranging 
strategies to determine the ED50 for loperamide, methadone and sufentanil. These pilot data 
were used to select a dose that elicited approximately 80% MPR with respect to the standard 
criteria endpoint.  In comparison, an ED50 calculated using the modified criteria endpoint 
would be much higher because of the lower response latency compared to the standard 
criteria.  An additional consideration is that fitting both sets of effect measurements with 
Model 1 (Figure 6.1) would recover two very different EC50 values, with the value for the 
modified criteria effect being much higher compared to the standard criteria effect.  
Furthermore, selecting the modified criteria as a measure of centrally-mediated 
antinociception would result in a poor fit of the pharmacodynamic model to the observed 
effect.  Loperamide and sufentanil brain EC50s are 2- and 6-fold greater when calculated 
when recovered using the standard (Eqn. 6.1) versus the modified criteria (Eqn. 6.2; Tables 
6.2 and 6.2).  In contrast, methadone is more potent in the brain when effect is assessed using 
the modified criteria, evidenced by a 1.5-fold decrease in brain EC50, compared to the 
standard criteria.  These EC50 observations suggest that some opioids may have a more 
substantial central contribution than others, and that characterizing the peripheral 
contributions with the modified criteria may reveal unique opioid characteristics.  The 
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differences in EC50 values highlight one source of the inter-laboratory variability in 
recovered PD parameter values for a single compound.   
This study is the first example of an assay that appears to concurrently assess central 
and peripheral opioid antinociception.  Results indicate that when performing the hot plate 
latency assay, reflexive behaviors of hind limb licking and shaking are representative of a 
combination of peripheral and central contributions to antinociception, inferred by the 
correspondence to both serum and brain opioid concentrations, whereas the centrally-
processed behaviors of jumping and licking of the hind paw are more reflective of central 
receptor occupancy (driven solely by opioid concentration in brain tissue).  Future work will 
be required to assess the sensitivity of the modified criteria by perturbing central and 
peripheral contributions to antinociception.  Overall, this study highlights the importance of 
selecting suitable hot plate latency assay methodology based on what type of antinociceptive 
response is to be characterized.   
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Table 6.1.  Pharmacokinetic parameter estimates [mean (% CV)] derived using non-linear 
regression analysis. 
Parameter loperamide methadone sufentanil 
Ka (min-1) 0.064 (25) 0.57 (23) 0.30 (37) 
Cl (ml·min-1·kg-1) 58 (12) 140 (8.7) 19 (16) 
Vc (ml·kg-1) 32000 (8.1) 8300 (5.8) 380 (22) 
Clup (ml·min-1·kg-1) 0.039 (140) 5.2 (12) 8.6 (40) 
Clefflux (ml·min-1·kg-1) 0.31 (160) 2.1 (15) 6.0 (48) 
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Table 6.2.  Pharmacodynamic parameter estimates [mean (% CV)] by fitting Model 1 to the 
standard effect data using non-linear regression analysis. 
Parameter loperamide methadone sufentanil 
EC50 (ng/g) 100 (6.1) 430 (7.5) 0.50 (30) 
γ 2.4 (20) 3.1 (30) 1.1 (32) 
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Table 6.3.  Pharmacodynamic parameter estimates [mean (% CV)] derived by fitting Model 
2 to the modified effect data using non-linear regression analysis. 
Parameter loperamide methadone sufentanil 
EC50,S (ng/ml) 1800 (12) 520 (5.9) 1.8 (30) 
γS 2.2 (55) 8.8 (35) 1.8 (37) 
EC50,B  (ng/g) 190 (11) 270 (6.8) 2.9 (26) 
γB 7.0 (55) 2.7 (16) 5.0 (135) 
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Figure 6.1.  Pharmacokinetic-pharmacodynamic models characterizing opioid disposition 
and antinociception.  Model 1 and 2 used to recover key PK-PD parameters by fitting a two-
compartment model to the time course of opioid serum and brain concentrations.  Model 1 
recovered pharmacodynamic parameters by fitting a sigmoidal Emax model to the brain 
concentration versus standard antinociception time profile.  Model 2 recovered key 
pharmacodynamic parameters by fitting sigmoidal Emax model to the serum- and brain-
concentration versus modified antinociceptive effect profile. 
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Figure 6.2.  Time course of observed and predicted (solid lines) opioid serum (closed 
symbols) and brain (open symbols) concentrations (mean ± S.E;  n ≥ 3) following 
subcutaneous administration of 50-mg/kg loperamide (A), 2-mg/kg methadone (B) and 
0.001-mg/kg sufentanil (C). 
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Figure 6.3.  Time course of observed and predicted (solid lines) opioid standard (solid 
symbols) and modified (closed symbols) antinociceptive effect (mean ± S.E; n = 4 to 36) 
following administration of loperamide (A), methadone (B) and sufentanil (C). 
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Figure 6.4.  Relationship between standard antinociceptive effect and concentration for 
loperamide (?), methadone (?) and sufentanil (?).  A)  The counterclockwise hysteresis 
between the standard effect and serum concentrations.  B) The sigmoidal relationship 
between standard effect and brain concentration.  Symbols represent observed data [mean ± 
S.E for concentration (n ≥ 3) and effect (n = 4 to 36)] and solid lines represent the fit of 
Model 1 to the standard antinociceptive effect and concentration data.   
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Figure 6.5.  Relationship between modified antinociceptive effect and serum (A) or brain (B) 
concentrations for loperamide (?), methadone (?) and sufentanil (?).  Symbols represent 
observed data [mean ± S.E for concentration (n ≥ 3) and effect (n = 4 to 36)] and solid lines 
represent the fit of Model 2 to the modified antinociceptive effect and concentration data. 
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Figure 6.6.  Contribution of serum (solid gray line) and brain (dashed black line) to overall 
observed (symbols; n = 4 to 36) and predicted (solid black line) modified antinociceptive 
effect for loperamide (?), methadone (?) and sufentanil (?). 
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Figure 6.7.  Pharmacodynamic parameter estimates for modified antinociceptive effect were 
used to simulate serum (solid black line)- and brain (dashed black line)-mediated 
contributions to modified effect for loperamide (A), methadone (B) and sufentanil (C). 
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CHAPTER 7 
INFLUENCE OF TRUNCATING THE DYNAMIC RANGE OF PHARMACOLOGIC 
EFFECT MEASUREMENTS ON PHARMACODYNAMIC PARAMETER ESTIMATES 
This chapter will be submitted for publication in Drug Metabolism 
Letters and is presented in the style of that journal. 
ABSTRACT 
Hotplate latency is commonly used to assess drug-associated antinociception in 
rodents.  Analysis of data generated by this assay often is confounded by the artificial ceiling 
imposed by cut-off times (e.g. censoring) for exposure to the thermal stimulus implemented 
to prevent tissue damage.  This study was conducted to examine the feasibility of estimating 
the true maximum effect (Emax) in the absence of an artificial ceiling in the analysis of typical 
pharmacodynamic data. This approach was evaluated by fitting a linked pharmacokinetic-
pharmacodynamic model, including a sigmoidal relationship between effect and hypothetical 
effect-compartment concentrations, to the time course of drug disposition and 
antinociception after subcutaneous administration of fentanyl (0.09 mg/kg) or morphine (3.6 
mg/kg) to mice.  Recovering an estimate of the true Emax, rather than truncating the dynamic 
range of effect, improved the fit of the model for both drugs, dynamic range of effect 
increased from 65% to 100% of the theoretical maximum effect, and estimates of ke0, EC50 
and γ more closely approximated previously-reported values.  Simulations were performed to 
examine the influence of effect-range truncation on estimates of EC50. Increasing degrees of 
truncation resulted in increased underprediction of EC50; the magnitude of underprediction 
was modulated by sigmoidicity in the relationship between effect and concentration.  In 
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summary, inclusion of Emax as an estimated parameter, rather than a fixed arbitrary ceiling 
value, represents an alternative method for analyzing antinociceptive effect data. The 
principles communicated herein are applicable to analysis of pharmacodynamic data 
generated by any pharmacologic model in which an arbitrary maximum response is 
implemented or assumed.  
INTRODUCTION  
Characterization of pharmacologic response requires the use of specific and sensitive 
assays that are validated and reproducible.  Quantifying antinociception in animal models is 
particularly challenging, and a diverse set of assays that utilize chemical, electrical, 
mechanical or thermal stimuli has been developed to evaluate alterations in rate, frequency, 
extent or time to response following opioid administration (D'Amour and Smith, 1941; Ercoli 
and Lewis, 1945; Collier et al., 1961; Paalzow, 1969b; Paalzow, 1969a; Hunskaar et al., 
1985).  In the hotplate assay, one of the more common systems utilized, an animal is placed 
on a metallic surface heated to a specified temperature (50 to 60°C) and the time interval 
until observation of a jump or hind paw lick is recorded (Woolfe and Macdonald, 1944).  
Data analysis can be quantal, presented as a percentage of animals that respond over a 
designated time period, or more often as a graded metric of response (Woolfe and 
Macdonald, 1944; O'Callaghan and Holtzman, 1975).  While quantal analysis avoids some of 
the methodological limitations imposed by graded analysis, it fails to utilize all available data 
and more crude estimation of efficacy.    
Graded analysis utilizes individual time-to-response data, and presents those data as 
absolute latency or as a percentage response.  When graded analysis is utilized, maximum 
exposure cut-off times, typically between 30 and 60 sec for the hotplate assay, are 
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implemented to prevent or minimize damage to tissues exposed directly to the thermal 
stimulus (Le Bars et al., 2001).  While an ethical necessity, exposure cut-off times can skew 
data and hinder the use of parametric statistical and pharmacodynamics analyses when 
subjects approach or reach the cut off time.  Use of cut-off times typically involves 
establishing individualized dynamic ranges for drug response ranging from 0% (i.e., pre-drug 
latency) to “100%” (i.e., the established cut-off time) of maximum possible response (% 
MPR).   
One disadvantage associated with this method of analysis is its sensitivity to 
experimental manipulations.  For example, by increasing cut-off time from 30 to 60 sec, a 
25-sec response time with a 5-sec pre-drug latency decreases the apparent response from 80 
to 36% MPR.  While a higher cut-off time may be justifiable, for example if a thermally-
insensitive strain of mice is used, the same absolute response time can impact the calculation 
of % MPR, and in turn will be reflected in estimates of EC50 and γ when relating response to 
metrics of drug exposure (Mogil et al., 1999).  Further complications associated with % MPR 
calculations in the presence of a ceiling effect occur when multiple subjects exhibit responses 
at or greater than the imposed cut-off time.  In this case, subjects will demonstrate identical 
apparent responses, while the actual biologic responses could be quite different. While 
various methods of data analysis have been proposed for this experimental situation, 
alternative approaches to data analysis are needed, particularly when performing integrated 
PK-PD analysis. In this specific case, the failure to produce elevations in antinociception 
commensurate with increases in drug concentration can significantly impede the ability to 
recover estimates of key pharmacodynamics parameters (Kitchen and Crowder, 1985).   
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The present study was conducted to investigate the influence of Emax truncation on the 
ability to analyze antinociceptive data with traditional PK-PD paradigms. To this end, an 
integrated PK-PD model was fit to effect vs. time and concentration vs. time data for fentanyl 
and morphine in the mouse hotplate model. Two analysis approaches were evaluated: effect 
referenced to an arbitrary Emax of 100% MPR, or effect referenced to an Emax that was 
recovered as a parameter in the overall analysis scheme. The effect of Emax truncation on PD 
parameter estimates was examined further by simulating earlier cutoff times, thereby 
increasing degrees of truncation compared to the hypothetical value of Emax recovered by PK-
PD modeling.  The influence of Emax truncation on estimates of EC50, and the potential 
modulation of this effect by the degree of sigmoidicity in the effect vs. concentration 
relationship, also was explored through simulation experiments.   
MATERIALS AND METHODS 
Materials 
Fentanyl, loperamide, morphine, and oxycodone were purchased from Sigma-Aldrich 
(St. Louis, MO).  All other reagents were obtained from common sources, and they were of 
reagent grade or better. 
Animals 
Adult male CF-1 mdr1a(+/+)  and mdr1a(-/-) mice (30–40 g; Charles River 
Laboratories, Inc., Wilmington, MA) were maintained on a 12-h light/dark cycle in a 
temperature- and humidity-controlled room with access to water and food ad libitum. The 
experimental protocol was approved by the Institutional Animal Care and Use Committee of 
the University of North Carolina and was in accordance with the Guide for the Care and Use 
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of Laboratory Animals (Institute of Laboratory Animal Resources, Commission on Life 
Sciences, National Research Council, Washington, DC, 1996).   
Pharmacokinetic-Pharmacodynamic Study.  
Based on the results of pilot experiments, mdr1a(-/-) or mdr1a(+/+) CF-1 mice 
received a single equipotent subcutaneous dose of fentanyl (0.09 mg/kg) or morphine (3.6 
mg/kg), respectively.  Fentanyl was prepared in 50:50 propylene glycol/water, and morphine 
was prepared in 0.9% saline.  Antinociception was assessed using the hot plate latency assay 
as described previously (Kalvass et al., 2007).  Latency was defined as the time interval 
between placement on the hotplate (55°C; Columbus Instruments, Columbus, OH) and 
observation of a jump or hind paw lick.  Pre-drug baseline latency was determined in 
triplicate.  A maximum latency time of 60 sec was used to avoid tissue damage and animals 
with pre-drug latencies >25 sec were excluded from the study.  Post-drug latency was 
determined at designated time points and antinociceptive response was calculated as the 
percent maximum possible response (%MPR; Eqn. 7.1) with negative values set to zero. 
 %𝑀𝑃𝑅 =  𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑥 100% (Eqn. 7.1) 
Immediately following the terminal post-drug latency test, trunk blood was collected 
(n=4 animals per time point), allowed to clot for at least 30 min at room temperature and 
serum was harvested after centrifugation.  Serum samples were stored at –20°C until analysis 
by HPLC-MS/MS.  
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Bioanalysis Methodology 
Samples were prepared for analysis in an HPLC vial using a protein precipitation 
method, where an aliquot of serum (25 µl) was precipitated following the addition of 4- or 
10-volumes of methanol containing loperamide (5 ng/ml) or oxycodone (100 ng/ml) as an 
internal standard for fentanyl and morphine, respectively.  Prior to undergoing LC-MS/MS 
(PE-Sciex API-4000 triple quadrupole mass spectrometer) analysis, samples were vortex-
mixed and centrifuged.  Sample supernatant (3 µl; CTC Analytics autosampler, Zwingen, 
Switzerland) was injected onto a Phenomenex 2.0 x 30 mm, 5 µm Gemini 110A column 
(Phenomenex, Torrance, CA).  The initial column condition of 5 % methanol: 95 % 
ammonium acetate (pH 6.8; 10 mM) was immediately (fentanyl), or following 0.5 min 
(morphine), ramped to 95 % methanol over 2 min and held for 0.5 min before being returned 
to starting conditions in a single step.  The flow rate was concurrently increased from 750 to 
1500 µl/min over 2 min, held at 1500 µl/min for 1 min, and returned the initial flow rate of 
750 µl/min in a single step.  Column effluent was sent to the source of the mass spectrometer 
(Turbo V Ionspray source, 700˚C, PerkinElmerSciex Instruments, Boston, MA) from 1 to 2.5 
min.  Multiple reaction monitoring in the positive mode was used to measure fentanyl 
(337.1→188.3), loperamide (477.4→266.0), morphine (286.1→201.1) or oxycodone (316.0 
→ 298.0).  Standard curves were prepared in serum or buffer and were identical in 
composition to corresponding samples. Accuracy of standards and interassay variability was 
within ± 20%. 
Pharmacokinetic-Pharmacodynamic Modeling 
Fentanyl and morphine serum concentration-time profiles were fit with a one-
compartment model (Figure 7.1) incorporating first-order absorption (k01) of the dose (X0) 
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into the systemic circulation, contained in a central compartment of apparent volume Vc, with 
first-order elimination (k10) from the compartment.  Opioid disposition in the absorption site 
(XA) and in the central, serum compartment (XC) was characterized (Eqns. 2 and 3) using 
nonlinear least-squares regression (WinNonlin, Pharsight Corporation, Mountain View, CA). 
 𝑑𝑋஺𝑑𝑡 = −𝑘଴ଵ ∙ 𝑋଴ (Eqn. 7.2) 
 
𝑑𝑋஼
𝑑𝑡 ∙ 𝑉஼ = 𝑘଴ଵ ∙ 𝑋஺ − 𝑘଴ଵ ∙ 𝑋஼  (Eqn. 7.3) 
The dissociation between the time course of antinociception and serum concentrations 
was addressed by linking a hypothetical effect site with the central pharmacokinetic 
compartment, assuming a rate of equilibration governed by a first-order rate constant ke0 
(Figure 7.1; Eqn. 7.4). The relationship between antinociceptive effect and drug 
concentration in the hypothetical effect compartment was assumed to be sigmoidal (Eqn. 
7.5). The PD parameters ke0, EC50, and γ were estimated in a stepwise approach by fitting 
these equations to the observed antinociceptive response vs. time data, with Emax fixed at 100 
% or recovered as a parameter with no theoretical limit.   
 𝑑𝐶௘𝑑𝑡 = 𝑘௘଴ ∙ (𝐶௖ − 𝐶௘) (Eqn. 7.4) 
 𝐸 = ா೘ೌೣ ∙ ஼೐
ം
ா஼ఱబം ା ஼೐ം
 (Eqn. 7.5) 
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Pharmacodynamic Simulations of Emax Truncation 
The influence of Emax truncation on estimates of ke0, EC50 and γ was examined using 
fentanyl and morphine data sets.  Varying degrees of Emax truncation were simulated by 
fixing Emax between 60% and 150%, in 10% increments, and recovering estimates of the key 
PD parameters incorporated in the model equations.  Fentanyl and morphine PK parameter 
estimates recovered from nonlinear least-squares regression were held constant during all 
simulations. 
In a second set of simulations, the effect versus concentration relationship was 
simulated based on the sigmoidal Emax function (Eqn. 7.5) at three different degrees of 
sigmoidicity: γ =1, γ = 2, or γ = 4.  In all cases, EC50 was set at 100 concentration units, and 
effect was allowed to range from 0 to 100%. The effect versus concentration relationships 
then were truncated under five different maximum allowable response (MAR) scenarios: 
100% of the theoretical maximum (i.e., no truncation), or 80%, 60%, 40%, or 20% of the 
theoretical maximum.  Under each truncation scenario, the effect data were transformed 
relative to the MAR. The apparent EC50 recovered from each %MAR versus concentration 
relationship was obtained by inspection (n=1000 simulated data points per profile). 
RESULTS  
The fentanyl and morphine doses administered to mice produced robust 
antinociception with at least one time point at which effect reached the pre-defined cut-off 
(100 % MPR), as assessed using the hotplate latency assay.  For both drugs, the time course 
of serum concentrations was adequately described with a one compartment system 
incorporating first-order absorption from the site of administration and drug elimination from 
the serum compartment (Figures 7.2 and 7.3).  Drug distribution from serum to the site of 
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action was characterized using a biophase distribution model incorporating the first-order 
equilibrium rate constant ke0.   
The time course of antinociception was described by a sigmoidal Emax model with 
Emax fixed at 100% or as determined as a model parameter.  Estimates of relevant PK-PD 
parameters for the fixed and variable Emax models are presented in Tables 7.1 and 7.2, 
respectively.  The observed peak effect was underpredicted when Emax was fixed at 100% 
(Figure 7.2), whereas the inclusion of Emax as a variable parameter improved the fit (Figure 
7.3).   
The influence of Emax truncation on fentanyl and morphine parameter estimates and 
associated variability was assessed with simulation experiments by fixing Emax between 60% 
(representing the maximum degree of truncation) and 150% (no truncation).  As the value of 
Emax approached the theoretical maximum of 150%, the PD parameter estimates become 
more representative of the true parameter values.  The PD parameter that was most sensitive 
to Emax truncation was EC50, evidenced by a 1.8- and 3.3-fold increase in estimated parameter 
value for fentanyl and morphine, respectively, when Emax was increased from 100 to 150% 
(Figure 7.4). The sigmoidicity factor of both opioids decreased in concert with increasing 
values of Emax, whereas decreasing truncation moved estimates of ke0 in opposing directions. 
Additional simulations examined three effect versus concentration relationships 
representing varying degrees of sigmoidicity: γ =1, γ = 2, or γ = 4. As effect data were 
increasingly truncated (i.e., as MAR decreased from 100% to 20 %; Panel A in Figures 7.5-
7.7), the EC50 recovered from the %MAR versus concentration relationship decreased (Panel 
B in Figures 7.5-7.7). The influence of truncation on the EC50 was modulated by the degree 
 192 
of sigmoidicity in the relationship between the actual response and concentration (Figure 
7.8). As γ increased, the perturbation of EC50 associated with data truncation decreased. 
DISCUSSION 
The present study presents a modified approach to modeling antinociceptive effect 
data that are skewed by the presence of one or more data points at or near a pre-defined 
maximum degree of response.  The serum- and effect-time courses were described by a one-
compartment PK model linking serum concentrations to antinociception with a hypothetical 
effect compartment.  A sigmoidal Emax model, with Emax fixed at 100% MPR, was applied to 
the time course of fentanyl and morphine antinociception. While this traditional modeling 
approach adequately described the onset of effect, peak response was underpredicted (Figure 
7.2).  The inclusion of Emax as a variable in the PD model, as opposed to a fixed ceiling, 
improved the fit. The associated parameter estimates (Table 7.2) were used to predict the 
observed time course of antinociception as well as the time course of antinociception in the 
absence of a 60-sec cut-off (Figure 7.3).  As the extent of Emax truncation decreased, the 
dynamic range of effect increased from 65 to 100% of the theoretical range.  Consequently, 
the estimates of fentanyl and morphine EC50 increased, whereas the apparent degree of 
sigmoidicity decreased (Figure 7.4).  In contrast, the value of ke0, the rate constant of 
equilibrium between serum and the hypothetical effect compartment, increased for fentanyl 
but decreased for morphine (Figure 7.4).  This seemingly contradictory observation may be 
explained, in part, by differences in the time delay between serum concentrations and onset 
of effect.  As the value of Emax approached the theoretical estimate, the dissociation between 
concentration and effect increased for fentanyl, as evidenced by a decrease in the value of 
ke0. In contrast, the estimate for morphine, a drug with a modest degree of dissociation 
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between the time course of drug action and drug disposition, increased as the value of Emax 
increased.  The hypothesis that ke0 is better approximated as Emax approaches its hypothetical 
value is supported by the observed shift of predicted values towards previously-reported 
estimates of ke0 as 0.31 and 0.02 min-1 for fentanyl and morphine, respectively  (Gardmark et 
al., 1993; Cox et al., 1998).  Determining whether PD parameter estimates are better 
approximated when Emax approaches its theoretical value could be assessed further by 
administering lower opioid doses that do not reach or exceed the 60-sec threshold and 
comparing the recovered parameter values.   
The use of exposure cut-off times imposes an artificial ceiling on responsivity, which 
can result in the underestimation of EC50.  While the disagreement between predicted and 
theoretical parameter estimates is mitigated as the degree of sigmoidicity increases, drugs 
with small γ values are more common than those with large values, primarily because the all-
or-none, switch-like effects associated with large γ values present challenges in dose titration, 
particularly for drugs with a narrow therapeutic window (Dutta et al., 1996).  The present 
simulations demonstrate that Emax truncation influences parameter estimates and should be 
considered when translating estimates between species or into a clinical population.  While 
hotplate exposure cut-off times are emphasized in this study, the principles highlighted in 
these simulations can be extended to other methodological issues associated with the 
characterization of pharmacologic response.   
The opposing situation, of a theoretical maximum effect that exceeds the range of 
observable effects, presents similar complications in recovering parameter estimates by PK-
PD data analysis.  This situation may arise for a number of reasons, including the desire to 
achieve a minimal effect compared to a theoretical maximum, such as the antipyretic effects 
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of paracetamol, or the existence of intolerable side effects that limit characterization of the 
entire range of responsivity (Anderson et al., 1998).  In situations in which the entire range of 
effect cannot be examined, the relationship between maximum allowable response 
(expressed as a percentage of the theoretical maximum response) and the recovered EC50 
(expressed as a percentage of the true EC50) presented in Figure 7.8 can be used to 
extrapolate the theoretical value of Emax and EC50.  Previous studies characterizing the 
relationship between parameter estimates and observed effect found that the closer the 
observed response to Emax, the greater the reliability of recovered estimates (Dutta et al., 
1996; Schoemaker et al., 1998).  Because achieving 95% effect is not always feasibility, an 
alternative parameter, S0, has been proposed to represent the ratio of Emax/EC50 when a 
portion of the sigmoidal Emax curve is known (Schoemaker et al., 1998).  Continued 
examination of the relationship between observed and theoretical response in relation to 
maximum effect will ultimately improve pharmacodynamic characterization of diverse 
effects, over both large and small ranges. 
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Table 7.1.  Final parameter estimates from traditional PK-PD modeling. 
 
fentanyl morphine 
mdr1a(-/-) mdr1a(+/+) 
Parameter Estimate CV% Estimate CV% 
k01 (min-1) 0.02 30.5 0.25 24 
k10 (min-1) 100 12.4 96 13 
V (ml/kg) 1500 38 2800 12 
ke0 (min-1) 0.79 35 0.012 68 
EC50 (ng/ml) 2.8 9.7 29 84 
γ 2.3 14 1 83 
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Table 7.2.  Final parameter estimates from traditional PK-PD modeling. 
 
fentanyl morphine 
mdr1a(-/-) mdr1a(+/+) 
Parameter Estimate CV% Estimate CV% 
k01 (min-1) 0.02 31 0.25 24 
k10 (min-1) 100 12 96 13 
V (ml/kg) 1500 38 2800 12 
ke0 (min-1) 0.57 35 0.014 62 
EC50 (ng/ml) 5.2 62 96 58 
γ a 1.0 - 1.0 - 
Emax (%) a  155 - 150 - 
a  A stepwise approach was used to fit γ and Emax,.  The value of Emax was fixed as the 
estimate and γ was set as 1.0 prior to fitting ke0 and EC50. 
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Figure 7.1.  Scheme of the pharmacokinetic-pharmacodynamic model for opioid disposition 
and antinociception in mice.  Pharmacokinetic parameters were obtained by fitting the model 
to the time course of group averaged serum concentrations and estimates were obtained for 
the absorption rate constant (k01), central volume (V) and first-order elimination rate constant 
(k10).  The effect parameters k01, EC50, γ, and Emax were obtained by fitting an effect 
compartment model to the time course of serum concentrations and antinociception. 
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A 
 
B 
 
Figure 7.2.  Influence of Emax fixed at 100% on the time course of antinociception.  Data 
points represent observed antinociception (▲) and serum (?) concentrations following 
subcutaneous administration of 0.9 mg/kg fentanyl (A) or 3.6 mg/kg s.c. morphine (B) to 
mice.  Data are presented as mean ± S.E. (n ≥ 3, serum concentration; n = 4 to 18, 
antinociception).  Lines represent the fit of the model to the time course of antinociception 
(solid gray), serum (dashed black), and effect (solid black) compartment concentration data. 
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A 
 
B 
Figure 7.3.  Influence of a variable Emax on the predicted time course of antinociception.  
Data points represent observed antinociception (▲) and serum (?) concentrations following 
subcutaneous administration of 0.9 mg/kg fentanyl (A) or 3.6 mg/kg s.c. morphine (B) to 
mice.  Data are presented as mean ± S.E. (n ≥ 3, serum concentration; n = 4 to 18, 
antinociception).  Lines represent the fit of the model to the time course of antinociception 
(solid gray), serum (dashed black), and effect (solid black) compartment concentration data.   
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Figure 7.5.  Effect versus concentration relationships expressed as actual response (A) or 
relative to the maximum allowable response (MAR; B) when MAR was 100%, 80%, 60%, 
40%, or 20% of the theoretical maximum. Relationships were generated with a sigmoidal 
Emax model, γ=1. 
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Figure 7.6.  Effect versus concentration relationships expressed as actual response (A) or 
relative to the maximum allowable response (MAR; B) when MAR was 100%, 80%, 60%, 
40%, or 20% of the theoretical maximum. Relationships were generated with a sigmoidal 
Emax model, γ=2. 
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Figure 7.7.  Effect versus concentration relationships expressed as actual response (A) or 
relative to the maximum allowable response (MAR; B) when MAR was 100%, 80%, 60%, 
40%, or 20% of the theoretical maximum. Relationships were generated with a sigmoidal 
Emax model, γ=4. 
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Figure 7.8.  Relationship between the apparent EC50 (expressed as a percentage of the true 
EC50) and the maximum allowable response (expressed as a percentage of the theoretical 
maximum response) for truncated effect data. Effect versus concentration data were 
simulated with a sigmoidal Emax model, with γ =1, γ =2, or γ =4. 
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CHAPTER 8 
THE INFLUENCE OF PHARMACOKINETIC AND PHARMACODYNAMIC 
PARAMETERS ON HYSTERESIS LOOP AREA 
ABSTRACT 
Purpose: The objective of this study was to develop a computational method to 
quantitate the area bounded by a hysteresis loop (ABH) and to utilize this METHOD to 
determine the influence of pharmacokinetic (PK) and pharmacodynamic (PD) parameters on 
ABH. 
Methods: An effect-compartment (sigmoidal Emax) PK/PD model was used to 
simulate blood (CB) and biophase (CE) concentration- and effect-time profiles. The influence 
of PK/PD parameters on the effect vs. concentration relationships was examined by varying 
parameter values. ABH was calculated in Matlab by subtracting the area under the ascending 
curve was subtracted from the area of the descending curve.  An image processing program 
was used to validate measurements of ABH. 
Results:  Good agreement was observed between ABH measurements using Matlab 
and ImageJ (r2>0.99), suggesting that the computational approach returned a precise measure 
of the hysteresis area. The technique then was used to explore fundamental relationships 
between ABH and PK/PD parameters. The ABH for the effect vs. CB hysteresis increased 
linearly with dose, was inversely related to Cl and V, and asymptotically approached a 
limiting value as the value of Ka increased.  A biphasic relationship was observed between 
ABH and PD parameters, ke0 and EC50. 
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Conclusions: The approach for calculating ABH provided reliable estimates of the 
effect-CB ABH.  Simulations indicated that the ABH is sensitive to changes in PK/PD 
parameters, and that the relationship between ABH and PK/PD parameters would be 
amenable to laboratory investigation. 
INTRODUCTION 
In situations of receptor-mediated pharmacologic responses, the magnitude of 
response is assumed to be proportional to the fraction of the receptor population occupied at 
a particular drug concentration. In this case, if concentrations in the biophase (CE) are in 
immediate equilibrium with concentrations in blood (CB), and the effect (E) is elicited 
instantaneously, reversible, and time-invariant, the relationship between E and CB can be 
described with a sigmoidal Emax model.  A classic example of this simple pharmacodynamics 
case is the neuromuscular blocker turbocurarine, for which the relationship between degree 
of paralysis and blood concentrations is sigmoidal (Gibaldi and Levy, 1972).  In contrast to 
this simple time-independent relationship, a time-dependent dissociation between systemic 
drug disposition and the time course of pharmacologic effect produces a more complicated 
effect versus concentration relationship, often referred to as a hysteresis loop.  Hysteresis 
loops that progress chronologically in a counterclockwise direction are indicative of delays in 
effect elaboration compared to presentation of the agent to the systemic circulation, whereas 
hysteresis loops that progress in a clockwise direction, also known as proteresis, are most 
commonly observed in the presence of acute tolerance development. 
The prevalence of counterclockwise hysteresis loops in the effect versus systemic 
concentration relationship can be attributed in part to the diverse physiologic processes that 
mediate pharmacologic response. Many different mechanisms or factors can result in 
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hysteresis behavior. One such example is the formation of an active metabolite from a 
prodrug, for which the degree of dissociation between E and CB is related to the rate of 
metabolite formation and elimination (Gupta et al., 1993).  Hysteresis loops can also be a 
consequence of delayed effect elaboration after drug-receptor binding, e.g., when a signal 
transduction cascade is initiated and a series of events are required before an effect is 
realized. Finally, if the receptor biophase is pharmacokinetically distinct from the systemic 
circulation, a delay in drug equilibration between the target organ and/or biophase and blood 
will result in a temporal dissociation between E and CB. This situation was addressed by 
Shiner et al. (Sheiner et al., 1979) with the indirect-link PK/PD model, a parametric analysis 
approach that utilizes CB and E data to generate a time course for substrate concentrations in 
a hypothetical effect compartment (CE). A sigmoidal relationship between E and CE then is 
used to recover the primary PD parameters: EC50, the concentration resulting in 50% of 
maximum drug effect, and Emax, the maximal drug effect, in addition to a rate constant 
governing the time course of concentrations at the putative effect site, ke0, and a sigmoidicity 
factor, γ.  An alternative method of hysteresis minimization addresses the influence of 
sampling locales by including the rate of equilibration between arterial (CA) and venous (CV) 
concentrations, as well as between CA and CE.  If CA and CV equilibrate rapidly, but 
distribution from CA to CE is slow, sampling CA will yield a counterclockwise hysteresis for 
the E vs. CA relationship, whereas sampling CE will yield a sigmoidal curve in the 
relationship between E and CE (Verotta et al., 1989; Tuk et al., 1997).  Overall, a number of 
processes contribute to the observation of hysteresis loops and a variety of mathematical and 
experimental techniques have been developed to minimize the presence of hysteresis loops. 
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There is a relative lack of information regarding the degree to which the area bounded 
by a hysteresis loop (ABH) can be used as a meaningful system descriptor. For example, 
Gastonguay and Schwartz simulated multiple IV dosing for a drug that exhibits distributional 
delays to the effect site and acute tolerance (Gastonguay and Schwartz, 1994).  These authors 
utilized a computational technique that minimized the distributional hysteresis in order to 
reveal the true extent of tolerance.  A more quantitative approach developed by Upton and 
Doolette (Upton and Doolette, 2002) involved calculating drug transit time through an organ 
by examining the differential between the amount of drug entering and exiting organ, with 
the presence of a hysteresis loop between the efferent (Cout) vs. afferent (Cin) concentrations 
signifying a transport delay.  The mean transit time of transport delay was determined by 
calculating the difference in the area fractions between Cout and Cin area under the curve 
(AUC) at each time point normalized to total AUC.  While these techniques are valuable, 
alternative assessments of hysteresis behavior are likely to reveal important information 
regarding effect vs. concentration relationships. 
An alternative approach to understanding hysteresis behavior is to assess the area of 
the effect versus concentration profile that is associated with the hysteresis, and to use this 
information to make meaningful inferences about a particular drug.  These simulations were 
based on a sigmoidal Emax relationship embedded in an effect-compartment model of drug 
presentation to the effector to simulate concentration- and effect-time profiles.  ABH was 
assessed quantitatively in a manner analogous to calculating the area under the systemic 
concentration-time profile (AUC). The fundamental influence of PK/PD parameters on ABH 
was investigated by sequentially varying these model parameters and assessing the resultant 
size of the hysteresis loop. 
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MATERIALS AND METHODS 
Blood and biophase concentrations, as well as pharmacologic responses, were 
simulated using a standard effect-compartment model with a sigmoidal Emax relationship 
between effect and effect-site concentrations (Figure 8.1).  All simulations were performed 
assuming first-order input of a dose X0 with first-order elimination, first-order distribution to 
the effect site, and an immediately-elaborated pharmacologic response.   
The pharmacokinetic simulations of mass or drug concentrations in the absorption 
(Eqn. 8.1), central (Eqn. 8.2) and effect (Eqn. 8.3) compartments using the following 
equations: 
 𝑑𝑋஺𝑑𝑡 = −𝑘஺ ∙ 𝑋଴ (Eqn. 8.1) 
 
𝑑𝐶஻
𝑑𝑡 = (𝑘௔ ∙ 𝑋஺ − 𝑘௘௟ ∙ 𝑋஻)/𝑉஼  (Eqn. 8.2) 
 
𝑑𝐶ா
𝑑𝑡 = 𝑘௘଴ ∙ 𝑋஻ − 𝑘௘଴ ∙ 𝑋ா (Eqn. 8.3) 
where XA is mass in the absorption compartment, CB is the concentration in the central, 
blood compartment and CE is the concentration in the effect compartment, Vc is the apparent 
volume of the central compartment, and ka, kel, and ke0 are the first-order rate constants for 
absorption, elimination, and effect offset, respectively. 
A sigmoidal Emax model was used to simulate the relationship between pharmacologic 
effect and drug concentration at the effect site (Eqn. 8.4). 
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 𝐸 = 𝐸௠௔௫ ∙ 𝐶ா
ఊ
𝐸𝐶ହ଴ఊ + 𝐶ாఊ
 (Eqn. 8.4) 
where E is the effect, Emax is the maximum effect, CE is the effect compartment 
concentration, EC50 is the effect compartment concentration associated with 50% of the 
maximum effect, and γ is the sigmoidicity factor. 
Initial parameter values were selected in order to achieve a moderately-sized 
hysteresis (Table 8.1, Simulation 1).  Blood and biophase concentration-time and effect-time 
profiles were simulated in WinNonlin (version 5.0.1, Pharsight Corporation, Cary, NC) by 
systematically varying the PK/PD parameters, X0, V, ka, kel, ke0 and EC50 (15 values per 
parameter).  The influence of parameters on the size of the E vs. CB hysteresis was 
determined using Matlab (Release 12, The MathWorks, Natick, MA).  In all simulations, the 
E vs. CE relationship served as a negative control for the absence of hysteresis (i.e., 
statistically insignificant ABH) because the kinetic-dynamic dissociation in this model was 
due to equilibration delays between the effect site and the central compartment, as opposed to 
delay in elaboration of response after presentation of the drug to the effect site.  
Analysis of the concentration- and effect-time profile data files was completed using 
a program written in Matlab (Appendix).  This program was written to read the data file 
format and calculate the ABH for the polygon created by the effect vs. concentration 
relationship. Similar to methods for calculating AUC, the program calculates the area under 
the ascending effect-concentration profile and subtracts this value from the area under the 
descending effect-concentration profile to generate the ABH (Figure 8.2).  Following this 
principle, this program is capable of distinguishing a clockwise from a counterclockwise 
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hysteresis loop such that a positive value is representative of a proteresis and a negative value 
for a counterclockwise hysteresis. 
In order to validate the Matlab analysis, ten hysteresis loops of differing sizes were 
generated by sequentially varying the value of X0 (25-500 mg), while holding the remaining 
parameters constant as listed in Table 8.1, Simulation 1.  Matlab was used to determine the 
ABH for each loop, and the image processing program ImageJ (NIH, Bethesda, Maryland, 
USA) was used to calculate the number of pixels in the hysteresis normalized to the number 
of pixels per unit area in the plot (n=3 per hysteresis). 
RESULTS  
The blood and biophase concentration- and effect-time profiles for a one-
compartment model (Figure 8.1) with first-order input (Table 8.1, Simulation 1) are shown in 
Figure 8.3a. The lag in tmax for concentrations at the receptor biophase compared to blood is 
evidence of the distributional delay between the two compartments. The sigmoidal 
relationship between effect and biophase concentration reflects the time-independent nature 
of the E vs. CE relationship. In contrast, the counterclockwise hysteresis in the relationship 
between E and CB is indicative of time dependency due to distributional delay at the 
hypothetical effect site (Figure 8.3b).  The hysteresis is characterized by increasing blood 
concentrations at early time points with a delay in effect onset because drug is distributing to 
the biophase.  At late time points, blood concentrations are decreasing but effect persists 
because of the lag in drug elimination from the biophase.  
The ABH values generated using Matlab were verified using ImageJ.  Excellent 
agreement (r2≥0.99) was observed for ABH (%*mg/L) calculated by these two methods 
 214 
(Figure 8.4), validating the precision of the novel computational approach. Matlab therefore 
was used to calculate ABH in subsequent simulations. 
To examine the influence of parameter values on ABH, each parameter in the PK/PD 
model was varied at least 5-fold from the value in the original parameter space, and the 
resulting ABH was calculated. ABH was proportional to the administered dose (Figure 8.5a), 
whereas an inverse hyperbolic relationship between ABH and either kel or V was observed 
(Figure 8.5b-c).  In contrast, ABH asymptotically approached a limiting value as the value of 
ka increased (Figure 8.5d). The relationship between ABH and the PD parameters ke0 and 
EC50 was biphasic; the ABH increased, reached a maximum, and then decreased with 
increasing values of ke0 or EC50 (Figure 8.5e-f). 
The cause of the differences in shape between ABH and PK parameters 
(monophasic), or between ABH and PD parameters (biphasic), was investigated by 
examining the effect-blood concentration relationship for all parameter values.  Three 
representative values for each parameter (high, moderate, and low) were selected; the 
influence of changing these parameters on ABH is shown in Table 8.1.  The moderate values 
in each case represent the initial parameter space (Table 8.1, Simulation 1).  The 
corresponding effect-blood concentration profiles are presented in Figures 8.6 and 8.7 for the 
PK and PD parameters, respectively.  Figure 8.6 demonstrates that the relative shape of the 
hysteresis was independent of the PK parameter value.  In contrast, both the size and the 
shape of the hysteresis were dependent on the PD parameter value (Figure 8.7).  These 
changes in hysteresis shape may, at least in part, explain the biphasic relationship between 
ABH and the PD parameters.  As depicted in Figure 8.3, the blood concentration time course 
was independent of the PD parameters ke0 and EC50, whereas these parameters play a distinct 
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role in determining the extent and time course of effect.  A 5-fold decrease in the value of ke0 
(1 to 0.2 hr-1) or a 5-fold increase in EC50 (5 to 25 mg/L) altered the effect-time profile such 
that an overall reduction in effect was observed, characterized by a decrease in Emax from 62 
to 44 % and 25 % and a decrease in ABH from 954.8 to 927.0 %*mg/L and 386.0 %*mg/L 
for ke0 and EC50, respectively (Figure 8.7).  In contrast, allowing greater sensitivity of the 
system to the drug, by increasing the value of ke0 or decreasing the EC50, resulted in further 
decreases in ABH attributable to collapse of the hysteresis (Figure 8.7). 
DISCUSSION 
The fundamental goal of PK/PD analysis is to characterize the relationship between 
pharmacologic effect and drug concentrations, allowing estimation of an EC50 value.  The 
simplest relationships are developed when blood concentrations are directly linked to 
pharmacologic response.  A number of criteria must be met for this to occur: equilibrium 
between biophase and blood concentrations and receptor mediated pharmacologic response 
that is instantaneous, reversible, and time-independent.  If these criteria are met, then the 
relationship between effect and blood concentration can be described using a sigmoidal Emax 
model. However, a violation of any of these limiting assumptions can result in a hysteresis in 
the relationship between effect and blood concentration. 
The inclusion of a hypothetical effect compartment that drives effect is a common 
method of collapsing hysteresis loops (Holford and Sheiner, 1982).  Simulating drug 
concentrations in a hypothetical effect compartment allows for the recovery of EC50 and Emax 
from the sigmoidal curve in the E-CE relationship rather than the hysteresis between E-CB.  In 
the present simulations, a one-compartment link model was employed to generate 
concentration and effect data.  The selection of this model was based on the frequency with 
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which experimental data are fit with a blood and biophase compartment (Kalvass et al., 2006; 
Kalvass et al., submitted).  While this method is a useful approach in PK modeling and 
simulation, it results in a “collapsed” hysteresis loop. An important hypothesis underlying the 
present study was that the shape and size of the hysteresis loop may reveal meaningful 
information about the disposition of a particular drug. 
A program written for Matlab was used to accurately and reproducibly measure ABH 
with a method analogous to calculating AUC, where subtracting the area of the ascending 
curve from the descending curve yielded the area bound by the data points.  ImageJ was used 
to demonstrate that the measurements obtained using Matlab were reliable.  HysQuant offers 
greater accuracy, due to the elimination of user error, and improved throughput compared to 
an image analysis approach.  HysQuant is amenable to calculating ABH for experimentally 
derived data, in part because of its ability to calculate both clockwise and counterclockwise 
ABH.  The ability to calculate clockwise ABH would be valuable in experiments designed to 
assess the influence of acute PD tolerance on hysteresis area.  One limitation of this program 
is that it calculates the area of a polygon of a finite number of data points and not of a 
continuous loop.  However, this aspect actually may prove to be advantageous and the ABH 
could be a model-independent method of characterizing the system. 
It was expected that increasing or decreasing a particular parameter value would alter 
the blood and biophase concentration- and effect-time profiles, thereby influencing the ABH.  
A more interesting result was that there was a critical region over which small changes in 
PK/PD parameter values led to large changes in ABH.  Incremental increases in the values of 
kel, V, or ka affected ABH to a larger extent when the values were low compared to those 
same increases in the higher ranges (Figure 8.5b-d).  The critical regions for the PD 
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parameters, ke0 and EC50, were also at low ranges but led to sharp increases in ABH followed 
by sharp decreases (Figure 8.5e-f).  The locations of these critical regions may be important 
when fitting models to experimental data.  Models could be assessed for their sensitivity to a 
particular parameter, depending on where the parameter value fell on the ABH curve.  For 
example, Figure 8.5d reveals minimal increases in ABH when the value of ka is 25 hr-1 or 
greater. Therefore, if a model estimates a parameter to be within this region, the significance 
of the parameter may be minimal because absorption is nearly instantaneous. 
A particularly intriguing aspect of these simulations was the biphasic relationship 
between ABH and the PD parameters.  This relationship can, in part, be attributed to the 
shifting nature of the shape of the hysteresis on each side of the ABH maximum.  When ke0 
or EC50 deviate from the values that yield the ABH maximum, the hysteresis begins to 
collapse (Figure 8.7).  While this behavior is demonstrated within this series of simulations, 
it would not be evident in experimental data, which yield only one effect-concentration 
profile.  For example, if a drug exhibits a low percent effect, as is the case with the 
antihypertensives, a full blood concentration-time profile will be obtained but the small 
changes in the effect-time profile will resulting in a low ABH value. In contrast, a drug that 
is administered at doses that achieve near 100% effect will cover a full effect range and a 
large hysteresis will be formed between the effect-blood concentration profile.  The ratio of 
the effect-blood concentration ABH to effect-biophase concentration ABH for these two 
types of drugs will be small and large, respectively.  Therefore, caution must be exercised so 
as to not falsely identify a drug with a small effect range as a hysteresis simply because it has 
a small E-CB hysteresis to negative control E-CE ratio.  These simulations reveal that when 
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designating a particular effect-concentration relationship as a hysteresis, it is important to 
consider the concentration and effect ranges in addition to the ABH. 
The influence of sampling schedule on measures of ABH is an interesting aspect of 
hysteresis behavior that was identified in this and previous studies (Levy et al., 1994). The 
present work revealed that time point selection plays a role in dictating measures of ABH.  
For example, if 15 concentration-effect measurements are simulated, an equal distribution of 
sampling time points would yield different ABH values compared to a sampling scheme that 
concentrates half of the time points at the beginning of the absorption and the remaining half 
during the elimination phase.  The evenly distributed time points typically will yield a greater 
ABH compared to the latter scheme because the full shape of the curve is missed when 
sampling at the beginning and end of the profile.  Previous work examining the practicality 
of sparse sampling schemes in clinical trials found that adequate effect-concentration 
relationships could be made for drugs exhibiting pharmacodynamic hysteresis when 
sampling was performed near the end of the dosing interval (Ebling et al., 1996).  These 
simulations demonstrated the feasibility of sparse sampling when data are best fit by the 
indirect link model, although the inherent intra- and inter-individual subject variability is 
likely to produce parameter estimates that are less reliable than those produced by sampling a 
full concentration-effect profile.  Furthermore, sampling at the end of the dosing interval may 
provide the best initial parameter estimates, but may fail to fully characterize the hysteresis. 
Considering the observations made by Ebling et al. in light of the present simulations, the 
most useful clinical sampling scheme for drugs exhibiting pharmacodynamic hysteresis may 
be to preliminarily obtain a full concentration-effect data within a limited population in order 
to characterize the shape and size of the hysteresis studies and use these model independent 
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observations to identify critical time points for subsequent sparse sampling in a fully 
powered trial (Ebling et al., 1996). 
The present simulations are relevant to clinical research because blood concentration 
and effect are frequently the only data reported.  Biophase concentrations are rarely known, 
largely due to physiologic isolation and the cost associated with precise methods of 
quantitation.  By initially characterizing the effect-blood concentration hysteresis it is hoped 
that the relationship between effect and biophase concentrations will be better understood.  
Future work in this area will assess the influence of population variability on measures of 
hysteresis area and be used to develop a comprehensive definition of how large a hysteresis 
must be to differentiate it from a sigmoidal curve.  A quantitative definition of a hysteresis 
loop and a method to calculate ABH will allow identification in a manner more objective 
than the current approach of visual inspection.  An in vivo study by Cox et al. examined the 
relationship between effect, measured using an EEG, and blood concentrations for three 
opioids; results of this study revealed that alfentanil rapidly arrived at the receptor biophase 
and the effect-blood concentration relationship was sigmoidal whereas fentanyl and 
sufentanil exhibited moderate hysteresis behavior (Cox et al., 1998).  A comprehensive 
definition of hysteresis loops would allow effect-concentration relationships such as these to 
be definitively classified as sigmoidal or a hysteresis.  One critical component in developing 
this definition will be the incorporation of inter-individual variability, which is not always 
reported (Chen and Pollack, 1998; Cox et al., 1998; Kharasch et al., 2003).  The magnitude 
of variability compared to the magnitude of effect and concentration will be important in 
determining the presence of a hysteresis in the data, e.g. overlapping error bars yield a 
questionable hysteresis.  A final aspect that will be incorporated into future work is the 
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presence of indirect pharmacologic effects and other time-dependent processes into models 
of hysteresis behavior. These investigations will rely significantly on models developed by 
Jusko and colleagues (Krzyzanski and Jusko, 1997a; Krzyzanski and Jusko, 1997b). 
Ultimately, a number of factors contribute to hysteresis behavior and should be investigated.  
This paper presents a preliminary sense of the influence of PK/PD parameters on hysteresis 
loop area.  
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Figure 8.2.  Method of calculating ABH utilized by Matlab.  The hysteresis is divided into 
two segments at the Cmax, the ascending curve (dashed black line) and the descending curve 
(dashed gray line).  The area under the ascending curve (solid black lines) is subtracted from 
the area under the descending curve (solid gray lines). 
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Figure 8.3.  Representative pharmacokinetic and pharmacodynamic model output.  The left 
panel depicts blood (────) and biophase (────) concentration- and effect- ( ─ ─ ─ ) time 
profiles were simulated using the PK-PD model (Figure 8.1) and the parameters in Table 8.1, 
Simulation 1.  The right panel depicts the relationship between effect intensity and blood 
(────) or biophase (────) concentrations. 
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Figure 8.4.  Relationship between ABH calculated using ImageJ and Matlab.  The line 
represents the linear regression through the points (r2 > 0.99). 
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Figure 8.5.  The influence of PK-PD parameter values on measures of ABH.  The value of 
each parameter was sequentially varied (a) X0, 2.5-1000 mg; (b) kel, 0.2-50 hr-1; (c) V, 0.25-
25 L; (d) ka, 0.075 – 50 hr-1; (e) ke0, 0.05-5 hr-1;  (f) EC50,  0.05-50 mg and the remaining 
model parameters were held constant.  The ABH was calculated for the simulated effect vs. 
blood concentration hysteresis. 
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Figure 8.6.  Influence of PK parameter values on the effect versus blood concentration 
hysteresis.  The parameters (a) X0; (b) kel; (c) V and (d) ka were increased ( ─ ─ ─ ) or 
decreased (────) by 5-fold compared to the core parameter value (────), corresponding 
with the parameter values listed in Table 8.1, Simulations 1-9. 
 228 
 
Figure 8.7.  The influence of PD parameter values on the effect versus blood concentration 
hysteresis.  The parameters ke0 (a) and EC50 (b) were increased ( ─ ─ ─ ) or decreased 
(────) by 5-fold compared to the core parameter value (────), corresponding with the 
parameter values listed in Table 8.1, Simulations 1 and 10-13. 
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CHAPTER 9 
RELATIONSHIP BETWEEN AREA BOUNDED BY THE ANTINOCICEPTION-SERUM 
CONCENTRATION HYSTERESIS AND PHARMACOKINETIC-
PHARMACODYNAMIC PARAMETER ESTIMATES FOR A SERIES OF OPIOIDS 
This chapter will be submitted for publication in Pharmaceutical 
Research and is presented in the style of that journal. 
ABSTRACT 
Purpose: The objective of this study was to evaluate the relationship between 
pharmacokinetic-pharmacodynamic (PK-PD) parameters and the area bounded by the 
hysteresis loop (ABH) characterizing the antinociception versus serum concentration 
function for a series of opioid agonists. The potential modulation of this relationship by P-
glycoprotein (P-gp) expression in the blood-brain barrier (BBB) also was evaluated.    
Methods:  Five mu-opioid receptor agonists (alfentanil, fentanyl, loperamide, 
methadone and morphine) were administered at equipotent doses to P-gp-competent and P-
gp-deficient mice.  The time course of serum concentrations and antinociception, assessed 
using the hotplate latency assay, was determined.  An effect-compartment (sigmoidal Emax) 
PK-PD model was fit to the time course of serum concentrations and antinociception, and 
relevant parameter estimates were obtained.  Matlab was used to calculate the observed and 
predicted ABH.   
Results:  A pronounced hysteresis was observed in the relationship between 
antinociception and serum concentrations, with the exception of alfentanil in P-gp-deficient 
mice.  Good agreement was observed between ABH measurements for observed versus 
model-predicted data (r2>0.95).  The ABH correlated with area under the concentration curve 
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(AUC), the rate constant governing opioid distribution between serum and the hypothetical 
effect compartment (ke0), and serum EC50. Correcting for unbound concentrations improved 
the latter relationship.  The normalized difference between the time at which opioid 
maximum serum concentrations occurred and the time to peak observed effect served as an 
alternative predictive metric of the value of ke0. 
Conclusions: The present results indicate that ABH is a novel, nonparametric metric 
for expressing distributional delays that result in a hysteresis loop in the relationship between 
opioid antinociceptive effect and serum concentrations.   
INTRODUCTION 
Describing the link between pharmacologic effect and drug concentrations is 
particularly challenging for drugs with central nervous system (CNS) activity.  CNS 
concentrations, and consequently pharmacologic effect, are dictated by systemic 
concentrations of drug, and can be modulated by a variety of factors, including protein 
binding, blood-brain barrier (BBB) permeability, active transport, local metabolism, and 
cerebrospinal fluid (CSF) turnover.  The BBB is an anatomical, biochemical, and functional 
barrier situated between the CNS and systemic circulation that serves to supply the brain with 
essential nutrients, regulate entry of endogenous and exogenous substances, and to efflux 
potential neurotoxins.   
The predominant transmembrane efflux transporter expressed at the BBB is P-
glycoprotein (P-gp; ABCB1), a member of the ABC superfamily (Golden and Pollack, 2003).  
Two strains of mice deficient in P-gp are commonly used to characterize the impact of P-gp 
efflux: the CF-1 strain, which possess a naturally occurring mutation in the mdr1a(-/-) gene 
and the FVB strain, which serves as the platform for creating knockout mice deficient in both 
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mdr1 isoforms expressed in brain, mdr1a and mdr1b (Schinkel et al., 1996; Lankas et al., 
1997; Schinkel, 1997; Umbenhauer et al., 1997).  The collection of whole tissues from intact 
animals in P-gp-competent and P-gp-deficient mice is a frequently-used method of 
determining net distribution across the BBB (Chen and Pollack, 1998).  The use of knockout 
mice or naturally-occurring mutants has been instrumental in assessing the role of P-gp in 
attenuating brain uptake and antinociception of loperamide, methadone, DPDPE ([D-
penicillamine(2,5)] enkephalin) (Chen and Pollack, 1998; Thompson et al., 2000; Dagenais 
et al., 2004).  The diversity in chemical structure, BBB penetration, physicochemical 
properties, potency and duration of effect, make opioids an ideal group of compounds for 
probing a multiplicity of phenomena that determine CNS pharmacokinetics and 
pharmacodynamics.  Moreover, the opioids are an ideal class of drugs to use for 
characterizing the counterclockwise hysteresis loop that results from the distributional-
mediated dissociation between pharmacologic response and serum concentrations.    
Recovering pharmacodynamic parameter estimates from the relationship between 
antinociception and opioid serum concentrations is not feasible in the presence of hysteresis 
behavior because two distinct concentrations correspond with the same effect.  This effect-
concentration disconnect is commonly addressed with the application of an effect 
compartment PK-PD model, which uses the temporal relationships between effect and blood 
concentrations to predict the time course of drug concentrations in a hypothetical effect 
compartment (Holford and Sheiner, 1982).  Estimates of fundamental pharmacodynamic 
parameters (EC50 and γ) then can be recovered from the effect versus effect compartment 
concentration relationship. This analytical process is referred to as “collapsing the hysteresis 
loop”.   
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Alternative approaches to addressing hysteresis behavior have been examined in an 
effort to improve characterization of complex PK-PD systems.  The influence of sampling 
locales on the dissociation between arterial and venous concentrations and effect has been 
addressed by a number of groups (Verotta et al., 1989; Tuk et al., 1997; Hermann et al., 
1999).  Quantitative approaches have been developed to characterize lidocaine tissue transit 
time through and antibiotic tissue distribution (Ganzinger and Neumann, 1992; Upton and 
Doolette, 2002).  In addition, Cheng and Jusko identified an adaptation of disposition 
decomposition analysis that characterizes the biophase drug concentration-time function.  
Despite an understanding of the processes that contribute to hysteresis behavior and the 
mathematical and experimental techniques that have been developed to minimize the 
presence of hysteresis loops, there is a relative lack of information relating the area bounded 
by a hysteresis loop (ABH) to a meaningful system descriptor.   
A method of calculating ABH was developed in Matlab with which, in a manner 
analogous to calculating AUC, the area under the ascending curve was subtracted from the 
area under the descending curve (Chapter 8).  This aforementioned approach was utilized to 
assess the relationship between PK-PD parameter values of simulated effect-serum 
concentration and the corresponding ABH.  The present study utilized a PK-PD modeling 
approach to describe the time-course of serum concentrations and opioid antinociception 
using a hotplate latency assay.  Moreover, CNS penetration and pharmacologic effect was 
further modulated by characterizing the time course of response and concentrations in P-gp-
competent and P-gp-deficient mice.  The ABH of the antinociception-serum concentration 
hysteresis was calculated and related to estimates of PK-PD parameters.   
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METHODS 
Materials   
Fentanyl, loperamide, methadone, morphine, and oxycodone were purchased from 
Sigma-Aldrich (St. Louis, MO). Alfentanil was obtained from Taylor Pharmaceuticals 
(Decatur, IL). All other reagents were obtained from common sources, and they were of 
reagent grade or better.  
Animals 
Male CF-1 [mdr1a(+/+) and mdr1a(-/-)] and FVB [mdr1a/b(+/+) and mdr1a/b(-/-)] 
mice (30-40 g; Charles River Laboratories, Inc. Wilmington, MA; and Taconic, 
Germantown, NY, respectively) were maintained on a 12-h light/dark cycle in a temperature- 
and humidity-controlled room with free access to food and water. All procedures involving 
mice were approved by The Institutional Animal Care and Use Committee of the University 
of North Carolina and were conducted in accordance with “Principles of Laboratory Animal 
Care” (NIH Publication No. 85-23, revised in 1985).  
Pharmacokinetic-Pharmacodynamic Experiments 
Based on the results of pilot studies, 36 mdr1a(+/+) and 36 mdr1a(-/-) CF-1 mice 
received a single equipotent subcutaneous dose of alfentanil (0.2- or 0.067-mg/kg), fentanyl 
(0.09-mg/kg), loperamide (50- or 1-mg/kg), methadone (2- or 0.6 mg/kg), or morphine (only 
mdr1a(+/+); 3.6-mg/kg).  In a separate experiment, 36 mdr1a/b(+/+) and 36 mdr1a/b(-/-) 
FVB mice received an equipotent subcutaneous dose of loperamide (25- or 1-mg/kg). The 
loperamide and fentanyl doses were prepared in 50/50 propylene glycol/water, whereas the 
remaining opioids were prepared in 0.9% saline.  Antinociception was assessed at selected 
time points, and four mice of each strain per opioid were sacrificed by decapitation for 
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collection of blood samples.  Serum was harvested after blood was allowed to clot for ~30 
min at room temperature and following centrifugation. Serum samples were stored at –20°C 
until analysis by HPLC-MS/MS.  
Assessment of Antinociception 
Antinociception was assessed with the hotplate latency test as described elsewhere 
(Kalvass et al., 2007). Before opioid administration, baseline hotplate latency was 
determined for each animal in triplicate. Hotplate latency was defined as the time interval 
between placement on the hot plate (55°C; Columbus Instruments, Columbus, OH) and first 
observation of a jump or lick of the hind limb. Animals with an average baseline latency < 25 
s were used in the study. A cut-off latency of 60 s was used to avoid tissue damage. The 
degree of antinociception, expressed as percent maximum possible response (% MPR) was 
calculated as: 
 %𝑀𝑃𝑅 = 𝑇𝑒𝑠𝑡 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦60 − 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑥 100% (Eqn. 9.1) 
Bioanalysis Methodology  
An aliquot (2-25 µl) of serum was transferred to a HPLC vial, and protein was 
precipitated with 4 to 125 volumes methanol containing internal standard (5 ng/ml 
loperamide for alfentanil, fentanyl, and methadone; 20 ng/ml methadone for loperamide; and 
100 ng/ml oxycodone for morphine). The samples were vortex-mixed and centrifuged, and 
supernatant was analyzed by HPLC-MS/MS. Samples were injected (2–10 µl; autosampler, 
CTC Analytics, Zwingen, Switzerland) onto a Phenomenex Gemini 110A column (2.0 x 30 
mm, 5 µm; Phenomenex, Torrance, CA) maintained at room temperature. The total run time 
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was 3 min. Analytes were eluted with a linear gradient consisting of “A,” ammonium acetate 
(pH 6.8; 10 mM) and “B” methanol produced by two Shimadzu LC-10ADVP binary pumps 
(Kyoto, Japan). An initial condition of 5% “B” was ramped to 95% “B” over 2 min, held for 
0.5 min, and then returned initial condition of 5% B in a single step to re-equilibrate the 
column. During the run, the flow rate was increased from 750 to 1500 µl/min over the first 2 
min, held at 1500 µl/min for 1 min, and then returned the initial flow rate of 750 µl/min in a 
single step. For the morphine samples, the initial conditions were held for 0.5 min before 
ramping the gradient and flow rate. The entire column effluent was diverted from the source 
of the PE Sciex API-4000 quadrupole mass spectrometer (Turbo V Ionspray source, 700°C; 
PerkinElmerSciex Instruments, Boston, MA) for the first 1 min and last 0.5 min of the run. 
Alfentanil, fentanyl, loperamide, methadone, meperidine, morphine, oxycodone, and 
sufentanil were measured in positive ionization mode using multiple reaction monitoring 
(417.3→268.3, 337.1→188.3, 477.4→266.0, 248.3→220.3, 286.1→201.1, and 
316.0→298.0, respectively). Standard curves were prepared in serum, plasma, or buffer, and 
were identical in composition to corresponding samples. Accuracy of standards and 
interassay variability was within ± 20%.  
Pharmacokinetic-Pharmacodynamic Analysis  
The pharmacokinetic model depicted schematically in Fig. 9.1 was fit to the serum-
concentration-time data using nonlinear least-squares regression (WinNonlin 4.1; Pharsight 
Corporation, Mountain View, CA). The dose (X0) was assumed to exhibit first-order 
absorption (k01) into the systemic circulation, contained in a central compartment of apparent 
volume Vc, with first-order elimination (k10) from the compartment.  Opioid disposition in 
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the absorption site (XA) and in the central, serum compartment (XC) was characterized (Eqns. 
2 and 3). 
 𝑑𝑋஺𝑑𝑡 = −𝑘଴ଵ ∙ 𝑋଴ (Eqn. 9.2) 
 
𝑑𝑋஼
𝑑𝑡 ∙ 𝑉஼ = 𝑘଴ଵ ∙ 𝑋஺ − 𝑘଴ଵ ∙ 𝑋஼  (Eqn. 9.3) 
The dissociation between the time course of antinociception and serum concentrations 
was addressed by linking a hypothetical effect site with the central pharmacokinetic 
compartment, assuming a rate of equilibration governed by a first-order rate constant ke0 
(Figure 9.1; Eqn. 9.4). The relationship between antinociceptive effect and drug 
concentration in the hypothetical effect compartment was assumed to be sigmoidal (Eqn. 5).  
 𝑑𝐶௘𝑑𝑡 = 𝑘௘଴ ∙ (𝐶௖ − 𝐶௘) (Eqn. 9.4) 
 𝐸 = ா೘ೌೣ ∙ ஼೐
ം
ா஼ఱబം ା ஼೐ം
 (Eqn. 9.5) 
The pharmacodynamic parameters ke0, EC50, and γ were estimated in a stepwise approach by 
fitting these equations to the observed antinociceptive response vs. time data, with Emax fixed 
at 100 % or recovered as a parameter with no theoretical limit.   
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Calculation of Area Bound by the Hysteresis 
The size of the model-derived antinociception-serum concentration hysteresis loop 
was determined for each opioid using a Matlab (Release 12, The MathWorks, Natick, MA) 
as described in Chapter 8.  Briefly, the program written in Matlab was read the data file 
format and calculate the ABH for the dissociation between effect and concentration. Similar 
to methods of calculating AUC, the program calculated the area under the ascending effect-
concentration profile and subtracted this value from the area under the descending effect-
concentration profile to generate the ABH in units of %*mg/ml.  The program is capable of 
distinguishing clockwise and counterclockwise hysteresis loops such that a positive value is 
representative of a proteresis and a negative value for a counterclockwise hysteresis.  The 
antinociception versus effect compartment concentration relationship served as a negative 
control for the absence of hysteresis (i.e., statistically insignificant ABH).  The ABH was 
calculated for the observed and predicted hysteresis between antinociception and serum 
concentrations.   
Recovery of Fentanyl and Sufentanil Concentration-Effect Data from Literature 
An earlier investigation on the PK-PD relationship between fentanyl and sufentanil 
serum concentrations and the electroencephalogram (EEG) effect in rats was identified and 
estimates of the relationship between concentration and effect were obtained graphically 
(Cox et al., 1998).  The fentanyl and sufentanil ABH was calculated as previously described 
with Matlab (Release 12, The MathWorks, Natick, MA) and the correlation between ABH 
and estimates of PK-PD parameters was investigated.   
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RESULTS 
Results of preliminary dose-response experiments were used to select opioid doses 
that elicited 80-90% MPR on the hotplate latency assay.  Administered doses scaled four 
orders of magnitude, from 0.0067 for alfentanil [mdr1a(-/-)] to 50 mg/kg for loperamide 
[mdr1a(+/+)].  While the role of P-gp-mediated efflux in attenuating opioid CNS penetration 
was not explicitly characterized in this study, mdr1a(-/-) mice required 3-, 3.3- and 50-fold 
lower doses of alfentanil, methadone, and loperamide in order to elicit comparable 
antinociception.  Preliminary experiments revealed dose-limiting toxicities associated with 
administration of 50 mg/kg loperamide to mdr1a/b(+/+)  FVB mice that led to the 
substitution of a 25-mg/kg dose.     
The time course of opioid systemic concentrations was described adequately by a 
one-compartment pharmacokinetic model (Figures 9.1 and 9.2).  Estimates of k01, k10, and Vc 
are presented in Table 9.1.  The time course of antinociception and serum concentrations was 
linked by ke0, the first-order rate constant of distribution between serum and the hypothetical 
effect compartment (Figure 9.1).  A sigmoidal Emax model was fit to the relationship between 
antinociception and hypothetical effect compartment concentrations (Figure 9.2).  A fixed 
value of Emax at 100% adequately described the time course of opioid antinociception with 
two exceptions.  By arbitrarily fixing Emax at 100%, fentanyl [mdr1a(-/-)] peak effect for 
morphine [mdr1a(+/+)] was underpredicted. Inclusion of Emax as a variable model parameter 
improved the description of the data (Figure 9.2).  The rate of drug distribution between the 
serum and hypothetical effect compartments varied extensively, evidenced by ke0 values of 
0.004 to 36 min-1 for loperamide and alfentanil in mdr1a(-/-) mice, respectively.  A high 
degree of uncertainty was associated with alfentanil [mdr1a(-/-)] and loperamide 
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[mdr1a(+/+), mdr1a (-/-), and mdr1a/b(+/+)] pharmacodynamic estimates, particularly the 
value of ke0, as evidenced by CV% > 100 (Table 9.1).     
The relationship between antinociception and hypothetical effect compartment 
oncentrations was sigmoidal (Figure 9.3).  With the exception of alfentanil in mdr1a(-/-) 
mice, the relationship between opioid antinociception and serum concentrations evidenced a 
hysteresis loop progressing temporally in a counterclockwise direction (Figure 9.3).  The 
rapid distribution between serum and effect compartment concentrations, as described by a 
ke0 of 36 min-1, explains the absence of hysteresis behavior for alfentanil in mdr1a(-/-) mice.  
Moreover, the area calculations for alfentanil [mdr1a(+/+) and (-/-)] and fentanyl [mdr1a(-/-
)] indicated low values of ABH and a high degree of variability around the observed effect-
concentration hysteresis, a consequence of overlap in the ascending and descending curves 
for the observed points compared to the predicted fit.  The remaining calculations of ABH for 
observed effect-concentration data were within 2-fold of the values calculated for the 
predicted fit to the antinociception-serum concentration data (Figure 9.4).   
The degree of systemic exposure is commonly expressed as area under the 
concentration-time curve (AUC); the magnitude of pharmacologic response is, in part, 
dictated by the value of ke0 when a hypothetical effect compartment is utilized.  As it is a 
product of effect (% MPR) and concentrations (ng/ml), the area bounded by the 
antinociception-serum concentration hysteresis would be expected to correspond with PK-PD 
parameters.  The ABH is correlated with AUC and ke0, the latter relationship dictated in part 
by P-gp expression (Figures 9.5 and 9.6).  An alternative metric of effect and concentration 
that potentially correlates with ABH is EC50 (Figure 9.7A).  Figure 9.7B presents the modest 
improvement in the correlation when EC50 is corrected for protein binding.  Moreover, the 
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data points associated with the hysteresis between fentanyl and sufentanil EEG effect and 
serum concentrations were obtained graphically and used to calculate the ABH.  The 
literature-derived estimate of ABH correlated well with estimates of EC50 and EC50,u (Figure 
9.7).  In a final step, the reciprocal value of ke0 was observed to correlate with the normalized 
difference between time to maximum concentrations and time to maximum effect.   
DISCUSSION 
The opioids characterized in this study are diverse with respect to structural classes, 
physicochemical properties, BBB penetration, P-gp-mediated efflux, and receptor potency.  
The influence of these properties on systemic disposition is reflected in pharmacokinetic 
parameter estimates.  For example, the fu,plasma ranged from 0.03 to 0.5 for loperamide and 
morphine, respectively, and a ~30-fold difference in estimates of k10 was observed (Table 
9.1).  A one compartmental model adequately described the time-course of serum 
concentrations (Figure 9.2). 
A hypothetical effect compartment containing the receptor biophase was used to link 
serum concentrations and antinociception.  The inclusion of a hypothetical effect 
compartment was effective in describing the time-course of antinociception (Figure 9.2).  
Distribution between serum and the hypothetical effect compartment was slowest for 
loperamide in mdr1a(-/-) and mdr1a/b(-/-) mice, 0.0097 and 0.004 min-1, respectively, and 
fastest for alfentanil in mdr1a(-/-) mice, 36 min-1 (Table 9.1).  The sigmoidal relationship 
between alfentanil [mdr1a(-/-)] antinociception and serum concentrations (Figure 9.3B) 
yielded a negligible ABH value (28 %*mg/ml).  The absence of a hysteresis between 
alfentanil [mdr1a(-/-)] antinociception and serum concentrations suggests that a value of keo 
equal to or greater than 36 min-1 reflects a collapse in the separation of serum and 
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hypothetical effect compartment concentrations.  The remaining opioids exhibited a 
hysteresis between antinociception and serum concentrations (Figure 9.3). 
The ABH was best predicted for observed versus predicted data for large hysteresis 
loops (Figure 9.4).  With the exception of alfentanil [mdr1a(+/+) and mdr1a(-/-)] and 
fentanyl [mdr1a(+/+)], the use of 9 data points recovered ABH values within a 2-fold range 
of the predicted ABH calculation.  A bootstrap technique could be utilized in future 
investigations to characterize the reliability of ABH calculated for sparsely sampled data and 
to identify portions of the hysteresis that contribute to reliable estimates of ABH, although 
such an approach was beyond the scope of the current investigation.  The utility of ABH as a 
nonparametric parameter that characterizes the dissociation between concentration and 
pharmacologic effect will be strengthened if these studies identify sparse sampling schemes 
that reliably estimate the value of ABH. 
Preliminary experiments were performed to identify doses that elicit 80-90% MPR in 
the hotplate latency assay.  While systemic exposure is largely dictated by the absorption, 
distribution, metabolism and excretion (ADME) properties of a drug, pharmacologic effect is 
a function of both pharmacokinetic and pharmacodynamic processes.  It is therefore logical 
that the size of the hysteresis is related to metrics of systemic exposure and biophase 
distribution (Figures 9.5 and 9.6).  However, the relationship between ABH and the 
reciprocal of ke0 differs based on P-gp expression (Figure 9.6).  It is possible that decreasing 
the dose of alfentanil, methadone or loperamide administered to mice deficient in P-gp 
diminished the dynamic range of serum concentrations since greater CNS distribution 
enabled lower doses.  P-gp-competent mice receiving fentanyl were an outlier, a potential 
consequence of P-gp efflux that was addressed with a higher dose concentration compared to 
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the P-gp-deficient mice.  This observation is consistent with previous observations of 
fentanyl as substrate, albeit to a physiologically negligible extent, of P-gp at the BBB 
(Dagenais et al., 2004). 
A number of metrics, including ED50 and EC50, the effective dose and effective 
concentration that elicits a 50% response, are commonly utilized to characterize 
pharmacodynamics.  While ED50 is a straightforward, robust and easily-obtainable metric of 
potency, EC50 is preferred when a compound set exhibits pharmacokinetic diversity.  As a 
measurement of potency, the serum EC50 directly relates concentration to effect; as such, it is 
not surprising that this parameter is correlated with ABH (Figure 9.7A).  Correcting the 
serum EC50 for protein binding provides a more direct expression of the biologically-relevant 
concentration of drug, i.e., the substrate pool that can penetrate membranes (e.g., the BBB) or 
bind to receptors (e.g., the opioid receptor).  The serum EC50 corrected for protein binding 
improved the correlation with ABH (Figure 9.7B).  Similarly, Kalvass et al. (2007) identified 
brain EC50,u as the best correlate to clinical equipotent opioid dose, followed by brain EC50, 
serum EC50,u and lastly, serum EC50.  Considering the results presented by Kalvass et al. 
(2007), the correlations with ABH may be improved further by comparing this metric to 
brain EC50 and EC50,u, surrogates of biophase concentrations. 
Results obtained by Cox et al. (1998) were used to characterize the effect-serum 
concentration hysteresis of fentanyl and sufentanil.  Similar to observations in the present 
study, alfentanil did not exhibit a substantial dissociation between EEG effect expressed as a 
function of amplitude and serum concentrations.  The value of ABH for the extracted data 
was calculated and, using the published PK-PD parameter estimates, was found to correlate 
with the previously-established relationship between ABH and EC50 or EC50,u (Figure 9.7).  
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The posterior validation of the relationship between ABH and EC50 strengthens the 
conclusions of the present study, in part due to the different route of opioid administration via 
an IV-infusion and the characterization of effect using electroencephalography rather than 
the hotplate assay.  Further work relating ABH to EC50 that includes drugs from therapeutic 
classes other than opioids should be performed to test the generalizability of the approach 
described herein. 
While the relationship between the normalized difference in time to Cmax and Emax 
versus the reciprocal value of ke0 was not linear, it could be a useful and straightforward 
method of approximating the value of ke0 (Figure 9.8).  As evidenced in Table 9.1, ke0 is a 
poor estimator of the distributional relationship between serum and the hypothetical effect 
compartment.  Estimates of ke0 are often sensitive to minor changes in observed values or 
model parameters.  While eliminating the need to use ke0 is the optimal solution, 
characterizing biophase concentrations often requires the use of intensive and costly 
experimental approaches.  Thus, the ability to narrow the range of initial estimates of ke0 
using the time of maximum observed concentration and effect would be ideal. 
In summary, the present study presents the relevant PK-PD parameter estimates 
obtained from the time course of opioid antinociception and serum concentrations in P-gp-
competent and P-gp-deficient mice.  The area bounded by the hysteresis loop resulting from 
distributional dissociation between antinociception and serum concentrations was calculated 
and correlated with area under the curve or the rate constant of distribution between serum 
and the hypothetical effect compartment was observed.  A strong correlation was observed 
between ABH and EC50 and a modest improvement resulted when EC50 was corrected for 
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protein binding.  Finally, the relationship between the time difference in Cmax and Emax may 
be used as an initial representation of the value of ke0. 
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Figure 9.1.  Scheme of the pharmacokinetic-pharmacodynamic model for opioid disposition 
and antinociception in mice.  A stepwise approach was used to recover pharmacokinetic 
parameter estimates by fitting a one-compartment model to the time course of group 
averaged serum concentrations.  Estimates were obtained for the absorption rate constant 
(k01), central volume (V) and first-order elimination rate constant (k10).  An effect-
compartment, sigmoidal Emax model was used to describe the time course of 
antinociception.  PK parameter estimates were fixed and the values of ke0, EC50, and γ were 
recovered.  The value of Emax was fixed at 100% MPR or, in the case of fentanyl mdr1a(-/-) 
and morphine, fit as a model parameter.   
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Figure 9.2.  Time course of antinociception (▲), serum (?), and effect compartment 
concentrations following subcutaneous administration of (A) 0.2-mg/kg alfentanil to 
mdr1a(+/+) mice; (B)  0.067-mg/kg alfentanil to mdr1a(-/-) mice; (C)  0.9-mg/kg fentanyl to 
mdr1a(+/+) mice; (D)  0.9-mg/kg fentanyl to mdr1a(-/-) mice; (E)  50-mg/kg loperamide to 
mdr1a(+/+) mice; (F)  1-mg/kg loperamide to mdr1a(-/-) mice; (G)  25-mg/kg loperamide to 
mdr1a/b(+/+) mice; (H)  1-mg/kg loperamide mdr1a/b(+/+) mice; (I)  2-mg/kg methadone to 
mdr1a(+/+) mice; (J)  0.6-mg/kg methadone to mdr1a(-/-) mice; or (K)  3.6-mg/kg morphine 
to mdr1a(+/+) mice.  Data are presented as mean ± S.E. (n ≥ 3, serum concentrations; n = 4 
to 36, antinociception).  Lines represent the fit of the model to the time course of 
antinociception (solid gray), serum (dashed black), and effect (solid black) compartment 
concentration data.   
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Figure 9.3.  Relationship between opioid antinociception and serum or effect compartment 
concentrations of (A) alfentanil [mdr1a(+/+) mice]; (B)  alfentanil [mdr1a(-/-) mice]; (C)  
fentanyl [mdr1a(+/+) mice]; (D)  fentanyl [mdr1a(-/-) mice]; (E)  loperamide [mdr1a(+/+) 
mice]; (F)  loperamide [mdr1a(-/-) mice]; (G)  loperamide [mdr1a/b(+/+) mice]; (H)  
loperamide [mdr1a/b(+/+) mice]; (I)  methadone [mdr1a(+/+) mice]; (J)  methadone 
[mdr1a(-/-) mice]; or (K)  morphine [mdr1a(+/+) mice].  Symbols represent the mean ± S.E. 
of observed antinociception (n = 4 to 36) and serum concentrations (n ≥ 3).  Lines represent 
the fit of the model to the time course of antinociception (solid gray), serum (dashed black), 
and effect (solid black) compartment concentration data.   
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Figure 9.4.  Relationship between ABH calculated using observed data versus predicted fit 
of the model for a series of opioids (r2=0.95). 
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Figure 9.5.  Relationship between ABH and AUC for a series of opioids (r2=0.85).   
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Figure 9.6.  Relationship between ABH and 1/ke0 for a series of opioids in P-gp competent 
(?; r2=0.94) and deficient (?: r2=0.99) mice.   
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Figure 9.7.  Correlation between ABH normalized by EC50 (top; r2=0.49) or EC50,u  (bottom; 
0.67) and 1/ke0  for data obtained experimentally (?) or adapted from literature (?) (Cox et 
al., 1998).   
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Figure 9.8.  Relationship between 1/ke0 and the normalized time between maximum serum 
and effect compartment concentrations.   
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CHAPTER 10 
YOU CAN’T HAVE ONE WITHOUT THE OTHER:  IMPROVING THE MARRIAGE 
BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS 
 
In contrast to the straightforward situation of time-independent pharmacokinetics and 
pharmacodynamics (PK-PD), the relationship between drug concentrations and 
pharmacologic response is often complex and time-dependent.  Describing the time course of 
drug concentrations is a relatively uncomplicated process for most drugs, a feat largely 
attributed to improvements in analytical sensitivity and specificity coupled with advances in 
computational power.  In contrast, pharmacologic response is often poorly understood, 
making PD model development difficult.  Since therapeutic outcomes are based on whether a 
drug can produce the designated effect, to the desired extent, in the absence of toxicity and 
unwanted side effects, it is critical that pharmacologic effect is described adequately.  
Ultimately, the development of more precise and robust PD models requires an 
understanding of both the mechanisms that mediate pharmacologic response and a thorough 
understanding of pharmacokinetics and associated sources of variability.   
Describing the marriage between pharmacokinetics and pharmacodynamics is often 
difficult because the latter relies on the former.  Take the example of a central nervous 
system (CNS) active drug.  Systemic concentrations are dictated by absorption, distribution, 
metabolism and elimination (ADME) processes.  Entry into, and exit out of, the CNS is 
dependent not only on systemic drug distribution but also on passive and active uptake/efflux 
transport at the blood-brain (BBB) and -cerebrospinal fluid (BCSFB) barriers, protein 
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binding, CSF turnover, and biotransformation.  Moreover, drug distribution to the receptor 
biophase within the CNS is dependent on cerebral blood flow rate, brain capillary density 
and residence time, expression of transport proteins and metabolic enzymes, receptor 
distribution, and expression levels.  Finally, manifestation of pharmacologic effect is dictated 
by factors such as binding affinity and the specific downstream signaling events that mediate 
response.  Considering the magnitude and diversity of events that influence pharmacologic 
effect and the corresponding population variability around each of these factors, it is no 
surprise that characterizing the link between effect and concentration is challenging.     
The central aim of this dissertation project was to improve the analytical link between 
pharmacokinetics and pharmacodynamics.  This objective was addressed in two parts.  The 
first section of this dissertation characterized factors that mediate systemic and CNS drug 
disposition, and explored how these attributes might modulate pharmacologic response.  
Specifically, utilizing a series of opioids, the influence of protein binding on in vitro-to-
preclinical and preclinical-to-clinical relationships was characterized and the role of P-gp at 
the BBB on attenuating brain concentrations and antinociception.  The second part of this 
project employed novel parametric and non-parametric approaches to characterize the link 
between drug concentrations and responsivity, again utilizing opioids as a model 
pharmacologic class.   A PK-PD model was used to relate opioid-receptor binding within 
structurally distinct locales to different behavioral responses to nociceptive input.  A 
modification of the sigmoidal Emax model assessed the influence of artificially truncating the 
value of Emax on resultant PD parameter estimates.  The non-parametric approach utilized in 
this section related the calculated area bounded by a hysteresis loop (ABH) present in the 
effect versus serum concentration relationship to PK-PD parameters. This effort required 
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development of a new analytical approach, validation of that approach, and exploration of the 
potential utility of this new metric.  
The intent of this concluding chapter is to integrate the results of this dissertation 
project, to place these results in perspective within a larger body of scientific research, and to 
discuss the implications of these results and potential areas for future investigation. 
OPIOID TOLERANCE DEVELOPMENT 
The opioids are a classic example of compounds that exhibit reductions in 
pharmacologic effect following long-term, repeated drug exposure.  The rapid development 
of tolerance to the analgesic effects, but not the side effects of respiratory depression, nausea, 
and decreased gastrointestinal motility, limits dose-escalations and ultimately results in loss 
of analgesic efficacy (Inturrisi, 2002).  Despite significant research on the topic, a 
comprehensive characterization of the pharmacokinetic and pharmacodynamic alterations 
that accompany tolerance development was lacking.  Chapter 2 addressed this issue in detail, 
and discussed the pharmacokinetic mechanisms that may underlie opioid tolerance 
development, such as changes in metabolic enzyme activity and expression, or transporter 
functionality.  PK alterations are not the predominant mediators of opioid tolerance.  
Pharmacodynamic alterations, however, are responsible and can be attributed to changes in 
receptor expression and functionality, variations in the signal transduction pathways and 
existence of cross-tolerance.  The integrated PK-PD models that have developed to 
characterize the link between pharmacokinetics and pharmacodynamics were discussed in 
some detail. 
While a number of approaches have been implemented to delay the onset and severity 
of opioid tolerance, the underlying problem has not been addressed (World Health 
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Organization, 1996).  The prospect of developing drugs targeted to peripheral opioid 
receptors is particularly promising in that they are capable of producing antinociception 
while minimizing side effects associated with centrally-acting drugs (DeHaven-Hudkins, 
2003; DeHaven-Hudkins and Dolle, 2004).  While this approach could be used alone or in 
conjunction with a low-dose, centrally-active opioid, it requires the development of 
antinociceptive assays capable of differentiating peripheral and central contributions to 
antinociception. 
The feasibility of targeting peripheral opioid receptors is supported by a number of 
studies.  Rodents and humans express the μ-opioid receptor on and near cutaneous nerve 
fibers in normal and inflammatory states (Stein, 1993; Wittert et al., 1996; Labuz et al., 
2007).  These receptors are functional, as evidenced by analgesia produced following intra-
articular or intra-ligamentary injections of morphine sulfate in the treatment of pain 
associated with inflammation or post-surgical traume (Stein et al., 1991; Dionne et al., 2001).  
Topical application of morphine-6-glucuronide (M6G) or DAMGO (D-Ala2-MePhe4-
Gly(ol)5]enkephalin) to a mouse tail evidenced peripherally-mediated antinociception 
(Kolesnikov and Pasternak, 1999).  If opioids targeted to peripheral receptors are to increase 
in prevalence, assays of antinociception must be modified and improved to address 
antinociception mediated in the periphery.  
The predominant antinociception assays involve exposure of experimental animals or 
subjects to thermal stimuli (Le Bars et al., 2001).  One advantage of thermal assays is that, 
depending on the methodology, peripheral, spinal, or supraspinally-mediated antinociception 
can be assessed.  The hotplate latency assay is considered an approach to evaluate 
supraspinally-mediated antinociception, whereas the radiant heat tail-flick assay is 
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considered a measure of spinally-mediated antinociception (Woolfe and Macdonald, 1944; 
Irwin et al., 1951).  The primary method of characterizing peripheral antinociception 
involves a modified tail-flick assay where a low-dose opioid is topically applied to a segment 
of the tail and exposure to the radiant heat source is used to assess antinociception 
(Kolesnikov and Pasternak, 1999).  
 A novel approach to differentiating central and peripheral antinociception was 
developed in this dissertation project (Chapter 6).  This assay characterizes two sets of 
behavioral responses following exposure to the hotplate: a reflexive response (hind-paw 
lifting and shaking) or a processed response (jumping or licking of the hind-paw).  Latency to 
processed responses, such as jumping and licking was driven by brain concentrations, 
whereas reflexive responses, such as lifting and shaking of the paw, were predominately 
driven by serum concentrations with slight additive central contribution.  Prior to widespread 
implementation of this assay, further validation will be required.  Such validation steps could 
involve co-administration of a peripherally-restricted opioid receptor antagonist such as 
naloxone methiodide or a peripherally-restricted NMDA receptor antagonist such as 
LY235959 with an opioid to decrease or increase peripheral antinociception, respectively 
(Labuz et al., 2007).  This novel antinociceptive assay could be especially valuable in 
characterizing the results of co-administration of peripherally- and centrally-acting opioids.  
Chapter 6 improved the marriage between pharmacokinetics and pharmacodynamics by 
linking different behavioral responses to concentrations in brain and serum.    
P-GP-MEDIATED ATTENUATION OF CNS EXPOSURE  
The passage of endogenous and exogenous substances between blood and the CNS is 
restricted by the presence of the BBB and BCSFB.  The highly-developed structure of the 
 273 
BBB contributes to its role as an anatomical, biochemical, and functional impediment to 
CNS penetration.  These structures include brain capillary endothelial cells linked with tight 
junctions, an absence of fenestrations, low pinocytotic activity and structural support 
provided by astrocytes and glial cells (Engelhardt, 2003; Ohtsuki and Terasaki, 2007).  
Passive penetration of the BBB is largely dependent on chemical structure and 
physicochemical properties such as molecular weight, polar surface area, lipophilicity, and 
hydrogen bonding (Feng, 2002).  In order to maintain homeostasis, the CNS relies on the 
expression of active uptake and efflux transporters for essential nutrients, physiologic 
substrates and xenobiotics (Graff and Pollack, 2004; Hawkins et al., 2006).    
The diversity in chemical structure, BBB penetration, physicochemical properties, 
potency, and duration of effect exhibited by opioids makes this an ideal class of compounds 
for examining CNS disposition.  Some opioids readily penetrate the CNS, whereas others 
(e.g., loperamide) do not cross the BBB effectively and are devoid of centrally-mediated 
activity at therapeutic doses (Niemegeers et al., 1979).  This situation is, in part, due to P-gp 
expression on expression on the luminal surface of brain endothelial cells (Cordon-Cardo et 
al., 1989).  The use of P-gp-deficient knockout mice or naturally-occurring mutants has been 
instrumental in assessing the role of P-gp in attenuating brain uptake and antinociception of 
loperamide, methadone, and DPDPE ([D-penicillamine(2,5)] enkephalin) (Chen and Pollack 
1998; Thompson, Koszdin et al., 2000; Dagenais, Graff et al., 2004).  The readily measurable 
effect of antinociception makes this class of drugs ideal for characterizing the influence of P-
gp on CNS exposure and pharmacologic effect. 
Loperamide and methadone exhibit enhanced antinociception in P-gp deficient mice, 
suggesting the role of P-gp efflux in mediating CNS concentrations and effect of these 
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compounds (Thompson et al., 2000).  Chapters 4 and 5 characterized the impact of BBB P-gp 
on the time course of brain concentrations and antinociception of loperamide, methadone, 
fentanyl and alfentanil; the latter was identified as a P-gp substrate for the first time in this 
series of experiments (Chapter 5).  The higher opioid doses required to achieve equipotent 
antinociception in P-gp competent versus deficient mice compensated for the role of BBB P-
gp.  While the results of earlier studies led to speculation that an increase in brain tissue EC50 
of opioids in the presence of P-gp was related to P-gp-related impairment of opioid approach 
to receptor targets, the results of the present studies did not support that hypothesis (Chen and 
Pollack, 1998).  Ultimately, P-gp at the BBB impacts the relationship between systemic and 
central concentrations and subsequently, pharmacologic effect.  Yet, by understanding its 
role on CNS penetration of opioids and compounds representing other drug classes, the 
relationship between PK and PD is strengthened.  
IMPROVING ESTIMATES OF EC50 
Drug potency is commonly expressed as Ki or EC50, depending on whether 
measurements are obtained in vitro or in vivo, respectively.  EC50 tends to be more a more 
useful descriptor than Ki because it incorporates the influence of drug disposition and other 
dynamic factors (Leysen et al., 1983; Visser et al., 2003).  In situations of time-independent 
PK-PD, estimates of EC50 can be recovered from the relationship between effect and serum 
concentration.  As is more often the case, time-dependent PK-PD relationships, that is, the 
dissociation between the time course of effect and the time course of systemic 
concentrations, are observed, and are commonly addressed with the inclusion of ke0, the rate 
constant of distribution between serum and a hypothetical effect compartment containing the 
receptor biophase (Chapters 7 and 9).  While this approach is useful for recovering estimates 
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of relevant PD parameters (e.g., EC50 in the hypothetical effect compartment), it is no 
substitute for knowing actual biophase concentrations.  Seven µ-opioid agonists (alfentanil, 
fentanyl, loperamide, methadone, meperidine, morphine, and sufentanil) were selected in 
Chapter 3 to determine which measures of potency correlate best between in vitro-
preclinical-and-clinical situations.  The strongest in vitro-to-in vivo correlation was observed 
between Ki and unbound brain EC50.  While a strong correlation was observed between 
mouse serum and human plasma EC50, it was improved by correcting for protein binding.  
Improving estimates of EC50, by accounting for biophase concentrations and/or the free drug 
fraction, strengthens the link between pharmacokinetics and pharmacodynamics for the 
opioids and provides a basis for future studies of the importance of free drug fractions on 
estimates of EC50. 
Estimates of EC50 also are influenced both by pharmacodynamic and pharmacokinetic 
processes.  Chapter 7 examined the role of artificially truncating the value of Emax on 
estimates of PD parameters.  Assessing antinociception with the hotplate latency assay 
requires the implementation of a 60 sec latency cut-off time to prevent tissue damage 
(Hammond, 1989).  This requirement imposes an artificial ceiling of effect that results in 
skewed data when the cut-off time is reached.  In this study, mice receiving fentanyl (0.09 
mg/kg s.c.) or morphine (3.6 mg/kg s.c.) exhibited responses of 100% MPR at one or more 
time points.  A linked PK-PD model, including a sigmoidal relationship between effect and 
hypothetical effect-compartment concentrations, was fit to the time course of drug 
disposition and antinociception after opioid administration.  The data were best described 
when an estimate of the Emax was recovered from the model, rather than utilizing a truncated 
fixed value as a constant in the model.  Increasing the dynamic range of effect (by 65 to 
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100%) of the theoretical Emax improved estimates of ke0, EC50 and γ.  Simulations revealed 
that artificial Emax truncation influences parameter estimates to a greater extent when 
sigmoidicity is low (γ=1 vs. γ=4).  These results highlight the importance of assay 
methodology in measurements of pharmacologic response and the availability of modeling 
approaches to address limitations imposed by assay methodology.  Ultimately, incorporating 
new data analysis techniques the approach presented in Chapter 7 will improve the 
relationship between pharmacokinetics and pharmacodynamics. 
ABH:  A NON-PARAMETRIC DESCRIPTOR OF PK-PD DISSOCIATIONS 
The time-dependent dissociation between pharmacologic effect and blood 
concentrations can result from a number of physiologic processes:  indirect responses 
following drug-receptor binding, production of a pharmacologically active metabolite, or 
drug distribution to a structurally distinct compartment containing the receptor biophase.  
Dissociations between concentration and effect, known as hysteresis loops, can progresses 
temporally in the clockwise direction, such as in situations such as tolerance development or 
progress in the counterclockwise direction, such as in situations of distributional delays 
between serum and the receptor biophase.  It is assumed that the relationship between the 
receptor biophase and pharmacologic response is time-independent and sigmoidal.  Since 
biophase concentrations are unknown, PD estimates must be made using the relationship 
between serum and effect.   
The approach developed by Holford and Sheiner (1982), predicting the time course of 
drug concentrations in a hypothetical effect compartment based on the temporal relationships 
between effect and blood concentrations, was utilized in Chapters 8 and 9 to recover 
estimates of fundamental pharmacodynamic parameters (EC50 and γ).  The novel, non-
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parametric approach of calculating the area bounded by the effect-serum concentration 
hysteresis (ABH), described in Chapter 8, was utilized to determine if ABH may serve as a 
model-independent metric of the dissociation between serum concentrations and effect.  The 
time course of serum concentrations and antinociception for 5 μ-opioid receptor agonists 
(alfentanil, fentanyl, loperamide, methadone and morphine), administered at equipotent doses 
to P-gp-competent and P-gp-deficient mice, was used in Chapter 9 to recovered estimates of 
relevant PK-PD parameters and to calculate ABH.   
The ABH values calculated for this series of opioids correlated with the area under 
the concentration curve (AUC) and PK-PD model-derived descriptors, ke0 and EC50.  An 
alternative model-independent descriptor, the normalized time difference between maximum 
serum concentrations and peak effect, appeared to be a predictive metric of ke0.  While 
further validation of the relationships between ABH and model-derived parameters is 
necessary, Chapters 8 and 9 present a potentially high-impact, alternative approach to 
addressing concentration-effect hysteresis loops.   
SUMMARY 
This dissertation project addressed two methods of improving the link between 
pharmacokinetics and pharmacodynamics.  The first component addressed methods of 
improving correlations between concentration and response.  The influence of P-gp-mediated 
efflux on drug disposition was highlighted in Chapters 4 and 5, Chapter 3 identified the 
utility of correcting for protein binding, and Chapters 6 and 7 presented novel methods of 
relating concentration and response, by distinguishing central and peripheral contributions to 
antinociception based on behavioral responses and by using the theoretical value of Emax to 
improve PD parameter estimates.  The second component of this project identified ABH as a 
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model-independent descriptor of the relationship between concentration and response 
(Chapters 8 and 9).  The results of each of these global efforts indicated that the marriage 
between pharmacokinetics and pharmacodynamics can be improved by incorporating the 
components that influence concentration and response (e.g., protein binding, P-gp efflux, or 
distribution of the receptor biophase in different compartments) and by characterizing this 
relationship in novel manners (e.g. calculations of ABH).     
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APPENDIX:  MATLAB CODE 
%****************************************************************************************** 
% Hysteresis.m - Calculates area of hysteresis loops 
%****************************************************************************************** 
 
clear all; 
close all; 
format compact; 
tic; 
 
%========================================================================== 
% Read List of Files to Analyze 
%========================================================================== 
FileList='FileList.csv'; 
st=strcat(cd,'\',FileList); 
fid=fopen(st,'r'); 
 
f=0; 
while feof(fid)~=1            % while "end of file" has not been reached 
    f=f+1;                    % increment counter 
    line=fgetl(fid);          % get 1 line from file list. Format = 'foldername','filename' 
    [a,b]=strtok(line,',');   % get folder and file names from 'line' variable. 
    b=b(2:length(b));         % strip leading comma (from strtok command) from filename 
    FolderName{f}=a;          % save folder name to variable 'FolderName' 
    FileName{f}=b;            % save file name to variable 'filename' 
    FilePath{f}=strcat(cd,'\',a,'\',FileName{f},'.csv');   % create and save full file path 
end 
fclose(fid); 
 
%========================================================================== 
% Count files in each folder to group for figures 
%========================================================================== 
for f=1:length(FileName) 
    if f==1;                                         %If first file in list, then 
        FigNum(f)=1;                                 %   assign to subplot #1 on figure #1 
        FigSubplotNum(f)=1;                           
    else                                             %If file is not first on list, then 
        if strcmp(FolderName{f},FolderName{f-1})==1  %If foldername matches previous, then 
            FigNum(f)=FigNum(f-1);                   %  assign to next subplot on same figure 
            FigSubplotNum(f)=FigSubplotNum(f-1)+1;    
        else                                      %If foldername doesn't match previous, then 
            FigNum(f)=FigNum(f-1)+1;                 %   assign to subplot #1 on new figure 
            FigSubplotNum(f)=1; 
        end  
    end 
    GrpSize(FigNum(f))=FigSubplotNum(f);             % Determine size of each figure group 
end 
 
%========================================================================== 
% Get and Analyze Data From Files 
%========================================================================== 
for f=1:length(FileName); 
     
    %====================================================================== 
    % Get Header Info 
    %====================================================================== 
    fid=fopen(FilePath{f},'r');       % Open data file 
    x=fgetl(fid);                     % Get first line (column headers) 
    i=0; 
    while isempty(x)~=1;              % While x is not empty, look for more column headers 
        i=i+1;                        % Increment counter 
        [a,x]=strtok(x,',');          % Search for delimiters (comma) to separate header name 
        ColHdr{i}=a;                  % Save column header name 
        if isempty(x)~=1              % If another column is detected, 
            if strcmp(x(1:2),',,')==1   %    then check next column for text 
                break;                % Break if no header text detected 
            end 
        end 
    end 
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    %====================================================================== 
    % Read numerical data from file 
    %====================================================================== 
    numrowsmax=10000;                       % Maximum number of data rows to search 
    for i=1:numrowsmax 
        x=fgetl(fid);                       % Get data line from file 
        if feof(fid)==1;                    % Test to see if end of file has been reached       
            break;                          % Break loop if end of file 
        elseif strcmp(x(1:2),',,')==1;      % Test to see if line has no data, but has comma  
                                            %  delimiters 
            break;                          % Break loop if line has no data 
        else 
            for j=1:length(ColHdr) 
                [a,x]=strtok(x,','); 
                if isempty(str2num(a))~=1 
                    data(i,j)=str2num(a); 
                else 
                    data(i,j)=NaN; 
                end 
            end 
        end 
    end 
    fclose(fid);                            % Close data file 
     
    %====================================================================== 
    % Select Data Columns and Calculate Area 
    %====================================================================== 
     
    % Select Data Columns for X and Y Axes; 
    xcolnum=3; 
    ycolnum=5; 
     
    x_hdr=ColHdr{xcolnum}; 
    y_hdr=ColHdr{ycolnum}; 
    x=data(:,xcolnum); 
    y=data(:,ycolnum); 
     
    % Find index of maximum x value 
    [val,maxind]=max(x); 
    x1=x(1:maxind); 
    x2=x(maxind:length(x)); 
    y1=y(1:maxind); 
    y2=y(maxind:length(x)); 
     
    % Calculate Area 
    for i=1:(length(x1)-1) 
        Area1(i)=abs(mean(y1(i:i+1))*diff(x1(i:(i+1)))); 
    end 
    Area1=sum(Area1); 
     
    for i=1:(length(x2)-1) 
        Area2(i)=abs(mean(y2(i:i+1))*diff(x2(i:(i+1)))); 
    end 
    Area2=sum(Area2); 
     
    CurveArea(f)=abs(Area1-Area2); 
    if Area1-Area2<0 
        Direction{f}='CCW'; 
    else 
        Direction{f}='CW'; 
    end 
     
    %====================================================================== 
    % Plot Curves 
    %====================================================================== 
 
    % Set Location for Plot(figure number, subplot number)  
    figure(FigNum(f)); 
    if FigSubplotNum(f)==1                         % If first subplot in group, 
        rows=round(sqrt(GrpSize(FigNum(f))));      %   set subplot layout for rest of group 
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        cols=rows; 
    end 
         
    % Plot Data 
    subplot(rows,cols,FigSubplotNum(f)); 
    plot(x1,y1,'b',x2,y2,'r') 
     
    % Set Titles and Axis Labels 
    title(FileName{f},'fontsize',8,'verticalalignment','middle'); 
    xlabel(x_hdr,'fontsize',8,'verticalalignment','middle'); 
    if rem(FigSubplotNum,rows)==1 
        ylabel(y_hdr,'fontsize',8,'verticalalignment','middle'); 
    end 
    set(gca,'fontsize',8) 
     
    % Normalize axes for all plots on figure if plot is last in group 
    if FigSubplotNum(f)==GrpSize(FigNum(f)); 
        % Get X and Y axis limits for each plot 
        for i=1:FigSubplotNum(f); 
            figure(FigNum(f)); 
            subplot(4,4,i); 
            a=get(gca,'xlim'); 
            xlim_min(i)=a(1); 
            xlim_max(i)=a(2); 
            a=get(gca,'ylim'); 
            ylim_min(i)=a(1); 
            ylim_max(i)=a(2); 
        end 
        % Set Equal X and Y axis limits for each plot 
        for i=1:FigSubplotNum(f); 
            figure(FigNum(f)); 
            subplot(4,4,i); 
            set(gca,'xlim',[min(xlim_min) max(xlim_max)]); 
            set(gca,'ylim',[min(ylim_min) max(ylim_max)]); 
        end   
    end; 
     
    %====================================================================== 
    % Save Output Values 
    %====================================================================== 
    Output{f,1}=FigNum(f); 
    Output{f,2}=FigSubplotNum(f); 
    Output{f,3}=FolderName{f}; 
    Output{f,4}=FileName{f}; 
    Output{f,5}=x_hdr; 
    Output{f,6}=y_hdr; 
    Output{f,7}=CurveArea(f); 
    Output{f,8}=Direction{f}; 
     
    %====================================================================== 
    % Display Progress 
    %====================================================================== 
    clc; 
    disp(strrep(strcat('Completed:_',num2str(round(100*f/length(FileName))),'%'),'_',' ')) 
end 
 
% Plot loop area values for each figure group 
figure; 
for i=1:max(FigNum); 
    y=CurveArea(find(FigNum==i)); 
    subplot(3,2,i); 
    plot([1:length(y)],y,'-vb'); 
    xlim([0 length(y)+1]); 
     
    title(FolderName{min(find(FigNum==i))},'fontsize',8,'verticalalignment','middle'); 
    ylabel('Area','fontsize',8,'verticalalignment','middle'); 
    set(gca,'fontsize',8); 
end 
 
% Clear screen and display elapsed time 
clc; 
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t=toc; 
disp(strrep(strcat('Time Elapsed:_',num2str(round(10*t/60)/10),'_min'),'_',' ')) 
 
%========================================================================== 
% Select output filename and verify overwrite of existing file if needed 
%========================================================================== 
WriteOutputFile=0; 
while WriteOutputFile==0; 
    beep 
    disp(' '); 
    disp('Waiting for user input...'); 
    disp(' '); 
    OutputFileName=input('Name for output file: ','s'); 
     
    x=dir(cd); 
    for i=1:length(x) 
        MatchingFile(i)=strcmp(lower(x(i).name),lower(strcat(OutputFileName,'.txt'))); 
    end 
    MatchingFile=sum(MatchingFile); 
     
    if MatchingFile==0; 
        WriteOutputFile=1; 
    else 
        disp(' '); 
        disp(strcat(OutputFileName,'.txt already exists.')) 
        OverwriteFile=input('Do you want to replace it? (Y/N): ','s'); 
        if strcmp(lower(OverwriteFile(1)),'y')==1 
            WriteOutputFile=1; 
        else 
            WriteOutputFile=0; 
        end 
    end 
end 
 
%========================================================================== 
% Write to Output File 
%========================================================================== 
fid=fopen(strcat(cd,'\',OutputFileName,'.txt'),'w'); 
fprintf(fid,'Folder\tFile\tX_Data\tY_Data\tCurve Area\tDirection\r\n'); 
fprintf(fid,'------\t----\t------\t------\t----------\t---------\r\n'); 
for f=1:size(Output,1) 
    if f~=1 
        if Output{f,1}~=Output{f-1,1} 
            fprintf(fid,'\r\n'); 
        end 
    end 
%     fprintf(fid,'%s\t%s\t%s\t%s\t%s\t%g\r\n',... 
%         Output{f,3},Output{f,4},Output{f,5},Output{f,6},Output{f,7},Output{f,8}); 
     
    fprintf(fid,'%s\t',Output{f,3}); 
    fprintf(fid,'%s\t',Output{f,4}); 
    fprintf(fid,'%s\t',Output{f,5}); 
    fprintf(fid,'%s\t',Output{f,6}); 
    fprintf(fid,'%g\t',Output{f,7}); 
    fprintf(fid,'%s\r\n',Output{f,8}); 
end 
fclose(fid); 
 
%========================================================================== 
% Save Plots to jpeg Format 
%========================================================================== 
for f=1:length(FileName) 
    n=Output{f,1}; 
    PlotName{n}=strcat(OutputFileName,'_',Output{f,3}); 
end 
PlotName{max(FigNum)+1}=strcat(OutputFileName,'_','Area Curves'); 
 
for i=1:length(PlotName) 
    figure(i) 
    set(figure(i),'PaperOrientation','portrait') 
    set(figure(i),'PaperPosition',[0.25 0.25 8 10.5]) 
 285 
    disp(strrep(strcat('Generating 
Image_',num2str(i),'_of_',num2str(Output{size(Output,1),1}), '...'),'_',' ')) 
    print(i,'-dtiff','-r300',PlotName{i}) 
end 
 
 
%========================================================================== 
% Display Status 
%========================================================================== 
clc; 
fprintf('***DONE***\r\n\r\n') 
fprintf('Output data saved to:\r\n\t%s\r\n\r\n',strcat(OutputFileName,'.txt')) 
fprintf('Plots saved to: \r\n') 
for i=1:length(PlotName) 
    fprintf('\t%s\r\n',strcat(PlotName{i},'.tiff')) 
end 
fprintf('\r\n') 
fprintf('File Location: %s\r\n\r\n',strcat(cd,'\')); 
disp(strrep(strcat('Time Elapsed:_',num2str(round(10*t/60)/10),'_min'),'_',' ')) 
beep 
